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SUMMARY
Rapidly growing, glycolytic tumours which are poorly differentiated 
were shown to contain functional mitochondria capable of oxidative 
phosphorylation. Mitochondria were isolated and assessed for use in 
screening potential antimitochondrial agents in vitro. As this model 
proved to be unsuitable, a second model, intact cells were employed 
for screening purposes. The effect of antimitochondrial agents on the 
metabolism of cultured tumour cells was compared to that in freshly 
isolated rat hepatocytes.
Rhodamine-6G (R6G) a cationic, fluorescent mitochondrial probe, 
altered oxygen consumption rates and increased lactate production in 
tumour cells in vitro. At the same concentrations R6G had little 
effect on the metabolism of isolated hepatocytes. Lamprene, an 
antileprosy agent also altered cellular oxygen consumption rates in 
tumour cells at comparable concentrations to R6G. Classical 
mitochondrial inhibitors were used to demonstrate that R6G has a 
biphasic action upon cellular oxygen uptake. Initially oxygen uptake 
is uncoupled from ADP phosphorylation, followed by subsequent 
inhibition of oxygen consumption suggesting that electron transport is 
also inhibited. Lamprene behaves like a classical uncoupler of tumour 
mitochondria, stimulating oxygen consumption in the presence of an 
inhibitor of phosphorylation.
Growth of tumour cells in vitro in the presence of 5 fluorouracil 
(5FU) did not appear to inhibit mitochondrial biogenesis as assessed 
by the activity of specific mitochondrial enzymes. It was concluded 
that either the drug concentration required to inhibit mitochondrial 
biogenesis was cytotoxic or the duration of exposure to drug was too 
short to adequately dilute mitochondrial protein.
Tumour cells grown in glutamine as the major sources of carbon depend 
upon their mitochondria for energy production. Although the 
phosphorylation inhibitor oligomycin did exhibit an enhanced toxicity 
toward cells grown in glutamine, R6G showed identical toxicity to
cells grown either in glucose and glutamine or glutamine alone. This 
suggests that the toxicity of R6G might not be due to an anti- 
mitochondrial action.
Combining lamprene with the antiglycolytic agent 2-deoxyglucose did 
appear to delay growth of a human tumour xenograft implanted in 
athymic mice, though this was not clearly observed, due to a reduced 
food intake by animals. However, R6G and 5FU did significantly delay 
tumour growth, although the mechanism of action remains to be 
established.
This study has shown that antimitochondrial agents may be of some 
value in anticancer chemotherapy and highlights methods by which 
potential agents might be identified.
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CHAPTER 1
GENERAL INTRODUCTION 
Limitations of Conventional Cancer Chemotherapy
Conventional anticancer agents tend to act non-selectively, altering 
the metabolism of both neoplastic cells and non-tumour cells within 
the cancer patient (Malpas, 1986). It is generally assumed that all 
tumours grow rapidly with cell turnover rates which are far greater 
than host cells within a patient. Those tumours successfully treated 
with conventional chemotherapy do have rapid growth rates such as for 
example, Hodgkin’s disease, testicular teratoma or Burkitt*s lymphoma 
(Pitot, 1986). There are however, normal tissues within the body, 
such as, GI tract and bone marrow which would be affected by the j 
|drugs used.
Conventional chemotherapy is directed at tis^ eswith a large growth
fraction. Such tissues have a substantial percentage of cells
undergoing division at any one time. Therefore, use of cytostatic or
cytotoxic drugs is limited by the toxicity of such agents to bone
also
marrow or GI tract, whichAhave a large growth fraction (Pitot, 1986; 
Tannock, 1987). Slow growing tumours such as pulmonary or gastric 
cancers and others, where the growth fraction is small are less 
affected by inhibitors of DNA synthesis which comprise a large 
fraction of the drugs used in chemotherapy (Pitot, 1986).
Energy Metabolism in Normal and Neoplastic Tissues
A major aim of this thesis is to explore a selective approach to 
chemotherapy. Mammalian cell survival is dependent upon the ability 
of the cell to metabolize suitable carbon sources to generate 
Adenosine triphosphate (ATP) for biosynthetic or maintenance purposes, 
a feature common to both neoplastic and normal cells. Turnover 
between ATP, Adenosine diphosphate (ADP) and inorganic phosphate (Pi) 
enable both tumour and normal cells to regulate their environment.
The oxygenated state of the cell is thought to determine by which 
metabolic pathways ATP is generated. Under anaerobic conditions
glycolysis yields 2 molecules of ATP from a hexose substrate such as 
glucose and 2 molecules of NADH. NAD may be regenerated following 
reduction of pyruvate to lactate.
Utilisation of ATP by membrane bound Na^ K4* ATPases will regenerate 
ADP and this together with NAD+ will stimulate further glycolysis 
(Saier, 1987). Under aerobic conditions mitochondrial pathways will 
be activated, oxidation of the glucose derived carbon skeleton in the 
tricarboxylic acid (TCA) cycle will generate reducing equivalents NADH 
or FADH. According to the chemiosmotic theory, oxidation of reduced 
nucleotides , obtained via both glycolysis and the TCA cycle, to water, 
with oxygen as the final electron acceptor generates a proton gradient 
which is used to synthesize ATP (Mitchell, 1975; Mitchell, 1976). 
Complete oxidation of glucose yields 36 molecules of ATP. Thus 
whether pyruvate is oxidised through TCA cycle activity or reduced to 
lactate is dependent on oxygenation of the cell and thus is the key to 
respiratory control of metabolic flux.
In 1930, Warburg observed that malignant tumours exhibited high rates 
of glycolysis. Furthermore, whereas normal cells in the presence of 
oxygen underwent aerobic respiration with reduced or no lactate 
production (Pasteur effect), , tumour cells exhibited high
rates of lactate production even in the presence of oxygen (Warburg, 
1930; Weirihouse, 1972; Weinhouse, 1982). Warburg postulated that 
cancer was essentially'- related to the reduced capacity of oxygen to 
reduce glycolysis. However, recent worl!?~IMp?^ that although
rapidly growing tumours were highly glycolytic, such tumours were 
poorly differentiated (Pedersen, 1978). Slower growing, well- 
differentiated tumours could utilise oxygen, coupling oxygen 
consumption to phosphorylation, thus indicating the intactness of the 
mitochondrial respiratory chain (Gregg, 1972; Racker, 1976; Pedersen, 
1978). Explanations for how slow growing, well-differentiated 
hepatomas exhibited abnormal patterns of energy metabolism were based 
on altered expression of glycolytic enzymes. Such tumours were 
thought to have a mitochondrially bound hexokinase (ATP:hexose 6- 
phospho transf erase E.C. 2.7.1.1). Thus the tumour could use 
glycolytic pyruvate for mitochondrial metabolism without expressing
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the high rates of glycolysis seen in poorly differentiated hepatomas 
(Pedersen and Bustamante, 1982; Bustamante et al, 1981). High rates 
of glycolysis in poorly differentiated tumours have been accounted 
for, according to some workers by abnormally increased activity of 
membrane-bound Na+ K+ ATPases generating large quantities of ADP. 
Thus glycolysis is stimulated by ADP (Racker and Spec tor, 1981). To 
some extent detailed evidence for this has been discredited (Racker, 
1981). It is clear that while some tumours exhibit high rates of 
glycolysis, this is not a universal feature as confirmed by studies in 
vivo (Reichard et al, 1964; Weinhouse, 1982; Sauer and Dauchy, 1986). 
A study of fatty acid oxidation in both well-differentiated and poorly 
differentiated hepatomas indicated that lower substrate oxidation 
rates obtained, in comparison to normal liver, were explained more by 
defects in fatty acid shuttles rather than a defect in mitochondrial 
respiratory function (Cederbaum and Rubin, 1976).
Although the degree of differentiation of a particular tumour cell may 
indicate preferred metabolic paths for ATP generation, substrate 
availability plays a key role in determining whether tumour cells in 
vitro preferentially undergo glycolysis at the expense of 
mitochondrial metabolism. Glucose and other c<-glucopyranoses such as 
galactose, mannose or fructose are primary glycolytic substrates 
(Lehninger, 1975). Ample evidence correlates glycolysis with glucose 
utilisation in tumour cells (Weinhouse, 1972; 1982). However recent 
evidence has shown that cultured HeLa cells and other tumour cells 
utilise glutamine, even when glucose is present with up to 35% of the 
amino acid used to derive ATP from oxidative metabolism (Kovacevic and 
Morris, 1972; Reitzer et al, 1979; Moreadith and Lehninger, 1984). In 
some cultured cell lines however, although glutamine might support ATP 
production, glucose was a preferred substrate. Cells are unable to 
maintain ATP if deprived of glucose (Demetrakopoulos et al, 1978; 
1982; Nakashima et al, 1984). In order for mitochondrial substrates 
to be utilised, oxygen must be present. Access to oxygen in tumours 
in vivo is dependent upon how well supplied with blood the tissue is. 
Hypoxic regions, as shown by certain models in vitro cannot utilise 
glutamine and thus glucose is of more importance (Sutherland et al, 
1986; Tannock et al, 1986; Hlatksy et al, 1988). However, the largest
tumour cell growth fraction is often in oxygenated regions, where 
glutamine utilisation could in theory occur. Evidence for utilisation 
of mitochondrial substrates has been obtained for rapidly growing, 
poorly differentiated tumours (Sauer et al, 1982; Sauer and Dauchy, 
1983; Mares-Perlman and Shrago, 1988). In summary, the relative 
contributions of glycolysis or mitochondrial metabolism to ATP 
generation in the tumour cell is dependent not only on the 
differentiated state of the cell, but also on the availability of 
substrates and oxygen.
Mitochondria are found in both poorly differentiated and well 
differentiated tumour cells. Morphological differences observed in 
glycolytic, poorly differentiated tissues compared to normal cells of 
the same cell lineage have been attributed to a reduced capacity to 
oxidise carbon substrates. Certain substrates such as B-OH butyrate 
show reduced oxidation rates or cannot be metabolised when compared to 
preparations of isolated normal mitochondria (Kaschnitz et al, 1976; 
Cederbaum and Rubin, 1976; Nakashima et al, 1984). Yet in their 
capacity to oxidise other substrates tumour mitochondria obtained from 
either well differentiated or poorly differentiated tumours do not 
show any differences compared to normal tissues of the same lineage. 
Thus generalisations about tumour mitochondria, as compared to normal 
mitochondria, are difficult to make (Pedersen, 1978).
Inhibition of Tumour Cell Energy Metabolism 
Mitochondrial Inhibitors
It was thought that the cytotoxicity of alkylating agents, used in 
conventional cancer chemotherapy, could be explained partly by an 
antimitochondrial action (Gosalvez et al, 1974; 1976; Bernal et al, 
1982(a); Belousova, 1984). However until recently, few compounds had 
been shown to exert a selective toxicity toward tumour cells.
The rhodamine dyes rhodamine!23 (RL23)and rhodamine 6G both cationic 
fluorescent dyes are thought to exert a selective toxicity toward 
tumour cells. R123 has been shown to accumulate in living cells only 
and its associated fluorescence was localised in mitochondria for the 
rodent cell lines screened (Johnson et al, 1980). Selective
accumulation in mitochondria of living cells was interpreted as 
dependence on the high transmembrane potential generated across the 
inner-mitochondrial membrane (Johnson et al, 1981). The retention 
time of R123 was increased in virus transformed mink fibroblast cells 
compared to untransformed cells, indicating that transformed cells 
have a defective transmembrane potential. Nigericin an ionophore 
exchanging H+ions for K+ions eliminates the mitochondrial membrane pH 
gradient, but increases the electrical gradient and increased R123 
retention. Thus R123 can be used as probe for the abnormal metabolic 
state of the mitochondrion (Johnson et al, 1982). The compound 
appeared to halt cell cycle activity as inhibition of cell energy 
metabolism blocked replication causing reduction in accumulation of 
ribosomal RNA (Darzykiewicz et al, 1982). The compound was used as a 
probe to indicate whether mitochondrial function was inhibited by 
anticancer drugs (Bernal et al, 1982(a)). However evidence for 
possible anticancer activity was indicated by the unusually long 
retention of R123 in transformed epithelial cell lines or carcinoma 
cells compared to normal cells (Summerhayes et al, 1982). Exposure to 
R123 selectively reduced the clonal growth of carcinoma cells in vitro 
and selective toxicity was observed in carcinoma cells relative to 
untransformed cell lines in vitro (Bernal et al, 1982(b); Lampidis et 
al, 1983; Nadakavukaren et al, 1985).
Combining R123 with antiglycolytic agents for treatment against 
Ehrlich ascites tumours implanted in mice, showed some improvement in 
animal survival (Bernal et al, 1983). Thus the differences in 
retention times of R123 between normal and neoplastic cells is 
attributed to differences in transmembrane potential across the inner- 
mitochondrial membrane between cells. Depolarising agents decrease 
R123 fluorescence and retention, causing tumour cells to resemble 
normal cells, whereas hyperpolarising the membrane of non-neoplastic 
cells increases R123 fluorescence and retention (Davis et al, 1985). 
The antimitochondrial action of R123 is thought to be directed at the 
FIFO ATPase complex with possible secondary effects on electron 
transfer (Modica-Napolitano et al, 1984; Bnaus et al, 1986; Modica- 
Napolitano and Aprille, 1987).
Glioma !s induced in rat brain with avian sarcoma virus have shown to 
retain R123 as compared to normal rat brain in vivo (Beckman Jr et al, 
1987). It is clear that precise comparisons of tumour and non-tumour 
sensitivity to R123 are only valid between tissues from the same
species, as well as comparisons of tumour with normal cells from the
same lineage (Gupta and Dudani, 1987). However, to be of value in
chemotherapy a general reduction in toxicity to all host tissues is 
important.
R6G was shown to inhibit coupling of phosphorylation with oxygen 
consumption in rat liver mitochondria, interpreted as due to an
inhibition of ADP translocation (Gear, 1974). However further work 
indicated that R6G inhibited H*ion ejection during electron transport 
across the mitochondrial membrane (Higuti et al, 1980). There is some 
evidence to suggest that at low concentrations R6G and R123 inhibit 
mitochondrial protein synthesis in tumours as well as in normal cells 
(Kuzela et al, 1986; Abou-Khalil et al, 1986).
Certain agents in clinical use have been described as exhibiting 
antimitochondrial activity. The antileprosy agent clofazamine 
(lamprene) has been shown to exert an inhibition of cell respiration 
in bacteria and yeast (Barry et al, 1948; Rhodes and Wilkie, 1973). 
Studies on isolated rat liver mitochondria and yeast were thought to 
indicate that lamprene acted as an electron acceptor bypassing 
cytochrome oxidase. In support of this theory, lamprene was thought 
to have structural similarities to the well characterised electron 
acceptor phenazine methosulphate (Rhodes and Wilkie, 1973). Other 
agents thought to inhibit eukaryotic mitochondria were the tricyclic 
antidepressants chlorimipramine (Anafranil) and maprotiline 
(ludiomil). The compounds are also similar in structure to phenazine 
methosulphate. Fairly high concentrations of Anafranil used to 
inhibit yeast respiration ranged between 70uM and 280uM (Hughes and 
Wilkie, 1970). A selectively toxic effect between transformed 
fibroblasts and untransformed cells was demonstrated. Primary 
activity suggested that the drug restricted energy metabolism, 
reducing respiration. Inhibitory effects of the drug could be 
reversed by addition of ATP to cultured cells (Wilkie and Delhanty,
1970). Figure 1.1 illustrates the chemical structures of the drugs 
investigated.
Inhibitors of Glycolysis
Early studies, attempting to use glycolytic inhibitors in anticancer 
chemotherapy focussed on inhibitors which had been used to examine 
metabolic flux in glycolysis. As neoplastic transformations were 
viewed in the light of Warburgfs observations, agents such as 
iodoacetate and iodoacetamide were investigated. However, not only 
were the compounds non-selective, affecting both tumour and host 
tissue, but were also very toxic (Aisenberg, 1961; Webb, 1966).
2-Deoxyglucose an antimetabolite of glucose was one of the earliest 
glycolytic inhibitors which appeared to show a specific effect against 
animal tumour models (Woodward and Hudson, 1954; Ball et al, 1957). 
More recent studies have indicated that when administered with R123, 
the combination potentiated the survival of mice implanted with the 
ehrlich ascites tumour compared to mice administered with R123 alone 
(Bernal et al, 1983).
Other compounds implicated include the indazole-carboxylic acid 
lonidamine. Lonidamine depressed aerobic glycolysis in tumour cells, 
but elevated glycolysis in non-tumour cells. This action was related 
to possible inhibition of the mitochondrial hexokinase, an enzyme 
thought to be absent from normal differentiated cells (Floridi, et al, 
1981(a); Floridi, et al, 1981(b); Pedersen and Bustamante, 1982-; 
Bustamante et al, 1981). Another agent Quercertin was used to inhibit 
glycolysis indirectly by inhibiting membrane bound Na+K+ ATPases, thus 
reducing ADP for stimulation of glycolysis (Suolinna et al, 1974). An 
antihelminthic drug levimasole has recently been shown to exert a 
selective effect upon ehrlich ascites tumour cells without affecting 
mouse liver and muscle. This activity is thought to be related to 
similar effects of the amino acid L-cysteine, exhibiting structural 
similarity to a part of the levimasole molecule (Kedryna et al, 1983; 
Guminska et al, 1986).
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Figure 1.1: The Chemical Structures of Compounds investigated in
these studies 
I Rhodamine 6G 
II Rhodamine 1,2,3 
III Clofazamine (Lamprene)
IV Chlorimipramine (Anafranil)
V Maprotiline (Ludiomil)
Combinations of antiglycolytic and antimitochondrial agents
used to inhibit tumour energy metabolism in vivo
Some attempts have been made to use antiglycolytics with 
antimitochondrial agents to selectively inhibit tumour cell energy 
metabolism vivo.
Methylglyoxal Bis (guanyl hydrazone) (MGBG) has been used to block 
mitochondrial replication in tumours in vivo, and this effect has been 
potentiated with hypoglycaemic agents such as phenethylbiguanide 
(Byczkowski et al, 1982). As mentioned some potentiation of the 
antimitochondrial agent R123 has been achieved with 2-deoxyglucose in 
prolonging survival times of mice bearing the ehrlich ascites tumour 
(Bernal et al, 1983). R6G combined with either the antiglycolytic, 2- 
deoxyglucose or the hypoglycaemic agents, 3-mercaptopicolinic acid or 
hydrazine sulphate reduce tumour growth in rats bearing the W256 
tumour (Fearon et al, 1985(a); 1987).
Aims of Thesis
Evidence reviewed thus far, implies that there may be differences 
between the energy metabolism of normal and neoplastic cells. It 
might be possible to inhibit tumour cell energy metabolism with agents 
which show a specificity for tumour mitochondria. However, leaving 
the glycolytic component of the cell unaltered could allow the cell to 
maintain ATP through breakdown of substrate carbon to lactate. Thus 
it is hoped that combining tumour selective antimitochondrial agents 
with inhibitors of glycolysis, tumour cell energy metabolism might be 
blocked without deleterious effects upon host metabolism (Wilkie, 
1979; Fearon, 1984; Wilkie and Fearon, 1985). Highly glycolytic 
tumours targetied by such therapy would have their ATP production 
limited by the nature of the antiglycolytic agents used. Normoxic 
regions of the tumour undergoing oxidative metabolism would receive 
antimitochondrial therapy. As the ratio of ATP production generated 
by anaerobic metabolism relative to aerobic respiration is 1:18, even 
reduced mitochondrial function in such tumours would generate 
substantial quantities of ATP.
Slow growing, well differentiated tumours tend to resemble normal host 
tissue in structure and metabolic function. Effectiveness of the 
therapy would be more dependent upon the selectivity of the 
antimitochondrial agents used. If mitochondrial metabolism is more 
critical for highly differentiated tumours it might be possible touse 
a combination of functional inhibitors of tumour mitochondria together 
with tumour specific inhibitors of mitochondrial replication or 
biogenetic inhibitors to block energy metabolism in tumours (Van den 
Bogert, 1983).
Thus the aims of the experimental work described in this thesis may be 
stated as follows:
A screening system is required, whereby the selectivity of 
antimitochondrial agents used in this study might be evaluated against 
tumour and non tumour system in vitro. A further series of studies is 
required to confirm that those agents selected inhibit mitochondrial 
metabolism in vitro. Finally the ability of such agents in 
combination with recognised tumour selective antiglycolytic agents to 
halt the growth of tumours in vivo needs to be confirmed.
Thesis Layout
Each Chapter is self-contained, containing introduction, methods, 
results and discussion. Chapter 2 describes the general methods 
applied to experiments carried out in more than one chapter. A 
background to parameters of mitochondrial function examined is also 
described.
Experiments described in Chapter 3 evaluated whether mitochondria 
isolated from a rat tumour and normal rat liver are suitable models 
for evaluating the effectiveness of possible antimitochondrial agents 
directed at tumour energy metabolism. Results indicated that although 
viable, coupled organelles could be obtained from a poorly 
differentiated, glycolytic tumour, certain disadvantages of this 
system, discussed in Chapter 3, made it unsuitable for an 
investigation of antimitochondrial agents.
A second model system was evaluated in Chapter 4, for assessing 
whether antimitochondrial agents described in the literature had 
potential as tumour selective inhibitors of energy metabolism. Whole 
tumour cells obtained from continuous cultured cell lines were 
compared with freshly isolated cells obtained from normal rat tissue 
in their responses to antimitochondrial agents. It was clear that 
both mitochondrial function and anaerobic metabolism could be assessed 
in such a model and was thus adopted for assessment of 
antimitochondrial agents.
From experiments in Chapter 4, the fluorescent cationic dye R6G and 
the antibacterial agent lamprene showed promise as possible metabolic 
inhibitors of tumours. However, evidence for antimitochondrial 
activity was indirect. A series of experiments described in Chapter 5 
were designed to assess the potency of the antimitochondrial effect on 
tumour cells by comparing these agents with classical anti­
mitochondrial agents.
Experimental evidence presented in Chapter 6 was an evaluation of the
5-fluorouracil (5FCJ) 
conventional anticancer agent a which at non-cytotoxic
concentrations was thought to induce inhibition of mitochondrial
biogenesis. Unfortunately, the response to continuous exposure of 5FU
on expression of mitochondrial enzymes did not provide conclusive
evidence of inhibition of mitochondrial biogenesis.
Any inhibitor of mitochondrial function might have other effects upon 
tumour cell metabolism. It was therefore necessary to examine whether 
the cytotoxic effect upon the tumour cell caused by the inhibitor was 
in fact due to specific inhibition of mitochondrial metabolism or due 
to some other effect. The approach in Chapter 7 attempted to 
determine this by making cells dependent upon carbon sources which 
required mitochondrial activity, and to see if such cells showed any 
enhanced sensitivity to inhibitors investigated. Although the 
approach was successful, a selective antimitochondrial effect with R6G 
was not demonstrated upon tumour cell toxicity.
Chapter 8 described experiments which evaluated how successful 
combining inhibitors of tumour mitochondrial function and, either 
inhibitors of tumour cell glycolysis, or inhibitors of tumour 
mitochondrial biogenesis, were in reducing the growth rate of a human 
tumour xenograft implanted in athymic mice. Of the combinations used, 
both lamprene in combination with the antiglycolytic agent 2- 
deoxyglucose and 5FU combined with R6G achieved some delay in tumour 
growth.
Finally, Chapter 9 is a general summary and discussion of the 
experimental evidence presented in this thesis, together with 
conclusions of the studies undertaken. Although this approach to 
manipulating tumour cell energy metabolism was shown to be partly 
successful, a truly conclusive study required a more effective 
selection of inhibitors, preferably from agents already in clinical 
use, rather than experimental compounds.
CHAPTER 2
GENERAL METHODS 
INTRODUCTION
Most of the experimental methods described in this chapter are 
applicable to more than one chapter of this thesis. These techniques 
may be broadly classified into six sections. The initial sections 
will describe routine maintenance of animals used in these studies as 
well as the tumour types selected. General tissue culture methods for 
maintenance and growth of continuous tumour cell lines will then be 
described. Assays applicable to studies in more than one chapter will 
also be described. Finally, methods for investigating the respiratory 
activity of mitochondrial preparations or intact whole cells by oxygen 
polarography will be described.
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METHODS
Animals
Female Wistar rats, weighing between 200 and 300 grams were purchased 
from Charles Rivers, Margate, Kent. Alternatively, animals were 
obtained from stocks bred in the Department of Medical Oncology. 
Animals were maintained in the animal house of the Department of
Medical Oncology. Animals had free access to fresh water and food
(Wm Macarthur & Co, Glasgow) •
Tumours
Isolated mitochondria were obtained from the Walker 256 
carcinosarcoma. This rat tumour is a poorly differentiated, rapidly 
growing tumour characteristic, of the highly glycolytic tumours 
originally described by Warburg (1930). Tumour tissue for 
subcutaneous implantation in Wistar rats were obtained from two 
sources. Cells were obtained from cells grown in suspension culture. 
Alternatively tumour fragments stored in liquid nitrogen (-160°C) were 
thawed and used to initiate tumour growth. Animals were anaesthetised 
with anaesthetic grade diethyl ether. Animals were then placed with 
the dorsal surface facing upward. Tumour sections measuring between 2
o
and 3mnr were surgically inserted onto the surface of hind limb muscle 
beds. The wound was secured with autoclips (Vicary Davidson, 
Glasgow). Animals were then allowed to recover. Where cell 
suspensions were used to initiate tumour growth, cells were injected 
into the region above the hind limb with a sterile syringe and needle 
(Becton Dickinson, Cowley, Oxfordshire). Tumour was passaged at 7 day 
intervals thereafter. Tumour was obtained from freshly killed animals 
and tumours were removed to sterile petri dishes. Fat, connective 
tissue and necrotic material were removed. Viable tissue obtained 
from the tumour surface was divided into sections measuring between 2
o
and 3mm0. Tumour passage was continued as described.
General Tissue Culture Methods
Tissue culture was carried out under sterile conditions in a vertical 
air flow hood.
Maintenance and Growth of Tumour Cell Lines
WIL, a human non small cell lung tumour line was used for the
experiments described in this thesis. It is characteristic of tumours
which resemble the host tissue, showing differentiation and yet
exhibiting rapid growth rates. The cell line was maintained in
monolayer culture in flasks (Nunc, 75cm^ and 150cm^*G3jf~CelJ s S were
routinely grown in Hams F10 and Dulbecco*s Modified Eagles Medium
(F10:DMEM, 50:50, GIBCO, Paisley) supplemented with glutamine, 2mM and
foetal calf serum (FCS), 10% (Biocon, Eardiston, Worcestershire).
Stocks of this cell line were originally obtained from the Ludwig
Institute, Sutton. Cells were stored in liquid N2 in medium
supplemented with dimethyl sulphoxide, 10% as preservative. Cells
were routinely passaged twice weekly following treatment with trypsin
[0.25% in phosphate buffered saline (PBS) (V:V), containing ImM
ethylene diamine tetra-acetic acid (EDTA)]. Cells were harvested from
at least two N75 flasks, pooled and resuspended in fresh medium in
sterile 30ml universal containers (Sterilin, Middlesex). Cell number
was determined with a Coulter Counter (Model ZB1, Coulter Electronics,
Luton, Beds). Cell viability was assessed by dye exclusion (0.02%
Trypan in PBS) and viewed under phase contrast (Olympus C.K.2
: Olympus Optical Co/London).
Microscope, . ' x Viability routinely exceeded 95%. Fresh cultures
were seeded into sterile flasks at a dilution of 1:10. Monolayers
reached saturation density after 4 days. At 6 month intervals fresh
stocks were obtained from the liquid nitrogen freezer and old stocks
were discarded.
Walker 256 (W256), a rat carcinosarcoma tumour described previously as 
characteristic of poorly differentiated, highly glycolytic tumours 
was maintained in suspension culture. Cells were grown in flasks 
(Nunc, 75cm^ and 150cm^) containing F10:DMEM (50:50) supplemented with 
glutamine, 2mM and FCS, 10%.
Cells were maintained by routine passage as described for WIL. 
Passage was routinely carried out at 3 day intervals during which time 
viable cell number reached a maximum in each flask. Cells were 
harvested by decanting cells into sterile 30ml universal containers. 
Cells were sedimented in a bench top centrifuge at 160g (MSE
Instruments). Cell number and viability was determined as described 
for WIL. Cell viability routinely exceeded 90%. Fresh cultures were 
seeded at a dilution of 1:10 into fresh medium. At 6 month intervals 
stocks were discarded and fresh cultures were seeded from stocks 
obtained from the liquid nitrogen freezer.
Photographic Studies
Cells (WIL) plated into tissue culture flasks (25cm )^ were routinely 
photographed under phase contrast with a 35mm single lens reflex (SLR) 
camera attachment (Olympus C.K.2 Microscope; Olympus 0.M.2 SLR Camera, 
). Microscope settings gave magnification of X33 and X66. 
Plates were obtained with 35mm ASA 160 film. Exposure times were 
automatically adjusted for lighting conditions. Routinely exposure 
times were between 0.25 and 1 second at different aperture settings.
Cells were prepared for fluorescent photography as described in
Chapter 7 (p 110)• Fluorochrome uptake was examined with a polyvar
microscope with a 35mm camera attachment (Reichart Jung,Cambridge 
Instruments, Bar Hill, Carribsj .
^ For R6G as the riuorochrome the G-l-filter setting was used
(546nm). R6G, under aqueous conditions exhibits an absorption maximum
in the range 460nm to 560nm and emits in the range 530nm to 605nm,
(Loveland, 1970). Plates were taken with Ektachrome 35mm ASA 1600
film. Film exposure was automatically corrected for light conditions
and exposure times varied between 0.125 and 1.00 seconds. From
microscope settings, magnification was calculated at X225.
Estimation of Cell Growth Rates
Cells (WIL) were seeded onto 24-well plates at a concentration of 3 x 
104 cells per well in tissue culture medium described previously. 
Cells were allowed to attach and grow for 72 hours. Medium was then 
removed from plates and cells were incubated either in fresh medium 
(control) or in fresh medium containing drug. After 24 hours drug was 
removed and all plates were fed with fresh medium. Thereafter plates 
were fed daily. Cell number was determined daily in triplicate wells 
from all plates. Following treatment with trypsin, cell number could 
be determined with the Coulter Counter. Experiments were carried out 
for 7 to 8 days (Chapter 5).
Experiments described in Chapter 7 were modified as follows:
Growth medium consisted of Minimal Essential Medium (MEM) supplemented 
with FCS, 10% containing either glucose, 5.5mM and glutamine, 2mM or 
glutamine, 2mM only. Cell number was determined at 48 hour intervals 
as described previously. Experiments were continued for 14 to 16 
days.
Assay of Cytotoxicity
Chemosensitivity was determined by an assay recently established 
within the Department of Medical Oncology. The assay is based upon a 
method described by Mossman (1983) (see also Cole, 1986; Carmichael et 
al, 1987).
The assay is dependent upon the reduction of a tetrazolium dye, MIT 
(3-(4, 5-dimethylthiozolyl-2-yl)-2, 5 diphenyl-tetrazolium bromide) to 
a purple formazan product by live, but not dead cells. Cells are 
plated onto 96 wells and allowed to attach and grow. Cells are then 
exposed to cytotoxic drug for a fixed period of time. Drug is removed 
and cells are allowed to recover and divide. Surviving cells are then 
indicated following incubation with MTT. Formazan production is thus 
an endpoint to this assay.
Cells (WIL) were seeded onto the central 80-wells of 96-well plates at 
a density of 500 cells per well. Cells were incubated at 37°C in an 
atmosphere of 2% CO2, in air and allowed to attach and grow for 48 
hours. Rows 1 and 12 of each plate contained medium only. Medium was 
then removed and cells were fed with fresh medium, 0.2ml. Drugs were 
diluted in tissue culture medium. Drug, 0.05ml was added to cells in 
row 3 of the plate. The drug was then serially diluted along each row 
of the plate using 0.05ml aliquots. The procedure was continued upto 
row 10. Rows 2 and 11 were fed medium only and were used as controls. 
One of the drugs studied, lamprene, required solubilisation in DMS0 
prior to dilution in tissue culture medium. For this drug only 6 drug 
concentrations were used (rows 5 to 10). Cells in row 4 were fed with 
medium containing DMS0. Cells in row 3 were fed with medium and wells 
in row 2 were cell free, fed with medium containing lamprene (500uM). 
After 24 hours drug was removed from each plate. Plates were fed with
fresh medium on consecutive days thereafter. Three days after removal
of drug 0.05ml MIT, 5mg per ml in PBS was added to each well. Plates
were wrapped in foil and placed in a 2% CO2 incubator at 37 °C for 4
hours. Medium was removed and the formazan produced was solubilised
by addition of DMSO, 0.2ml. To each well was also added Tris-HCl
buffer (0.1M, pH 9.5), 0.025ml. All formazan present was as a single
species with an absorption maxima at 570nm. Formazan crystals were
dissolved as plates were subjected to gentle agitation on a plate
shaker (Titertrek, Flow Laboratories, Irvine, Scotland). Absorbance
was measured at a wavelength of 570nm with an ELISA plate reader 
Bromley,Kent).
(Biorad, a From each row of 8 wells, corresponding to a 
particular drug concentration a mean absorbance at 570nm was 
calculated and this was plotted against drug concentration. The 
amount of drug required to kill half the cells was determined as the 
concentration of drug required to reduce the absorbance of the wells 
to half that of the control, drug free, cells.
Experiments described in Chapter 7 were modified as follows. Cells 
were plated out at an initial cell density of 1000 cells per well. 
Exposure to drug was carried out for 24 hours (R6G) or 1 hour 
(oligomycin). Oligomycin was solubilised in ethanol, 100% and diluted 
in culture medium. The final concentration of ethanol was less than 
1% and was not toxic.
This assay is dependent upon a linear relationship between cell number 
and absorbance, for each cell line examined. A plot of absorbance 
verses cell number to show linearity of the assay is shown in figure 
2.1 (courtesy of Dr J A Plumb). From this plot a linear relationship
o
exists between absorbance and cell numbers ranging between 1 x 10° and 
20 x 103 cells.
A typical dose response curve for WIL exposed to R6G for 24 hours and 
recovery measured by the MIT assay after 3 days is shown in figure
o
2.2. At a drug concentration of 10 °M or less, no toxicity was
o c
observed. At drug concentrations between 1 x 10"°M and 5 x 10"°M the 
final absorbance per well is reduced. From this curve an ID^q value
33.
is obtained at the point where 50% of the absorbance value intersects 
the curve.
Total Cell Protein
Total cell protein was determined by the method of Lowry et al (1951). 
Cell protein was solubilised in sodium deoxycholate, 5%, prior to 
protein determinations as described by Wang et al (1985). Samples 
were stored at -20°C for subsequent analysis.
Total Cell DNA
Total cell DNA content was determined by the method of Le Pecq and 
Paoletti (1966) with modifications according to Karsten and 
Wollenburger (1972) and Gardner and Plumb (1979).
The method is based on the enhancement of the fluorescence of ethidium 
bromide by DNA. Cell homogenates are treated with pronase to remove 
histones and other proteins associated with DNA. Endogenous nuclease 
activity is also inhibited following cell disruption. RNA is removed 
from the sample by digestion with ribonuclease (RNAse) free of any 
deoxyribonuclease (DNAse) activity. Ethidium bromide intercalates 
with released DNA in a stoichiometric manner and can be measured at 
580nm following excitation of the sample at a wavelength of 360nm.
Fresh cell homogenates were prepared by suspending cells in sterile
6 -1distilled water at a concentration of 1 x 10° cells ml . Samples 
were homogenized in a Potter-Elvehjem type homogenizer (teflon on 
glass) with 20 to 30 strokes.
Reagents were as follows:-
Phosphate buffered saline (PBS):
g/L mM
CaCl2 6H20 0.196 0.90
KC1 0.200 2.70
kh2po4 0.200 1.50
MgCl2 6H20 0.100 0.50
NaCl 8.00 137
Na2 HP04 1.15 8.0
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Absorbance at 570nm following Formazan production by 
WIL expressed against concentration of R6G. For each 
drug concentration N « 8 + SEM. A typical dose 
response curve for WIL exposed to R6G for 24 hours. 
Formazan production was recorded 3 days after cell 
exposure to drug by the MIT assay. An ID^q value was 
obtained where the dotted line intersected the curve.
Buffer was adjusted to pH 7.5 with NaOH, 1M prior to making upto 
volume.
The following solutions were prepared just before use:- 
Pronase : Pronase, 6mg dissolved in PBS, 100ml
RNAse : RNAse, 20mg dissolved in distilled water, 1ml
DNA Standard : DNA, 5mg dissolved in saline, 0.9%, 100ml.
DNA solubilised at 4°C, 6 to 8 hours before use. 
Ethidium Bromide : Ethidium bromide, 2.5mg dissolved in PBS, 200ml.
Samples (0.2ml) were placed in pyrex test tubes in duplicate. To each 
tube was added PBS, 1ml, pronase, 0.8ml and RNAse, 0.04ml. Tube 
contents were mixed thoroughly and tubes were sealed with parafilm and 
incubated at 37°G for 60 minutes in a water bath. Ethidium bromide
(0.025mg in 2ml) was then added to each tube. Samples were read in a
r-, i . Beaconsfield,Bucks) .-
fluorescence spectrophotometer (Perkins-Elmer, ^ at an
excitation wavelength of 360nm and an emission wavelength of 580nm. A
standard curve was prepared with calf thymus DNA. DNA content was
determined from the regression line fitted to the standard curve. The
reaction was linear upto 10 micrograms of DNA.
Measurement of the Respiratory function of whole cells or 
isolated mitochondrial preparations
The respiratory activity of freshly isolated mitochondria or 
preparations of intact whole cells were measured by a polarographic 
method (Estabrook, 1967; Knapp, 1983).
The Clark-type oxygen electrode (Rank Brothers, Bottisham, Cambs) is 
summarised in figure 2.3. The electrode consisted of an airtight 
chamber enclosing a platinum electrode which is in contact with a thin 
teflon membrane. Dissolved oxygen in the chamber diffuses through the 
membrane and is reduced at the platinum surface. The other half cell 
incorporates a silver-silver chloride electrode. A salt bridge 
containing saturated potassium chloride completes the circuit. In 
stirred, air saturated aqueous solution at 30°C a current flows 
through the circuit which is proportional to the partial pressure of
Figure 2.3:
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oxygen in the solution. When the solution becomes anaerobic, i.e. all
the oxygen is utilised, the current falls to zero. The electrode was
calibrated with air saturated buffer to 80 to 90% full scale 
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of zero deflection, a few crystals of sodium dithionate was added to 
the chamber, depleting the oxygen contents. The dissolved oxygen 
concentration in aqueous buffer was. obtained from published tables 
(Forstner and Gnaiger, 1983). At 30°C, oxygen content was estimated 
at 236 nanomoles oxygen per ml air saturated buffer. At 37°C, oxygen 
content was estimated at 210 nanomoles oxygen per ml of air saturated 
buffer.
Parameters of Mitochondrial Function
The parameters of mitochondrial function used to assess rat tumour or 
rat liver mitochondrial preparations are defined as follows 
(Estabrook, 1967):
Oxygen Consumption = (chart recorder) slope x 236 x 2 x Total volume 
ng atoms min“^  (Recorder) in e^ectro<^ e
deflection in 
divisions
oxygen consumption x volume of mitochondria
ng atoms min x  introduced
protein content of 
volume introduced
Respiratory Control Ratio = Oxygen Consumption in State 3
Oxygen Consumption in State 4
ADP:0 ratio = ATP produced
Oxygen consumed
Since ADP consumed = ATP produced
and Oxygen consumed obtained from State 3 respiratory rate 
ADP:0 ratio = ADP consumed
Oxygen consumed
Oxygen Consumption =
. -1 -1ng atoms m m  mg x
protein
A typical trace of the respiratory activity of isolated rat liver 
mitochondria is shown in figure 2.4. Addition of isolated rat liver 
mitochondria to the oxygen electrode, show mitochondria respiring at a 
basal level . utilising endogenous substrates and ADP to respire. 
Addition of oxidisable substrate such as succinate enables 
mitochondria to use endogenous phosphate to undergo phosphorylation, 
although exhibiting a respiratory rate limited by availability of ADP. 
State 4 respiration describes this phenomenon. Subsequent addition of 
a known amount of excess ADP, enables phosphorylation hence oxygen 
consumption to occur unrestricted. ATP synthesis is coupled, to an 
increased oxygen consumption rate. This describes State 3 
respiration. Once the ADP is used up, State 4 respiration is 
regained. Oxygen consumption is reduced due to ADP depletion limiting 
phosphorylation.
Parameters of Whole Cell Respiratory Activity
The parameters of cell respiratory activity with which to assess 
intact rat hepatocytes or intact tumour cell preparations are as 
follows:
Oxygen consumption rate = (chart recorder) slope x (210 x 2) x Total 
ng atoms min"^ divisions min“  ^ Recorder volume
deflection e^ec” 
trode
Oxygen consumption rate = Oxygen consumption rate x Volume of cells
-1 -1 -1ng atoms min mg protein ng atoms min introduced______
or
. -1 -1ng atoms min ug DNA
protein/DNA 
content in 
volume introduced
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added sequentially at points indicated. Parameters of 
mitochondrial function were calculated as described in 
the text.
CHAPTER 3
A COMPARISON OF THE RESPIRATORY PROPERTIES OF MITOCHONDRIA FROM TUMOUR 
AND NON-TUMOUR CELLS
INTRODUCTION
In mammalian cells, the main site of cellular oxidative energy 
metabolism is the mitochondrion. A major aim of the studies described 
in this thesis is to identify specific antimitochondrial agents which 
might alter the energy metabolism of tumour cells. One way to achieve 
this aim was to study isolated mitochondria obtained from tumours and 
compare standard respiratory parameters with those of isolated 
mitochondria obtained from normal tissue. Thus an examination of 
mitochondrial metabolism would highlight differences between tumour 
and non-tumour organelles and could be exploited as a consequence. A 
critical assessment of the methods employed to obtain mitochondria 
from both tumour and normal tissues would determine whether such 
methods would be suitable for studying the behaviour of selective 
antimitochondrial agents.
An essential feature of such a study is a screening method whereby it 
would be possible to identify possible antimitochondrial agents for 
ultimate use in humans. Therefore it would be especially useful to 
identify compounds already in clinical use which may have tumour 
specific antimitochondrial activity. There is some evidence to 
suggest that antidepressants such as chloriinipramine (anafranil) and 
maprotiline (ludiomil) may have antimitochondrial activity (Wilkie and 
Delhanty, 1970; Wilkie, 1979). A second approach is to assess novel 
compounds which might have antimitochondrial activity, such as, for 
example, Rhodamine 6G. Attempts have been made in anticancer therapy 
to use novel inhibitors (Webb, 1966). The antimitochondrial agent 2,4 
Dinitrophenol has been used unsuccessfully in attempts to alleviate 
obesity(!) (Racker, 1976).
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Animal studies as a basis for selecting agents which would have 
potential as mitochondrial inhibitors of tumour cells are slow and 
give little indication as to the particular aspects of cell metabolism 
which are blocked. Techniques selected in this study enable the 
metabolism of intact tumour mitochondria to be examined, whereby a 
high degree of control may be exerted over organelle function. There 
can however be no critical assessment of the efficacy of a particular 
antimitochondrial at the level of the intact animal. The approach is 
admirably suited to obtaining data indicating the potential of a 
particular mitochondria inhibitor and whether it might then exert a 
selective action upon mitochondrial activity, hence energy metabolism 
of tumours. Ultimately, an examination of the effectiveness of the 
compounds that then show most promise must be examined in more complex 
systems, i.e. the intact cell or intact animal or human, where the 
degree of respiratory control that can be exerted is much less. It 
would then be possible to assess the possible therapeutic role such an 
agent might have in cancer chemotherapy.
Rat liver is the source of the most intensively studied mitochondria 
and has become the standard to which other mitochondrial preparations 
are compared. Mammalian liver has a high concentration of 
mitochondria (30 to 33% of liver protein) and the tissue can be easily 
homogenised to obtain isolated mitochondria with minimal damage 
(Schneider and Hogeboom, 1951; Johnson and Lardy, 1967; Gregg, 1972).
The experiments described in this chapter were designed to determine 
whether the ultrastructural and quantitative differences observed 
between tumour and non-tumour mitochondria are reflected in 
differences in respiratory function. Previous studies with 
mitochondria isolated from both rapidly growing, poorly differentiated 
hepatomas and slow growing, well differentiated hepatomas indicated 
that such mitochondria were capable of coupled respiration with normal 
phosphorylating capacity and respiratory control ratios ranging from 2 
to considerably more than 10 (Kaschnitz et al, 1976). Similar results 
have been obtained from mitochondria isolated from other tumours 
(Sordahl et al, 1969; Pedersen, 1978).
The parameters of respiratory function which may be compared when 
isolated mitochondria from each source are examined, provide 
information about energy metabolism in each type of organelle. 
Mitochondria may be supplied with different oxidisable substrates when 
incubated in the Clark-type oxygen electrode to determine which 
substrates can be utilised. The coupling of ADP phosphorylation to 
oxygen consumption can also be examined when preparations of isolated 
tumour mitochondria or normal mitochondria are incubated in the oxygen 
electrode (Estabrook, 1967; Gregg, 1972; Nakashima et al, 1984).
Models required for this study are mitochondria from a well charact­
erised normal tissue. As described previously rat liver mitochondria 
are the accepted standard as a source of 1normal1 isolated organelles. 
The respiratory activity of isolated mitochondria obtained from rat 
liver were thus selected for this study.
The Walker 256 (W256) rat carcinosarcoma exhibits growth charact­
eristics indicative of a highly glycolytic, poorly differentiated 
tumour. Previous studies have already shown that a significant delay 
in tumour growth can be achieved following administration of agents 
which are though to inhibit tumour cell energy metabolism, hence 
mitochondrial metabolism in vivo (Fearon et al, 1985a). Mitochondria 
were isolated from W256 tumours implanted subcutaneously in Wistar 
rats.
Isolated mitochondrial preparations from both liver and W256 tumours 
were examined with a polarographic oxygen sensor. The response to a 
variety of exogenous oxidisable substrates was determined from 
respiratory control indices, ADP:0 ratios and oxygen consumption 
rates.
Isolation of Mitochondria
All stages carried out at 4°C.
Solid Tumours 
Liver
1. Tissue minced, suspend in isolation 
medium (225mM Mannitol, 150mM Sucrose. 
400uM EGTA, 2mM MOPS, 0.5% BSA, PH7.2), 
25% W/V.
2. Homogenize 5 strokes (Teflon on glass).
3. Centrifuge 10 mins, llOOg.
Supernatant
Centrifuge 15 mins, 6780g.
'V'
Sediment
1. Resuspend in isolation medium to 
original volume.
2. Centrifuge 10 mins, llOOg.
Supernatant
Centrifuge 10 mins, 6780g.
vl/
Sediment
1. Wash pellet l-2x respiration medium 
(200mM Mannitol, 50mM Sucrose, lOmM 
NaH2P04, 20mM MOPS, PH 7.2).
2. Resuspend in 1ml respiration medium, 
keep on ice.
MITOCHONDRIA
Figure 3.1: A summary of the procedure used to obtain preparations of
isolated mitochondria from both rat liver and walker 256 
tumours.
METHODS
Animals
Rat liver mitochondria were prepared from female Wistar rats weighing 
between 200 and 300 grams. Prior to each experiment, animals were 
given food (SDS, Essex) and water adlibitum. Tumour mitochondria were 
isolated from W256 tumours grown subcutaneously in female Wistar rats. 
Animals were given food and water adlibitum prior to each experiment.
Preparation of Isolated Mitochondria
Isolated mitochondria were prepared essentially as described by 
Cummings et al, 1984 (see also Wehrle and Pedersen, 1982). The 
procedure for isolation of mitochondria is summarised in figure 3.1.
Animals were killed by cervical dislocation and tissues were rapidly 
removed. All subsequent steps were carried out at 4°C. Tissues were 
weighed and placed in isolation medium (25% weight : volume)
consisting of mannitol (225mM), sucrose (150mM), EGTA (400uM), MOPS 
(2mM) and bovine serum albumin (BSA, 0.5%). The pH of the medium was 
adjusted to 7.2 before use. Fat and connective tissue were removed 
with a fine pair of scissors. In the case of tumour, only regions of 
viable tissue contained in the outer rim of the neoplasm were 
included. Necrotic material from the core of the tumour was 
discarded. Tissue was minced in cold isolation buffer and washed 2 to 
3 times. The tissue was then suspended in fresh isolation medium and 
homogenised by means of a Potter-Elvehjem type homogeniser (teflon on 
glass) (Jencons Scientific, Bedfordshire). Five strokes were used. 
Differential centrifugation was carried out with a high speed 
refrigerated centrifuge (Sorvall RC-5B, Du Pont, Connecticut, USA) to 
obtain a mitochondrial pellet as follows. Homogenate was centrifuged 
for 10 minutes at llOOg and 4°C to obtain a cell supernatant 
containing cytoplasmic organelles. This was centrifuged for 15 
minutes at 6780g and the crude mitochondrial pellet was collected. 
Purification of the pellet was carried out to remove both nuclear and 
cytoplasmic contaminants (particularly lysosomal). The pellet was 
resuspended in isolation medium and centrifuged for 10 minutes at 
llOOg. The supernatant containing the mitochondrial fraction was
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centrifuged for 10 minutes at 6780g to obtain a relatively pure 
mitochondrial pellet. The pellet was then washed in respiration 
buffer consisting of mannitol (200mM), sucrose (50mM), NaH2P04 (10mM) 
and MOPS (20mM). The pH was adjusted to 7.2 prior to use.
Assay of Mitochondrial Protein
Protein content of the mitochondrial suspension was measured by the 
biuret method, essentially as described by Layne (1957).
Assay
Biuret reagent was prepared as follows:
Solution A 1.5g CuS04 5H20
6g K4 Na C4 H4 06 4H20 
Dissolved in 500ml distilled water
Solution B 10% (weight:volume) NaOH in distilled water 
300ml
Solution C lg KI solubilised in 10ml distilled water.
Solution A was mixed with Solution B. Stirring was continued and 
Solution C was added. The reagent was diluted to 1 litre with 
distilled water and stored at room temperature. This solution was 
stable for several months. Reagent was discarded when a red 
precipitate of oxidised copper formed in the solution. A standard 
solution of BSA (Cohn Fraction V), lOmg per ml was prepared. 0.1ml 
of the mitochondrial suspension was diluted to 1ml with distilled 
water. The suspension contained 1 to lOmg of protein. 4mls of biuret 
reagent was then added. The solution was mixed thoroughly and allowed 
to stand in glass test tubes at room temperature for 30 minutes. A 
standard curve containing BSA, 1 to lOmg was prepared. The assay 
blank contained lml distilled water and 4ml biuret reagent. The 
absorbance of samples and standards were read against distilled water 
at a wavelength of 550nm in a spectrophotometer. The reaction was 
linear up to lOmg of BSA. Unknowns were determined from the standard 
curve.
Measurement of Respiratory Activity
The respiratory activity of freshly prepared mitochondria were 
measured by a polarographic method as described in chapter 2. 1 to
2mg of mitochondrial protein (0.075 to 0.2ml of suspension) in a final 
volume of 3ml of respiration buffer, air saturated at 30°C was 
incubated in the electrode.
The final concentration of substrates included in the incubation were 
pyruvate (8mM) with malate (2mM), succinate (10mM) or B-OH butyrate 
(10mM). ADP (800 nanomoles) was added to stimulate respiration. 
Respiratory activity was measured following sequential addition of 
oxidisable substrates to isolated mitochondrial preparations in the 
oxygen electrode.
RESULTS
Respiratory Activities of Isolated Rat Liver Mitochondria 
Table 3.1 shows the respiratory control index, ADP:0 ratio and oxygen 
consumption rates for preparations of isolated rat liver mitochondria 
supplied with different oxidisable substrates following incubation in 
the oxygen electrode. Liver mitochondria were able to oxidise each of 
the three substrates supplied (malate/pyruvate, succinate arid B-OH 
butyrate). ADP:0 ratios for pyruvate and B-OH butyrate approached 3, 
while the ratio for succinate was close to 2. With all substrates 
utilised, oxygen consumption rates increased following stimulation 
with ADP (state 3 respiration). For both B-OH butyrate and 
malate/pyruvate the state 4 respiratory rate was similar prior to and 
after stimulation with ADP. However, state 4 respiratory activity 
with succinate, following ADP utilisation was much greater than the 
initial state 4 respiration rate.
Respiratory Activity of Isolated Walker 256 Mitochondria 
Table 3.2 shows the respiratory control index, ADP:0 ratio and oxygen 
consumption rates for preparations of isolated Walker 256 mitochondria 
incubated in the oxygen electrode following addition of different 
oxidizable substrates. Respiratory control indices for
malate/pyruvate and succinate as fuels were similar to values obtained 
with rat liver mitochondrial preparations. The ADP:0 ratio when 
mitochondria were supplied with malate/pyruvate was close to 3. 
However the ADP:0 ratio when succinate was supplied was greater than 
the expected value of 2. Oxygen consumption rates for both state 3 
and state 4 respiration were much lower than rates obtained with liver 
mitochondrial preparations when either succinate or malate/pyruvate 
were supplied as respiratory fuels. In both cases the state 4 
respiration rates prior to and after ADP stimulation were comparable. 
A striking feature of these results is the inability of W256 
mitochondria to metabolise B-OH butyrate.
Substrate RCI ADP:0 Ratio Oxygen Consumption 
ng atoms/mg/min
N
Malate / 2.92 3.14 State 4 18.03 (2.06) 23
Pyruvate (0.15) (0.10) State 3 57.28 (5.08) 23
State 4 22.13 (2.03) 23
Succinate 3.62 2.16 State 4 37.42 (2.79) 28
(0.11) (0.07) State 3 144.00 (8.05) 28
State 4 60.24 (17.20) 28
B-OH 3.05 2.94 State 4 15.10 (1.37) 11
Butyrate (0.16) (0.08) State 3 47.71 (4.72) 11
State 4 18.44 (1.89) 9
Table 3.1: Respiratory Control Indices (RCI), ADP:0 ratios and
oxygen consumption rates for isolated rat liver 
mitochondria incubated in the oxygen electrode at 30°C. 
Isolated organelles were supplied with Malate/pyruvate, 
succinate or B-OH butyrate. Oxygen consumption rates are 
expressed per milligram protein. Figures in parenthesis 
are standard errors of mean values recorded.
Substrate RCI ADP:0 Ratio Oxygen Consumption 
ng atoms/mg/min
N
Malate / 3.54 3.38 State 4 4.04 (0.65) 4
Pyruvate (0.64) (0.31) State 3 14.21 (1.20) 5
State 4 5.52 (1.67) 4
Succinate 3.17 2.88 State 4 10.27 (1.26) 4
(0.37) (0.35) State 3 32.10 (6.95) 4
State 4 13.58 (1.21) 4
B-OH Not Metabolized
Butyrate
Table 3,2: Respiratory Control Indices (RCI), ADP:0 ratios and
oxygen consumption rates for isolated W256 mitochondria 
incubated in the oxygen electrode at 30°C.
Isolated organelles were supplied with Malate/pyruvate, 
succinate or B-OH butyrate. Oxygen consumption rates are 
expressed per milligram protein. Figures in parenthesis 
are standard errors of mean values recorded.
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DISCUSSION
These results indicate that isolated rat liver mitochondria can be 
prepared which exhibit tight coupling between ADP phosphorylation and 
oxygen consumption. When compared with published work these results 
are consistent in terms of ADP:0 ratios and oxygen consumption rates 
(Johnson and Lardy, 1967; Kaschnitz et al, 1976). Mean RCI values 
were lower than published values, however individual determinations 
did approach the values of 4 and 5 quoted in the literature (Pedersen 
et al, 1978; Pedersen, 1978). It should be noted that published 
figures often indicate an individual result which authors claimed was 
representative of the data obtained from the study (Sordahl et al, 
1969; Pedersen et al, 1970). Mean values of the RCI obtained in this 
study for substrates succinate and B-OH butyrate were 3.62 and 3.05 
respectively. These values were well within the range of RCI values 
published by other groups (Kaschnitz et al, 1976).
Results obtained with W256 mitochondria also indicated that tightly 
coupled preparations could be obtained with a characteristic oxidative 
function. Although oxygen consumption rates expressed per mg protein 
were much lower than liver, ADP:0 ratios and RCI values compared 
favourably.
Comparison of the respiratory parameters with rapidly growing poorly 
differentiated hepatoma mitochondria for the substrate succinate 
indicated that RCI values were in agreement, but not ADP:0 ratio which 
was greater than values published (Kaschnitz et al, 1976; Pedersen et 
al, 1970; Sordahl et al, 1969). State 3 respiratory rates were lower 
than reported for hepatoma. Similar ADP:0 ratios for malate and RCI 
values of succinate and malate were reported with lymphoma 
mitochondria and Ehrlich ascites tumour mitochondria (Gregg, 1972; Wu 
and Sauer, 1967). State 3 respiratory rates were however, lower than 
reported for lymphoma. From sources quoted in the literature, the 
mean RCI values obtained for substrates malate/pyruvate and succinate 
of 3.54 and 3.17 respectively were within the range of published 
figures for tumour mitochondria and individual results compared 
favourably with data from the literature (Gregg, 1972; Wu and Sauer,
1967; Kaschnitz et al, 1976; Pedersen et al, 1970; Sordahl et al, 
1969).
Liver mitochondrial suspensions supplemented with succinate registered 
a state 4 respiratory rate which was not regained following complete 
utilisation of exogenous ADP. This implies that a contaminating 
ATPase was present in the preparation which was able to regenerate ADP 
for continued phosphorylation. A possible source of ATPase could have 
been mitochondria damaged during preparation in such a manner that the 
ATP synthase responsible for ATP synthesis was now operating in the 
reverse direction, proton flow being generated to stimulate ATPase 
activity. Yet coupling ADP phosphorylation to consumption of oxygen 
was still observed with substrates malate/pyruvate and B-OH butyrate. 
It is more likely that the higher state 4 respiratory rate resulted 
from an over estimate of the state 4 respiratory before a steady state 
had been reached. Thus complete ADP utilisation had not in fact 
occurred. Subsequent estimations of the state 4 respiratory with 
other substrates following ADP utilisation were more accurate because 
the state 3 respiratory rates were less and therefore, complete 
utilisation could be more precisely assessed.
W256 tumour mitochondrial preparations showed a higher than expected 
ADP:0 ratio with succinate. The value of 3 obtained was reproducible. 
In classical terms B-OH butyrate or malate/pyruvate are respiratory 
fuels which utilise the NAD-linked pathway of electron transport. The 
ratio of moles of ADP consumed to moles of oxygen consumed is 3:1 
which results, according to the chemiosmotic theory, from the 3 sites 
which protons can pass through the mitochondrial membrane and be 
utilised by the ATP synthase (Mitchell, 1976). Succinate however is 
an FAD linked substrate and electrons released following substrate 
utilisation feed into the electron transport pathway entering at a 
point further along the mitochondrial electron transport chain. The 
ratio of moles of ADP utilised to moles of oxygen consumed is only 
2:1. Results obtained with malate/pyruvate fit this model well. 
Results with succinate give a much higher ADP:0 ratio unlike other 
tumour mitochondria which have ADP:0 ratios of between 1 and 2 (Gregg, 
1972; Wu and Sauer, 1967; Kaschnitz et al, 1976; Pedersen, 1970;
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Sordahl et al, 1969). The ADP:0 ratio obtained when succinate was 
utilised as the respiratory fuel implies that the preparation may have 
been uncoupled somewhat. Low oxygen consumption rates with tumour 
mitochondria probably reflect the difference in protein content of the 
preparation rather than defects in oxygen utilisation. Rates obtained 
with hepatoma correlate more closely with liver as expected if protein 
content of both tissues were similar (Kaschnitz et al, 1976; Sordahl 
et al, 1969).
Other explanations for low oxygen uptake rates obtained with W256 
mitochondria as compared to liver mitochondria could also be possible. 
The preparations may have contained a low yield of viable organelles. 
It was not possible to assess the viability of the preparation 
incubated in the oxygen electrode. However a reduction in the size of 
the mitochondrial pellet was noted implying fewer mitochondria were 
present. To obtain a measurable response a 2 to 3 fold increase in 
the volume of suspension relative to the liver mitochondrial 
suspension was required. Alternatively tumour mitochondria may have a 
lower functional efficiency in terms of their ability to metabolize 
exogenous oxidisable substrates.
Tumour mitochondria are thought to be more fragile than organelles 
isolated from normal cells. This results from differences in 
mitochondrial membrane composition between normal cell and neoplastic 
cell organelles (Pedersen, 1978; Wehrle and Pedersen, 1982). Hence 
viable organelles are more likely to be destroyed during preparation 
of tumour mitochondrial suspensions. Furthermore uncoupling agents 
and membrane damaging agents present in the homogenate may also be 
responsible for reducing the viability of the preparation (Pedersen, 
1978; Wehrle and Pedersen, 1982).
W256 mitochondria were unable to oxidise B-OH butyrate. Other groups 
have documented both decreased and non-utilisation of B-OH butyrate as 
a respiratory fuel by isolated hepatoma mitochondria (Pedersen et al, 
1970; Kaschnitz et al, 1976; Nakashima et al, 1984). This is not 
thought to be a result of any defect in the electron transport 
pathways of tumour mitochondria. Instead it has been postulated that
defects in fatty acid oxidation and associated transmembrane shuttles 
prevent entry of fatty acid substrates into the organelle (Cederbaum 
and Rubin, 1976). B-OH butyrate is a ketone body Which under extreme 
conditions (e.g. starvation) is produced by the liver from fatty 
acids. It is as an energy source for utilisation in the brain and 
other tissues following depletion of carbohydrate sources (Tisdale, 
1982). In order to utilise B-OH butyrate several enzymes are required 
in the cell which enable the substrate to be converted to Acetyl CoA, 
a TGA cycle intermediate. The pathway proceeds as follows in 
mitochondria:
B-OH Butyrate — —  Acetoacetate --- Acetoacetyl CoA ---  Acetyl CoA
B-OH butyrate 3-0xo Acid Acetoacetyl CoA
Dehydrogenase CoA transferase Thiolase
[3-Hydroxybutyrate]
[Dehydrogenase ]
E.C. 1.1.1.30
(Williamson et al, 1971; Robinson and Williamson, 1980).
Recent evidence indicates that activities of both 3-0xo acid CoA 
transferase and acetoacetyl CoA thiolase are reduced in W256 cells. 
B-OH butyrate dehydrogenase activity does compare favourably with 
normal tissue (Tisdale and Brennan, 1983; Fearon et al, 1985(b)). Not 
all tumour tissues are depleted of these enzymes and expression of the 
3-0xo acid CoA transferase is found in other tumour cells including 
hepatoma (Tisdale and Brennan, 1983; Fenselau et al, 1976).
It is possible that cleaner preparations, obtained by alternative 
methods of purification might have resulted in mitochondria both from 
liver and tumour with greater viability which exhibited higher RCI 
values for example. In retrospect, with tumour organelle 
preparations, intactness of the individual components of the electron 
transport chain could have been assessed by addition of selective 
inhibitors of mitochondrial function with exogenous oxidisable
[Succinyl-CoA:] [Acetyl-CoA ]
[3-0xo-acid ] [transferase]
[CoA transferase]
E.C. 2.8.3.5 E.C. 2.3.1.9
substrates. Examples include inhibitors such as rotenone which 
inhibits NAD+-linked electron transport. Thus when administered with 
succinate the integrity of the FAD+-linked path could have been 
determined in tumour mitochondrial preparations (Chance and Williams, 
1956; Slater 1967).
The W256 carcinosarcoma is a poorly differentiated, highly glycolytic 
tumour. There are tumours which show varying degrees of 
differentiation and such tumours have normal or near normal 
mitochondria showing closer correlation in metabolic function to 
normal cell organelles (Pedersen, 1978).
The studies described in this chapter may be summarised as follows. A 
comparison of the respiratory properties of freshly isolated rat liver 
mitochondria and W256 tumour mitochondria reveal tightly coupled 
preparations which appear to be functionally intact. Certain 
metabolic differences are apparent, W256 mitochondria appear to be 
unable to metabolise B-OH butyrate lacking enzymes which enable 
utilisation of this substrate. However, mitochondria isolated from 
W256, a highly glycolytic poorly differentiated tumour do appear to be 
functional with respect to RCI and ADP:0 ratios. Lower rates of 
oxygen consumption may be attributed to low protein content of the 
suspensions rather than a defect in electron transport itself.
This type of study does not reveal much information about the 
integration of the mitochondrial pathways of energy metabolism into 
whole cell energy metabolism in tumours. Therefore the effects of 
antimitochondrial agents upon metabolism within this system could not 
assess any anaerobic compensation, essentially a cytoplasmic process. 
Whole cell energy metabolism, that is both glycolysis and 
mitochondrial energetic function can only be studied in the intact 
cell. Limited information is provided about mitochondrial metabolism, 
and little could be determined about the state of mitochondria in 
tumour tissue. In conclusion, for the amount of information obtained, 
this study would be unsuitable for screening antimitochondrial agents 
against tumour cell energy metabolism. A better approach might be to 
study energy metabolism in the intact cell. Although the degree of
control that can be exerted over the system in vitro, is less than 
over isolated mitochondria, the effect of antimitochondrial agents 
upon bioenergetic function in the intact tumour cell can be assessed. 
This approach is described in chapter 4.
CHAPTER 4
THE EFFECT OF POTENTIAL ANTIMITOCHONDRIAL AGENTS ON CELLULAR ENERGY 
METABOLISM
INTRODUCTION
The main aim of the studies described in this chapter is to identify 
compounds which may be used to selectively inhibit tumour cell energy 
metabolism leaving normal cell energy function relatively intact. By 
exploiting differences between the cellular energy metabolism of 
normal and neoplastic cells, it is hoped that antimitochondrial agents 
can be selected which will alter the bioenergetic function of tumour 
cell mitochondria at doses which will have little or no effect upon 
mitochondria within the intact normal cell.
Clearly the ultimate aim of the work described in this thesis is to 
inhibit tumour cell energy metabolism in the whole animal. However, 
the study of energy metabolism in man or even in animal tumour models 
is complex and hence the mode of action of a potential 
antimitochondrial would be very difficult to establish. In chapter 3 
an attempt was made to study the metabolism of isolated mitochondria 
from both normal and tumour cells. The study highlighted several 
problems with this approach and it was concluded that the model was 
unsuitable for the study of potential antimitochondrial agents. 
Although the whole cell is a more complex system it still has a number 
of advantages over the major complexity,;.; ;of the whole animal. Thus, 
the studies described in this chapter examine the effects of selective 
antimitochondrial agents on whole cell energy metabolism. The effect 
of potential antimitochondrial agents upon whole cell oxygen 
consumption in vitro as a measure of mitochondrial activity was 
investigated. Although substrate level depletions are harder to 
achieve with this model, any compensation of the anaerobic component 
of cell energy metabolism following exposure of cells to 
antimitochondrial agents may be investigated.
Whole cells may be obtained from two sources. Tumour cells may be 
obtained from either solid tumours grown up as xenografts in athymic 
mice or malignancies implanted in rats,following dispersion of tumours 
with collagenase. However, cells obtained by such methods not only 
contain quantities of necrotic cells, but also much stromal tissue, 
raising doubt as to the cell type responding to the drugs under 
investigation. Furthermore, contamination of the cell preparation 
with necrotic material is likely to occur. Pure tumour cell 
populations could however be obtained from continuous cultured cell 
lines. Such cells would be hanogeneous and representative of the 
original tumour albeit a specific subpopulation of cells obtained from 
the original tumour whose growth was favoured by culture conditions. 
The experiments described in this chapter examine the effects of 
antimitochondrial agents for any selective action these compounds 
might show on aerobic or anaerobic metabolism of tumour cells obtained 
from a tissue culture source.
Pathways which exist in cells for generating energy in the form of ATP 
are dependent to some extent on the availability of oxygen. Where 
oxygen availability is limited, cell ATP production occurs primarily 
by anaerobic glycolysis. A major byproduct of anaerobic metabolism is 
lactic acid which in the whole animal in vivo is rapidly removed from 
cells. Under aerobic conditions, ' cell ATP
production is generated largely through mitochondrial activity. 
Glycolysis generates the mitochondrial substrate pyruvate from hexoses 
and this in turn is used to generate mitochondrial ATP via TGA cycle 
activity and associated oxidative phosphorylation. A third pathway, 
the pentose phosphate pathway, associated both with glycolysis and 
mitochondrial pathways, exists for degradation of hexose carbon. The 
pentose phosphate pathway however is mainly used to generate reducing 
power in the extra mitochondrial cytoplasm as NADPH, to convert 
hexoses into pentoses for biosynthesis of nucleic acids and to 
complete oxidative degradation of pentoses converting them into 
hexoses which can subsequently enter the glycolytic sequence. It is 
not the main pathway for obtaining energy from oxidation of glucose in 
animal cells (Lehninger, 1975).
Both glycolytic and mitochondrial pathways do appear to be intact in 
tumour cells, whether tumour cells are characterised as poorly 
differentiated (chapter 1) or well differentiated (Pedersen, 1978).
Methods for examining glycolysis and mitochondrial bioenergetic 
function were selected from those which could be studied in the intact 
cell.
Glycolytic flux may be studied by monitoring activities of enzymes 
such as phosphofructokinase [E.C. 2.7.1.1] a key regulatory enzyme in 
the pathway. However, such an approach would require disruption of 
the cell and destruction of cell integrity (Guminska et al, 1986).
An alternative method applicable to whole, intact cells is to study 
the effect of drugs upon the metabolic endpoint of the pathway, i.e. 
lactate production following incubation of cells with drug (Racker and 
Spector, 1981; Nakashima et al, 1984).
Oxidative function in cells may be studied in isolated mitochondrial 
preparations or even submitochondrial particles consisting of some of 
the mitochondrial enzyme complexes. As described however, such 
methods would yield little information about whole cell oxygen 
metabolism. Early methods for studying mitochondrial function 
indirectly in either whole cell preparations or tissue slices relied 
upon manometric methods, which though accurate in determining 
respiratory function were not sensitive to slight functions in 
respiratory activity (Umbreit et al, 1972). A more accurate method, 
oxygen polarography which was sensitive to respiratory fluctuations 
became available for studying whole cell oxygen uptake (Estabrook, 
1967; Gregg et al, 1968). The effect of agents which altered cellular 
bioenergetic function could be studied following incubation of such 
agents with whole cell preparations in a Clark-type oxygen electrode 
(Knapp, 1983).
Cell types selected for this study were both neoplastic and non­
neoplastic in origin.
WIL, a non small cell lung tumour line is representative of a 
relatively slow growing malignancy with some degree of 
differentiation. The WIL tumour both as a cell line and in xenograft 
form from studies in vitro and in vivo has been shown to be very 
resistant to conventional chemotherapy (Merry et al, 1986; Merry et 
al, 1987). WIL grew as an anchorage-dependent monolayer under culture 
conditions as a continuous cell line in vitro. Preliminary studies 
with W256 grown as a solid tumour in Wistar rats indicate that this 
tumour does respond to novel forms of chemotherapy directed at tumour 
energy metabolism (Fearon et al, 1985(b)). The W256 carcinoma is 
representative of a rapidly growing poorly differentiated tumour which 
is very dependent upon aerobic glycolysis for continued growth. Under 
tissue culture conditions W256 cells grew as a suspension culture in 
vitro.
All continuous cell lines to some extent are transformed cells. In 
order to propagate over generations normal cells from animal sources 
will lose their normal phenotype and transform in culture (Ruddle 
1961; Yerganien and Leonard, 1961; Hayflick and Moorhead, 1961; Todaro 
and Green, 1963). Therefore a normal cell type for the purposes of 
this study had to be obtained from freshly isolated cells. One of the 
most well characterised cell types, whose metabolic, properties have 
been well documented are rat hepatocytes (Seglen, 1976; Lebrecque and 
Howard, 1976; Pogson et al, 1984). Freshly prepared rat hepatocytes 
were used as a source of non-neoplastic cells for the purpose of drug 
screening.
Studies described in this chapter were designed to evaluate the 
potential of proposed tumour specific antimitochondrial agents. 
Agents selected for this study included Rhodamine-6G (R6G). The 
rhodamine dyes, more specifically Rhodamine 1, 2, 3 (R123) have been 
shown to exert a selective cytotoxic effect against tumour cells with 
little effect upon normal cells (Bernal et al, 1982(b); Lampidis et 
al, 1983; Nadakavukaren et al, 1985). Other compounds included in the 
study were clofazamine (lamprene), chlorimipramine (anafranil), and 
maprotiline (ludiomil). All these compounds are in clinical use and 
are thought to show antimitochondrial activity in both higher and
lower eukaryote systems (Hughes and Wilkie, 1970; Wilkie and Delhanty, 
1970; Rhodes and Wilkie, 1973).
Compounds were screened for their effects upon whole cell oxygen 
consumption in tumour cell preparations, WIL and W256, as well as 
freshly prepared rat hepatocytes. Oxygen consumption rates were 
determined with a Clark-type oxygen electrode. A measure of the 
mitochondrial response to these agents could thus be obtained from 
such a study. The glycolytic component of cellular energy metabolism 
was assessed from the effect these agents had on whole cell lactate 
production, determined by an enzymatic method.
METHODS
Preparation of Isolated Rat Hepatocytes
Rat hepatocytes were prepared essentially as described by Seglen 
(1976) (see also Berry and Friend, 1969).
Female Wistar rats weighing between 200 and 300 grams were 
anaesthetised with ether and positioned on their back. An incision 
was made to expose the abdominal wall. Epidermal layers were 
separated from the abdomen wall with scissors and forceps. With fine 
tipped scissors, the abdomen was opened. The intestine was removed 
from the abdominal cavity and positioned to the left of the animal. 
The hepatic portal vein was identified and 3 loose ligatures were 
placed around the vessel. A 20 gauge Venflon Cannula (Viggo, Swindon, 
Wilts) was inserted into the vessel. Successful cannulation ensured 
that a flow of blood was observed along the length of the cannula as 
the needle was withdrawn, leaving the cannula in place. The cannula 
was secured with ligatures. The organ was cleared of blood by passing 
50ml of calcium-free modified Berry medium (KQ1 5.4mM, NaCl 140mM, 
MgS0^.7H20 0.8mM, Na^PO^ 0.8mM, Na HCO3 25mM, glucose 15mM adjusted 
to pH 7.4 (Berry, 1974). Buffer was supplemented with 25 
international units of heparin per ml buffer, to keep blood vessels 
dilated enabling continued perfusion of the organ. This heparinized 
medium was passed through the organ by two discharges of a 20ml 
syringe. An incision in the posterior vena cava enabled fluid to 
drain into the abdominal cavity. Modified Berry medium was 
equilibrated for 30 minutes prior to use and during perfusion with 
02:C02 (95:5) at 37°C. A flow rate of 20ml per minute was maintained 
by a peristaltic pump (Shuco Scientific Ltd, London). As blood 
drained from the organ, the tissue changed from red to brown in 
colour. A bubble trap ensured that microbubbles in the buffer did not 
accentuate perfusion damage. The liver was excised out of the 
abdominal cavity, taking care not to disturb the cannula. It was 
suspended on a 100 micron nylon mesh. The mesh was attached across a 
plastic funnel suspended above a reservoir of collagenase 0.5% 
(collagenase Type IV, Sigma) in modified Berry medium supplemented
with CaCl2 (5mM) equilibrated with C^rCC^ (95:5) and maintained at 
37°C.
Recirculation of collagenase through the organ was achieved by means 
of a 3 way tap in the perfusion circuit.
After 20 to 30 minutes, the organ was removed to a petri dish and 
fresh buffer perfused through it. The liver was gently disaggregated 
with two pairs of fine forceps. The resulting suspension was filtered 
twice through 100 micron nylon mesh into 30ml universal containers. 
The vessels were centrifuged in a bench top centrifuge (MSE, FSA, 
Loughborough, Leics) at between 3 to 5g for 5 minutes in order to 
sediment cells. The supernatant was discarded and cells were 
resuspended in F10:DMEM (50:50) containing 2mM glutamine, 10% foetal 
calf serum (FCS) and 0.5ug per ml deoxyribonuclease (DNAse). Addition 
of DNAse prevented cells from adhering to one another by means of DNA 
released from damaged cells. Cells were counted in a haemocytometer 
under a phase contrast microscope. Cell viability was determined by 
dye exclusion (Howard et al, 1973).
0.2% trypan blue was made up in phosphate buffered saline (PBS).
0.1ml of dye was added to 0.5ml of cell suspension. To this was added
0.5ml of PBS. Only preparations where cell viability was at least 60% 
were used for further studies.
Tumour Cell Lines
Tumour cell lines WIL and W256 were maintained in tissue culture in 
vitro as described in Chapter 2. Harvesting of WIL, grown as a 
monolayer in vitro was facilitated with trypsin as described in 
chapter 2. Trypsinised cells from each flask were pooled and 
resuspended in fresh F10:DMEM and placed in 30ml universal containers. 
Cell number was determined with a Coulter Counter. Cell viability was 
assessed by dye exclusion (0.02%) trypan blue) and viewed under phase 
contrast. Viability exceeded 95%.
W256 cells were maintained in vitro as described in chapter 2. 
Harvesting of W256 cells was carried out by decanting cells into
Tumour Cell Preparation
1. Walker 256 Rat carcinosarcoma grown in suspension culture
2. WIL Human lung tumour line grown as monolayers in culture 
Both lines maintained in F10:DMEM+ Glutamine* 10% FCS.
1. W256 cells sedimented at lOOOg and resuspended in medium
2. WIL cells trypsinised and resuspended in medium 
Viability determined by Trypan blue exclusion and cells 
counted in Coulter Counter.
Cells washed and resuspended in aerated Chance-Hess medium 
(154mM NaCl, 6.16mM KC1, 9.35mM Na2HP04, 1.65mM NaH2P04 PH 7.4) 
at a concentration of 1 x 10  ^cells per ml.
Measure Oxygen consumption of 1 x 10^ cell aliquots in 3 ml of 
respiration buffer (above) total volume supplemented with 
6mM Glucose in a Clarlc-type Oxygen electrode.
Figure 4.1 A summary of the procedure for preparing tumour cells for 
studies of whole cell oxygen uptake.
sterile 30ml universal containers. Cells were sedimented in a bench 
top centrifuge at 130g. Cells were resuspended in fresh medium. Cell 
number was determined with a Coulter Counter. Cell viability was 
assessed by dye exclusion (0.02%) trypan blue and viewed under phase 
contrast. Viability exceeded 90%. Cell preparation is summarised in 
Figure 4.1.
Total Cell Protein
Total cell protein was determined by the method of Lowry et al (1951) 
essentially as described in chapter 2.
Total Cell DNA
Total cell DNA content was assessed by the method of LePecq and 
Paoletti (1964) with modifications according to Karsten and 
Wollenburger (1972) and Gardner and Plumb (1979) as described in 
chapter 2.
Measurement of Cellular Respiratory Activity
Cellular respiratory activity was monitored by means of a Clark-type 
oxygen electrode (see chapter 2).
Cells were washed at least once in Chance-Hess respiration medium. 
This buffer consisted of NaC& 154mM, KC1 6.16mM, Na2HP04 9.35mM, 
NaH2P04 1.65mM, equilibrated to pH 7.4. Cells were resuspended in 
fresh buffer at a concentration of 1 x 1$ cells per ml.
Cells were incubated in a total volume of 3ml of air saturated medium
o 6at 37 C in the oxygen electrode at a concentration of between 5 x 10° 
and 1 x 10? cells per 3ml. The medium contained glucose (6mM). Drugs 
were introduced by means of a hamilton syringe once the rate of oxygen 
consumption was established. Cellular oxygen consumption rates were 
determined prior to drug addition and throughout the experiment in 
order to assess the viability of the preparation. Incubations were 
carried out for between 15 and 20 minutes. The oxygen uptake rate 
varied between preparations. In order to compare results between 
preparations the oxygen consumption rate in the presence of drug was 
expressed as a percentage of the rate prior to drug addition.
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Figure 4.2: Lactate production as nanomoles of lactate per mg protein 
for WIL expressed against time in minutes. The production 
of lactate by WIL is linear with time over a 40 minute 
period. For each time point duplicate results were 
recorded.
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Lactate Production Rates
Cells were prepared as described previously (chapter 2 p 29 )• Cells 
were resuspended in 3ml of fresh Chance-Hess medium at a concentration 
of 2.5 x 10^ cells per ml.
Cells were preincubated at 37°C with drugs in sealed 25ml pyrex flasks 
in a shaking waterbath for 10 to 15 minutes. Addition of glucose 
(6mM) stimulated glycolysis and the reaction was thus initiated. 
Incubations were continued for 30 minutes, during which time the rate 
of lactate production was linear (see figure 4.2). At 10 minute 
intervals 0.2ml samples were removed, placed in eppendorf tubes on 
ice. Cells were sedimented immediately at 160g by means of a bench 
top refrigerated centrifuge (Jouan, Saint Herblain, France). The 
supernatant was collected and stored at -20°C. 0.1ml samples were
assayed for lactate.
Lactate was measured by the method of Noll (1974) (see also Nakashima 
et al, 1984).
Assay Principle
The assay is based upon an enzymatic reaction which is linked to the 
reduction of NAD+ to NADH. The reaction is followed on a 
spectrophotometer at a wavelength of 340nm. In order to drive the 
reduction of NAD+ to NADH, when lactate is oxidized to pyruvate, the 
equilibrium conditions of the reaction must be shifted to the right. 
Pyruvate is used to transaminate glutamate to form L-alanine andrtrketo 
glutarate (2-oxoglutarate), a reaction catalysed by the enzyme 
glutamate pyruvate transaminase [L-alanine:2oxo-glutarate amino­
transferase E.C. 2.6.1.2]. Figure 4.3 summarises the procedure used 
and the basis of the reaction.
Estimation of Lactate
Samples (0.1ml) were placed in glass test tubes. Distilled water, 
2.1ml followed by glutamic acid, 0.67ml (525mM in NaOH, 1M) and NAD+,
0.1ml (28mM) was then added. 0.015ml of glutamate pyruvate
transaminase (GPT) stock suspension (L-alanine:2oxo-glutarate amino­
transferase E.C. 2.6.1.2, from pigheart, 80 international units per mg
Lactate Production
c.
1. 2.5 x 10° cells per ml suspended in 3ml aerated Chance-Hess medium 
in sealed flasks and a shaking water bath at 37°C.
2. Preincubate appropriate drug concentration with cells for 10-15 
minutes.
3. Add 6 mM glucose to start reaction.
Incubate for 30 minutes
1. At 10 minute intervals collect 200ul samples in eppendorf tubes at 
4°C.
2. Centrifuge immediately at 160g to sediment cells.
3. Collect supernatant, use lOOul samples for Lactate Assay.
Enzyme Reaction:
Lactate Dehydrogenase (LDH) / Glutamate Pyruvate 
Transaminase (GPT) system.
NAD+ NADH
Lactate *-------------- > Pyruvate
LDH
Glutamate + Pyruvate— — > L-alanine + 2-oxoglutarate
GPT
GPT pulls the equilibrium of the LDH reaction to the right.
Absorbance read in a Gilford spectrophotometer at 
X = 340nm detecting NAD+ + H— N^ADH.
Figure 4.3: A summary of the procedure for measuring whole cell 
lactate production in tumour cell and rat hepatocyte 
preparations.
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protein) was added to each tube. Tube contents were vortex mixed and 
the absorbance measured at a wavelength of 340nm in a spectrophoto­
meter. The spectrophotometer was set to zero with water. Final 
concentration of reagents in the cuvette were glutamate 122mM, NAD+ 
0.97mM and GPT 12 international units.
An assay blank was set up containing distilled water 2.2ml, glutamate 
0.67ml (525mM in NaOH, 1M), NAD+, 0.1ml (28mM) and ammonium sulphate, 
0.15ml (3.2M).
Ammonium sulphate was used in place of GPT such that the reaction 
could not proceed in the assay blank, equilibrium conditions for the 
net reaction being unfavourable.
0.010ml of lactate dehydrogenase (LDH) enzyme suspension (L-lactate- 
NAD oxidoreductase E.C. 1.1.1.27, 550 international units per mg 
protein from rabbit muscle) was added to each tube. Each tube thus 
contained 28 international units final concentration of LDH. Samples 
were mixed with vortex mixer and allowed to stand at room temperature 
for 30 to 60 minutes by which time all the lactate had been converted 
to alanine and 2-oxoglutarate. The absorbance of the samples was read 
at 340nm. The change in absorbance was used to determine the amount 
of lactate in each sample following correction by the blank. The 
blank contained all reagents except GPT. Ammonium sulphate to correct 
for turbidity of this enzyme preparation was added to this reaction 
mixture instead. Any reduction of NAD+ which took place without GPT 
could be corrected for. A standard curve was prepared with known 
concentrations of lactate in the range 0 to 160 nanomoles per tube. 
Lactate concentrations were determined from the regression line fitted 
to the standard curve (Figure 4.4). Total lactate production was 
expressed as nmoles lactate per mg of total cell protein or per 
microgram total cell DNA. The lactate production rate was determined 
from the slope of the regression line from a plot of the total amount 
of lactate produced against incubation time. Production rates are 
expressed as nmoles lactate per minute per mg protein or per microgram 
DNA.
60.
To ensure that drugs under investigation did not interfere in the 
enzymatic reaction in the samples of supernatant assayed, a series of 
control experiments were run. The minute quantities of drug in each 
sample did not interfere in the absorbance change registered at a 
wavelength of 340nm.
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Figure 4.4: Absorbance at 340nm expressed against nanomole amount of 
lactate standard used in the enzymatic determination of 
lactate. A linear relationship exists between absorbance 
and nanomole amounts of lactate up to 140 nanomoles. 
Duplicate determinations were recorded for each lactate 
concentration.
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Figure 4,5: The rate of oxygen consumption in intact W256 cells 
incubatedsin Chance-Hess Medium at 37°C. The reaction was 
started by addition of W256 cells (1 x 10^ ) to Chance-Hess 
medium, 2 ml (pH 7.4) in the presence of glucose, 6mM. 
After a steady state rate of oxygen consumption was 
attained, R6G, 15uM was added as indicated. Following a 
transient stimulation of the respiratory rate, a final 
steady state response was observed.
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RESULTS
Effects of Rhodamine 6G on Oxygen Consumption Rates
Figure 4.5 is a representative trace obtained with W256 cells 
incubated in the oxygen electrode. At T=0, W256 cells (1 x 10^ cells) 
are added to give a total volume of 3ml in the electrode. Cells 
respire exhibiting a control rate of oxygen consumption. Addition of 
15uM R6G causes a stimulation of respiration, with an increase in the 
rate of oxygen consumption. This is transient however, and a steady 
state inhibition of oxygen consumption occurs as shown by a rate of 
oxygen uptake which is less than the control rate.
Figures 4.6A and 4.6B show the rate of oxygen uptake by WIL and W256 
respectively following addition of R6G. Addition of R6G (2-20uM) to 
both WIL and W256 resulted in a transient stimulation of oxygen uptake 
which lasted for about 5 to 10 minutes. This stimulation of the 
respiratory rate increased with increasing concentrations of R6G. 
Following this initial stimulation oxygen consumption decreased for 
both cell lines (Figure 4.7). For WIL, the inhibition of oxygen 
uptake is dose dependent for concentrations of R6G between 1 and lOuM. 
No further inhibition is observed at a higher concentration of R6G. 
The inhibitory response of W256 to R6G is maximal at a concentration 
of lOuM. At higher concentrations R6G appears to be less toxic. 
Isolated rat hepatocytes exhibited a significant inhibition of oxygen 
consumption at R6G concentrations of greater than 20uM. At 
concentrations of R6G between 1 and 15uM a slight, but not 
significant, inhibition of oxygen consumption was observed.
Effect of Anafranil on Oxygen Consumption Rates
Cellular oxygen consumption in the presence of anafranil for the cell 
lines WIL and W256 are shown in Figures 4.8A and 4.8B. Anafranil 
(25uM) inhibited cellular oxygen consumption in both WIL and W256. 
Lower concentrations of anafranil showed only a very small inhibition 
of oxygen consumption. Concentrations of between 25uM and 200uM 
anafranil resulted in further inhibition of oxygen uptake.
APERCENT OF C O N TR O L
WIL N = 4 T 0 7 iS E M
UM R HO DAHINE
PERCENT OF CONTROL
W 256 N = 4 ± S E M200
100
RH0DAM1NE
Figure 4.6A and 4.6B:
The rate of oxygen uptake by WIL (Figure 4.6A) and W256 
(Figure 4.6B) respectively, measured in a Clark-type 
oxygen electrode following addition of R6G. Cells were 
incubated at a concentration of 1 x 10^ cells in Chance- 
Hess medium, 3ml at 37°C. Transient response, measured 
as percentage change of oxygen consumption following 
addition of R6G, 1 to 20uM, over a 5 to 10 minute 
period.
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Steady state rate of oxygen uptake by WIL, W256 and rat 
hepatocytes, measured in a Clark-type oxygen electrode 
following addition of R6G. Cells were incubated at a 
concentration of 1 x 10^ cells in Chance-Hess medium, 
3ml at 37°C. Steady state response measured as 
percentage change of oxygen consumption following 
addition of R6G, 2 to 20uM.
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Figure 4.8A and 4.8B:
Rate of oxygen uptake by WIL (Figure 4.8A) and W256 
(Figure 4.8B) respectively, measured in the oxygen 
electrode, following addition of anafranil. Cells were 
incubated at a concentration of 1 x 10  ^cells in Chance- 
Hess medium, 3ml at 37°C. Steady state response 
measured as percentage change of oxygen consumption 
following addition of anafranil, 10 to 200uM.
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Effect of Lamprene on Oxygen Uptake Rates
Figures 4.9A and 4.9B show the rate of oxygen uptake by WIL and W256 
respectively following addition of lamprene. Incubation of lamprene 
(1 - 50uM) with both WIL and W256 resulted in a transient stimulation 
of oxygen uptake which lasted for 4 to 5 minutes. This stimulation of 
the respiratory rate increased with increasing concentrations of 
lamprene when incubated with WIL. The dose dependent stimulation of 
oxygen consumption by lamprene is not observed for W256. Following 
this initial stimulation, oxygen uptake exhibited a steady state 
stimulation of the respiratory rate. The steady state response 
(figure 4.10) is slightly lower than the initial respiratory burst for 
both cell lines WIL and W256. The stimulation of oxygen consumption 
by lamprene is dose dependent for the cell line WIL, but not for W256. 
Although lamprene was solubilized in dimethyl sulphoxide (DMSO), the 
presence of DMSO had no significant effect on oxygen uptake rates by 
either cell line.
Effect of Ludiomil upon Rates of Oxygen Consumption 
Table 4.1 shows the rate of oxygen consumption following addition of 
ludiomil (1 - lOOuM) for both cell lines WIL and W256. The rate of 
oxygen consumption by cells was decreased in the presence of ludiomil 
and this decrease was dose dependent for both cell lines WIL and W256.
Lactate Production Rates
Effect of R6G upon the rate of lactate production
Table 4.2 shows the effect of R6G on the rate of lactate production by 
WIL, W256 and freshly isolated rat hepatocytes. Production rates are 
expressed with reference to both cellular protein and DNA content. In 
the presence of R6G, lactate production rates for both WIL and W256 
increased. When expressed either in terms of mg of cellular protein 
or micrograms of cellular DNA the production rate increased with 
increasing concentrations of R6G. However when rat hepatocytes were 
incubated in the presence of R6G (5 - 20uM) there was no significant 
increase in lactate production rates.
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Figure 4.9A and 4.9B:
Rate of oxygen uptake by WIL (Figure 4.9A) and W256 
(Figure 4.9B) respectively, measured in the oxygen 
electrode following addition of lamprene. Cells were 
incubated at a concentration of 1 x 10^ cells in Chance- 
Hess medium, 3ml at 37°C. Transient response measured 
as percentage of oxygen consumption following addition 
of lamprene, 5 to 50uM (WIL) or 5 to 25uM (W256).
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Rate of oxygen uptake by WIL and W256 measured in the 
oxygen electrode following addition of lamprene. Cells 
were incubated at a concentration of 1 x 10  ^ cells in 
Chance-Hess medium, 3ml at 37°C. Steady state response 
measured as percentage change of oxygen consumption 
following addition of lamprene, 2 to 20uM.
W256
CONDITIONS
OXYGEN UPTAKE 
ng atoms/mg/min
OXYGEN UPTAKE 
ng atoms/ug/min
PERCENT OF 
CONTROL
control 9.61 0.145 100
luM Ludiomil 9.61 0.145 100
control 11.08 0.167 100
5uM Ludiomil 9.35 0.141 84
control 10.01 0.151 100
lOuM Ludiomil 10.01 0.151 100
control 12.14 0.183 100
20uM Ludiomil 9.71 0.146 80
control 11.26 0.169 100
50uM Ludiomil 7.09 0.107 63
control 8.66 0.130 100
lOOuM Ludiomil 6.78 0.102 . 78
WIL
CONDITIONS
OXYGEN UPTAKE 
ng atoms/mg/min
OXYGEN UPTAKE 
ng atoms/ug/min
PERCENT OF 
CONTROL
control 8.29 0.349 100
luM Ludiomil 7.25 0.305 87
control 8.82 0.371 100
5uM Ludiomil 7.21 0.303 82
control 10.25 0.431 100
lOuM Ludiomil 8.20 0.345 80
control 12.58 0.529 100
20uM Ludiomil 8.05 0.338 64
control 6.36 0.267 100
50uM Ludiomil 3.90 0.164 61
Table 4.1: Rate of oxygen uptake by WIL and W256 measured in the
oxygen electrode following incubation with Ludiomil.
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Cells were incubated at a concentration of 1 x 107 cells 
in Chance-Hess medium, 3ml at 37°C. Steady state 
response measured as percentage change of oxygen 
consumption following addition of Ludiomil, 1 to lOOuM. 
Oxygen uptake rates expressed as ng atoms oxygen per 
minute per mg protein or per ug DNA.
LACTATE PRODUCTION
nmoles lactate per min per ug DNA
R6G 0 5 10 20
WIL 0.26 0.73 0.84 0.84
W256 0.58 0.85 1.0 1.04
Hepatocytes 0.1 0.1 0.1 0.14
nmoles lactate per min per mg protein
R6G 0 5 10 20
WIL 5.65 15.71 18.28 18.06
W256 14.13 20.51 24.11 25.28
Hepatocytes 3.62 4.08 3.61 5.04
Table 4.2: Rate of lactate production by WIL and W256 measured by an
enzymatic method following incubation with R6G. Cells 
were incubated at a concentration of 2.5 x 10  ^cells per 
ml in Chance-Hess medium, 3ml at 37°C, for 30 minutes in 
sealed flasks. Incubation medium sampled at 10 minute 
intervals. Samples assayed for lactate by an enzymatic 
method. Production rates expressed as nmoles lactate per 
min per mg protein or per ug DNA. Results are from 
individual experiments•
Effect of Lamprene on the rate of lactate production 
Lactate production rates by WIL and W256 incubated in the presence of 
lamprene are shown in Table 4.3. There was an increase in the rate of 
lactate production when cells were incubated with lamprene (5-30uM). 
The rate of lactate production increased with increasing drug 
concentration for both cell lines studied.
Effect of Anafranil on the rate of lactate production 
Table 4.4 shows the rate of lactate production in both cell lines WIL 
and W256 following incubation with anafranil (25-100uM). The lactate 
production rate was not affected by anafranil up to a concentration of 
25uM. At greater concentrations there was a slight stimulation of 
lactate production in both cell lines.
Effect of Ludiomil on the rate of lactate production 
Table 4.5 shows the rate of lactate production in WIL and W256 
following addition of Ludiomil (5-50uM). Ludiomil had no consistent 
effect upon the rate of lactate production (when incubated) with WIL. 
Incubation of W256 cells with ludiomil resulted in a reduction in the 
rate of lactate production. This effect was dose dependent and 
increasing the concentration of ludiomil decreased the rate of lactate 
production further.
1ACTATE PRODUCTION
nmoles lactate per min per ug DNA
Lamprene______0  5_______ 10_______20_______30__________ uM
WIL 0.09 0.36 0.21 0.25 0.37
W256 0.237 0.27 0.331 0.556 0.436
nmoles lactate per min per mg protein
Lamprene 0 5 10 20 30 uM
WIL 3.7 14.45 8.33 10.0 18.5
W256 13.68 15.63 19.16 32.16 25.20
Table 4.3: Rate of lactate production by WIL and W256 following 
incubation with lamprene. Cells were incubated at a 
concentration of 2.5 x 10^ cells per ml in Chance-Hess 
medium, 3ml in sealed flasks at 37°C for 30 minutes. 
Incubation medium was samples at 10 minute intervals. 
Samples were assayed for lactate by an enzymatic method. 
Production rates expressed as nmoles lactate per minute 
per mg protein or per ug DNA. Results are from individual 
experiments.
LACTATE PRODUCTION
nmoles lactate per min per ug DNA
Anafranil 0_______ 25_______50_______ 100_____ uM
WIL 0.30 0.33 0.22 0.99
W256 0.62 0.63 0.67 0.71
nmoles lactate per min per mg protein
Anafranil 0_______ 25_______50_______100_____ uM
WIL 3.20 3.53 2.33 10.62
W256 20.02 20.38 21.89 23.07
Table 4.4: Rate of lactate production by WIL and W256 following 
incubation with anafranil. Cells were incubated at a 
concentration of 2.5 x 10° cells per ml in Chance-Hess 
medium, 3ml in sealed flasks at 37°C for 30 minutes. 
Incubation medium was sampled at 10 minute intervals. 
Samples were assayed for lactate by an enzymatic method. 
Production rates expressed as nmoles lactate per minute 
per mg protein or per ug DNA. Results are from individual 
experiments.
LACTATE PRODUCTION
nmoles Lactate per min per ug DNA
Ludiomil 0 5 10 20 50 uM
WIL 0.85 0.69
W256 0.72 0.70
nmoles Lactate per min per mg protein
Ludiomil______ 0________5_______10_______20_______50__________uM
WIL 29 24 20 31 25
W256 50 49 41 38 32
0.58 0.89 0.71
0.58 0.56 0.46
Table 4.5: Rate of lactate production by WIL and W256 following 
incubation with ludiomil. Cells were incubated at a 
concentration of 2.5 x 10^ cells per ml in Chance-Hess 
medium, 3ml in sealed flasks at 37°C for 30 minutes. 
Incubation medium was sampled at 10 minute intervals. 
Samples were assayed for lactate by an enzymatic method. 
Production rates expressed as nmoles lactate per minute 
per mg protein or per ug DNA. Results are from individual 
experiments.
DISCUSSION
These results confirm that rates of whole cell oxygen consumption 
rates obtained for cultured cells compare well with previously 
published results (Gregg et al, 1968; Nakashima et al, 1984). The 
results show that the compounds studied are able to alter cellular 
energy metabolism. Incubation of tumour cells with R6G resulted in a 
marked inhibition of oxygen uptake. In contrast the rate of lactate 
production by the cells was significantly increased. The results 
suggest that R6G is inhibiting oxidative phosphorylation in both 
tumour cell types under study. The selective inhibition of aerobic 
metabolism, in tumour cells by R6G in vitro may be compensated for, in 
part, by an increase in the rate of lactate production hence the rate 
of anaerobic metabolism. Other workers have shown that the exposure 
of tumour cells to specific inhibitors of mitochondrial function
results in compensation by the anaerobic component of metabolism 
(Bickis and Quastel, 1965; Gregg et al, 1968; Racker and Spector,
1981). The effect of R6G upon oxygen uptake in freshly isolated rat
hepatocytes was also inhibitory, but at concentrations that were 
greater than were required for tumour cell inhibition. Furthermore 
lactate production was not affected by the R6G concentrations 
selected. This suggests that although R6G may exert a toxic effect 
upon hepatocyte energy metabolism, this may be the result of a 
generalised cytotoxic effect rather than a specific effect directed 
primarily at energy metabolism.
The effect of lamprene on cellular oxygen uptake in the neoplastic 
cell lines examined was stimulatory. It is possible that ATP
production and thus tumour cell mitochondrial activity was stimulated 
as a result of incubation with lamprene. However, results which show 
an increase in the rate of lactate production in WIL and W256 suggest 
that the anaerobic component of energy metabolism may be compensating 
for the inhibitory effect of lamprene on tumour cell mitochondrial 
activity.
Anafranil affected cellular oxygen consumption in WIL and W256 at 
concentrations 2 to 4 fold greater than R6G or lamprene. All effects
of the drug were inhibitory. Similar concentrations of anafranil have 
been shown to inhibit cellular respiration in both yeast and 
transformed fibroblasts (Hughes and Wilkie, 1970; Wilkie and Delhanty, 
1971). However, a clear increase in the rate of lactate production 
with both cell lines was not apparent. This implies, particularly 
with the high concentrations required to reduce cell oxygen 
consumption, that any reduction in mitochondrial activity was more 
indicative of a cytotoxic effect on tumour cell metabolism rather than 
a more specific effect upon tumour cell energy production.
Exposure of cells to ludiomil resulted in an inhibition of cellular 
oxygen consumption in both cell lines. However, there was no 
consistent effect upon the rate of lactate production.
It is probable that any antimitochondrial effect observed with 
ludiomil, like the response to anafranil, were part of a generalised 
cytotoxic effect upon cellular metabolism. If this were so, an 
expected reduction in anaerobic metabolism may not have been observed 
within the time limits of the experiment, although for the W256 cell 
line a reduction in lactate production was observed.
It has been suggested, from recent evidence, that the differential 
effects of rhodamine dyes on different cell types might be explained 
by specific species related uptake and binding characteristics of 
these dyes. The uptake and binding of rhodamine is characteristic of 
cell types from a particular species. Therefore comparisons of the 
effects of rhodamine on tumour cells from one species with normal 
cells from another species might be invalid (Summerhayes et al, 1982; 
Bernal et al, 1982(b); Nadakavukaren et al, 1985; Gupta and Dudani, 
1987).
In this study, comparison of results obtained with rat hepatocytes and 
either W256 (rat) tumour cells or WIL (human) cells indicate that in 
both comparisons R6G has an effect upon the energy metabolism of the 
tumour cells and not on that of the non malignant cell type. 
Furthermore evidence from other groups indicate that toxicity to 
rhodamine of human fibroblast cell or breast epithelial cell lines
obtained either from foetal or normal subjects is limited (Lampidis et 
al, 1983; Gupta and Dudani, 1987).
Clearly, the criticism that early studies did compare the effects of 
rhodamine on tumour and non tumour cells from different species is 
valid. However, results obtained from experiments described in this 
chapter and evidence cited in the literature indicate that rhodamine 
toxicity is selective to both rat and human tumour cells, and it is 
likely that this toxicity occurs at concentrations which appear to 
have little effect on normal cells.
The studies described in this chapter may be summarised as follows 
The effects of potential tumour selective antimitochondrial agents 
upon the energy metabolism of intact tumour and non tumour cells was 
examined. Two tumour cell lines WIL and W256 were compared with 
freshly isolated rat hepatocytes, a source of non malignant cells. Of 
the compounds investigated R6G, lamprene, anafranil and ludiomil all 
had inhibitory effects upon tumour cell energy metabolism. Lamprene 
and R6G. exerted their action at concentrations which were lower than 
anafranil and ludiomil. Furthermore the effect of anafranil and 
ludiomil upon cellular energy metabolism in tumour cells was thought 
to be part of a general cytotoxic action upon these cells, rather than 
a specific inhibition of tumour cell energy metabolism. The effects
of R6G were found to be selective at the concentrations used.
less
Furthermore there was \ inhibition of the cellular energy metabolism
of the non malignant cell type used in the study, relative to the 
I tumour cells .
In conclusion, both R6G and lamprene are compounds which appear to 
have potential as possible inhibitors of tumour cell mitochondrial 
function. However, the evidence presented in this chapter which might 
indicate this is indirect. The studies have established a screening 
system by which potential agents might be selected for further study. 
A more direct measure of whether these agents are inhibitors of 
mitochondrial function in tumour cells can be obtained only by direct 
comparison of the effects of R6G and lamprene on tumour cell 
bioenergetic function with known classical inhibitors of mitochondria. 
The experiments in chapter 5 describe this approach.
CHAPTER 5
POSSIBLE MECHANISMS OF ACTION BY WHICH RHODAMINE 6G AND LAMPRENE
INHIBIT TUMOUR CELL OXIDATIVE METABOLISM
INTRODUCTION
From studies described in Chapter 4, two compounds, R6G and lamprene 
were identified which altered oxygen uptake in isolated cell 
preparations. It was concluded that this was probably due to 
interference with mitochondrial function and at the concentrations 
used, this alteration of respiratory activity was shown to be 
selective for tumour 'cells. If the mechanism by which respiratory 
activity was altered were known, specific defects in tumour 
mitochondrial metabolism might be identified. Such defects could then 
be exploited and might lead to the development of compounds designed 
specifically to inhibit tumour mitochondrial function.
One approach to the study of mitochondrial oxidative function involves 
the use of specific j inhibitors which block electron transport in 
mitochondria at certain points along the respiratory chain. In order 
to determine whether R6G and lamprene exert an action similar to 
classical inhibitors of mitochondrial function, it is necessary to 
understand the pathways by which cellular energy, in the form of ATP, 
is generated and how,1 following titration with specific inhibitors, 
these pathways might be defined.
Generation of ATP by normal mammalian mitochondria is dependent upon
I
the integrity of the electron transport system which allows oxidation 
of nutrient carbon sources to be coupled to the synthesis of ATP. 
Following breakdown of pyruvate or other sources of carbon (e.g. 
amino-acids such as glutamine) via the TCA cycle, reducing potential 
is generated in the form of NADH2 and FADH2. Oxidation of these 
intermediates is achieved along the mitochondrial electron transport 
chain, summarised in figure 5.1. Components of the chain are
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Figure 5.1s The complexes of the respiratory chain shown 
schematically together with the direction of electron 
flow along the chain (Prebble 1981).
intimately associated with the inner mitochondrial membrane. Tumour 
cells both from slow growing, well differentiated tumours and 
from rapidly growing, poorly differentiated tumours are thought to 
contain all the appropriate carriers required to carry out electron 
transport (Pedersen, 1978).
The electron transport chain can be dissected into regions. This is 
achieved by the use of specific inhibitors of mitochondrial 
metabolism. The combined use of different inhibitors has led to the 
elucidation of steps in the respiratory chain leading to the reduction 
of molecular oxygen (Slater, 1967; Lehninger, 1975; Prebble, 1981; 
Saier, 1987). With these well established inhibitors of mitochondrial 
function, it might be possible to identify how the potential 
antimitochondrial agents, R6G and lamprene inhibit respiratory 
function and subsequently identify points along the mitochondrial 
pathway at which these agents act.
The studies described in this chapter were designed to examine how 
inhibitors of tumour cell oxidative function exerted their action. In 
Chapter 4 it was shown that R6G and lamprene altered cellular oxygen 
uptake presumably by their action on mitochondrial function in tumour 
cell preparations. Furthermore there was some indication that this 
action is selective to tumour cells and is not a result of a general 
cytotoxic action upon ! tumour cell metabolism. If the mechanism by 
which R6G and lamprene inhibit tumour cell metabolism is understood, 
then it may be possible to identify potential sites and agents which 
would increase the selectivity of this approach.
There are two mechanisms by which an antimitochondrial agent may act. 
Either it may interfere with mitochondrial function impairing the 
organellefs ability to perform its* metabolic function. Alternatively 
it may inhibit mitochondrial biogenesis thus altering the ability of 
the organelle to reproduce itself. The present study is concerned 
with inhibition of mitochondrial function with classical mitochondrial 
inhibitors. Such inhibitors may be classified into three separate 
types; uncoupling agents, inhibitors of ADP phosphorylation and 
inhibitors of electron transport.
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Uncoupling agents cause dissociation of electron transport with the 
associated consumption of oxygen from phosphorylation of ADP to ATP. 
Oxygen consumption occurs at an unrestricted rate since the electron 
transport chain is no longer limited by the availability of ADP. 2, 4 
Dinitrophenol (DNP) is a classic uncoupler. This compound dissipates 
the proton gradient required for ATP formation and the inner 
mitochondrial membrane is made permeable to protons (Slater, 1967; 
Libermann et al, 1969; Heytier, 1979; Prebble; 1981).
Inhibitors of phosphorylation inhibit the conversion of ADP to ATP. 
In well coupled preparations, where oxygen consumption is indicative 
of phosphorylation, any block on ATP synthesis would be reflected in 
the reduced rate of cellular oxygen consumption. Oligomycin an 
inhibitor of phosphorylation blocks the mitochondrial ATP synthase 
responsible for harnessing proton generated energy to synthesize ATP 
(Slater, 1967; Shaw, 1967; Harold, 1972; Senior, 1979; Prebble, 1981).
Electron transport chain inhibitors interfere with the transfer of 
electrons between carriers of the mitochondrial electron transport 
chain. Examples of such inhibitors include rotenone and antimycin. 
Rotenone is thought to interfere with the ability of NADH2 to transfer 
electrons to ubiquinone. Inhibition is at the site of the NADH 
dehydrogenase enzyme complex I [E.C. 1.6.99.3]. Antimycin blocks 
electron movement between cytochromes b and cl. Inhibition is thought 
to be at the site of the ubiquinone-cytochrome C reductase complex III 
(ubiquinol:ferricytochrome-C oxidoreductase, E.C. 1.10.2.2). The 
compound is thought to bind to cytochrome b preventing further 
electron transfer (Slater, 1967; Rieske, 1967; Harold, 1972; Singer, 
1979; Prebble, 1981). Figure 5.2 summarizes inhibitors of 
mitochondrial oxidative function.
The effects of classical inhibitors of mitochondrial function upon the 
metabolism of the intact cell has been well established (Bickis and 
Quastel, 1965; Gregg et al, 1968; Gregg, 1972; Olivotto and Paoletti, 
1981; Backer et al, 1982; Nakashima et al, 1984).
70.
The cell types selected for this study have been described in some 
detail in previous Chapters (3 and 4). WIL, a non small cell human 
lung tumour line, shown to be resistant to conventional forms of 
chemotherapy was selected from a tissue culture model in vitro. W256, 
a rodent carcinoma cell line was obtained from a tissue culture 
source. This tumour, from studies conducted upon tumour implanted in 
animals does appear to respond to novel chemotherapies directed at 
tumour cell energy metabolism (Fearon et al, 1985'(a)). Isolated rat 
hepatocytes were obtained and used in these experiments to determine 
whether tumour cell selectivity applied to the antimitochondrial 
agents under study. Hepatocytes are a well defined experimental model 
in vitro for studying the action of drugs upon the metabolism of 
normal cells.
From studies in chapter 4, it was observed that both R6G and lamprene 
stimulated tumour cell oxygen consumption. It was unclear, however, 
whether this action represented a stimulation of ATP synthesis, by 
mitochondria or an uncoupling of respiration from ATP synthesis. The 
experiments described in this chapter were aimed at resolving this and 
confirming the mechanism of action of both of these compounds. In 
order to do this, it was necessary to determine whether preparations 
of tumour cells responded to classical inhibitors of mitochondrial 
function in the oxygen electrode, i.e. that respiratory activity was 
coupled to phosphorylation of ADP and could be uncoupled or inhibited 
with agents such as DNP, oligomycin, antimycin and rotenone.
With whole cells, examination of mitochondrial function is more 
difficult in that substrate level depletions are far harder to 
achieve. Therefore, parameters such as P : 0 ratios cannot be 
accurately assessed, | nor can acceptor control ratios, involving 
control of respiration by ADP. However, control of respiration 
induced by oligomycin can be investigated and this type of respiratory 
control is referred to as oligomycin-induced respiratory control. 
Addition of oligomycin to a fresh cell preparation reduces the 
respiratory rate to a level comparable to the State IV rate of intact 
mitochondria. Addition of DNP reopens the mitochondrial membrane, 
rendering it leaky to protons and results in stimulation of
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Figure 5.2 : Inhibitors of oxidative phosphorylation.
Schematic representation of points on the electron 
transport chain at which inhibition occurs (Prebble, 
1981).
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respiration back to State III (Pedersen et al, 1978; Nakashima et al, 
1984). Respiratory control indices obtained in this manner give some 
indication as to the respiratory capacity of a particular cell 
preparation and together with cellular oxygen consumption rates 
indicate to what extent antimitochondrial agents would influence 
respiration. Considerable evidence exists, which indicates that R6G 
might inhibit cellular bioenergetic function either by inhibiting 
translocation of adenine nucleotides across the mitochondrial 
membrane, altering the proton flux across the membrane and/or 
uncoupling phosphorylation from electron transport (Gear, 1974, Higuti 
et al, 1980; Conover and Schneider, 1981). Lamprene which shows some 
structural similarities to R6G has also been reported to have 
antimitochondrial activity (Rhodes and Wilkie, 1973). Other agents 
included in this study were anafranil (Cloimipramine hydrochloride) 
and ludiomil (maprotiline hydrochloride).
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METHODS
Isolated rat hepatocytes were prepared as described previously 
(Chapter 4). Suspensions of hepatocytes, WIL tumour cells and W256
tumour cells were obtained as described in Chapters 2 and 4.
Measurement of Cell Respiratory Activity
Cell oxygen consumption was determined following incubation of cells 
in a Clark-type oxygen electrode as described in Chapter 2. Total 
cell protein was determined by the method of Lowry et al (1951). 
Total cell DNA. was also determined as described in Chapter 2.
Characterisation of each cell preparation with classical inhibitors of 
mitochondrial function were carried out as follows. Cells were 
incubated in the oxygen electrode. A basal, control oxygen 
consumption was recorded over a 5 minute period. DNP was then added 
and the steady state response measured for 5 minutes. Oligomycin, was 
added for 5 minutes followed by antimycin or rotenone, for 2 to 3 
minutes. A second characterisation procedure was carried out upon a 
fresh preparation of cells. A basal oxygen consumption rate was 
recorded for a fresh preparation of cells for 5 minutes. Oligomycin 
was added and the oxygen uptake rate recorded for a further 5 minutes. 
DNP was then added for 5 minutes followed by antimycin or rotenone for 
2 to 3 minutes.
The antimitochondrial agents under study R6G, lamprene, anafranil and 
ludiomil were introduced into this system to determine if they 
exhibited respiratory inhibition or uncoupled respiration from 
phosphorylation. Drug concentrations were limited to lOuM as 
determined by previous screening experiments (Chapter 4). A basal 
oxygen uptake rate was recorded for fresh cell preparations incubated 
in the oxygen electrode for 5 minutes. Experimental drug was added 
and the oxygen consumption rate recorded for 5 minutes. Oligomycin 
was then incubated with cells for 5 minutes followed by antimycin or 
rotenone for 2 to 3 minutes. A second preparation of cells was 
incubated in the oxygen electrode. The basal rate of oxygen 
consumption was recorded for 5 minutes. Oligomycin was added and the
oxygen uptake rate was measured for 5 minutes. Experimental drug was 
added and the oxygen consumption rate was recorded for 5 minutes 
followed by addition of antimycin or rotenone to cells for 2 to 3 
minutes.
Although experiments were repeated 2 to 4 times, in order to relate 
each individual response of drug to control, results from single 
experiments are shown. Final concentrations obtained in the oxygen 
electrode were DNP lOuM, oligomycin 4.2uM or 5uM, antimycin 5uM and 
rotenone 3uM.
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Figure 5.4: The effect of sequential addition of antimitochondrial
agents upon the basal rate of oxygen uptake expressed 
as per cent of control in intact preparations of WIL. 
Following characterisation of fresh cell preparations 
with classical antimitochondrial agents DNP, oligomycin 
and rotenone (A and B), the effect of R6G upon the 
basal rate of oxygen uptake (C) and the oligomycin 
inhibited rate of oxygen uptake (D) in WIL was 
assessed. The dual response of cells to R6G is denoted 
by Rl and R2. An RCR value of 6.2 was obtained with 
this preparation.
RESULTS
Effect of Rhodamine 6G on the oxygen uptake- of cells following
manipulation with classic antimitochondrial agents 
Figure 5.3(A) shows the effect of sequential addition of DNP,
oligomycin and rotenone to a fresh preparation of tumour cells (WIL) 
incubated in the oxygen electrode. Addition of DNP (10uM), increased 
the basal rate of oxygen consumption by 20% to 30%. Subsequent 
addition of oligomycin (4.2uM), decreased the oxygen uptake rate by 30 
to 40% of that in the presence of DNP. Rotenone (3uM); inhibited
oxygen uptake completely. Figure 5.3(B) shows the effect of
sequential addition of oligomycin, DNP and rotenone to a fresh 
preparation of tumour cells (WIL). Addition of oligomycin (4.2uM) 
decreases the basal rate of oxygen uptake by about 80%. Addition of 
DNP (lOuM), stimulated oxygen consumption to a value within 10% of the 
basal rate. Oxygen consumption is completely inhibited following 
sequential addition of rotenone (3uM).
Addition of DNP (Figure 5.4A) to a fresh preparation of WIL stimulated 
oxygen consumption to a rate 40% greater than the basal rate. 
However, addition of oligomycin (4.2uM) to this preparation reduced 
oxygen consumption to about 50% of the basal .rate. Oxygen uptake was 
completely inhibited following addition of rotenone (3uM). When 
oligomycin was added to a fresh preparation of WIL, oxygen uptake was 
reduced by 80% (Figure 5.4B). Subsequent addition of DNP increased 
oxygen consumption to that of basal rates. Addition of rotenone (3uM) 
completely abolished oxygen uptake by WIL. Addition of R6G (lOuM) to 
a fresh preparation of WIL cells resulted in an initial increase in 
the rate of oxygen consumption to 40% above that of the basal rate 
(Figure 5.4C). Subsequently the oxygen consumption rate was reduced 
to a steady state value of about 75% of the basal rate. Oligomycin 
addition resulted in a further decrease in the oxygen uptake rate by 
10%. Oxygen consumption is abolished following addition of rotenone 
(3uM). Figure 5.4D shows the effect of addition of R6G to an 
oligomycin inhibited preparation of WIL. Initially R6G increased 
oxygen consumption to about 140% of basal values. This effect was 
transient and after between 5 to 10 minutes oxygen consumption was
reduced to a final steady state value of approximately 70% of the 
control oxygen uptake. Oxygen consumption was fully inhibited with 
rotenone (3uM).
Addition of DNP (lOuM) to a fresh preparation of W256 tumour cells 
(Figure 5.5A) results in a stimulation of oxygen uptake to 35% above 
basal rates. The addition of oligomycin (4.2uM) to this preparation 
reduced oxygen consumption to only about 30% of the basal rate. 
Oxygen uptake was fully inhibited following addition of rotenone 
(3uM). When oligomycin (4.2uM), was added to a fresh preparation of 
W256 cells, oxygen uptake was reduced by 75% (Figure 5.5B).
Subsequent addition of DNP (lOuM) increased the oxygen consumption 
rate to within 7% of the basal rate. Rotenone (3uM) however,
completely inhibited cellular oxygen uptake.
Addition of R6G (10uM), to a fresh preparation of W256 cells resulted 
in an initial increase in the rate of oxygen consumption by 3% (Figure 
5.5C). However, the oxygen consumption rate subsequently decreased to 
70% of the basal rate. Addition of oligomycin (4.2uM), reduced the 
rate of oxygen uptake only by a further 23%. Oxygen consumption is
completely inhibited following addition of rotenone (3uM). Figure
5.5D shows the effect of adding R6G (lOuM), to an oligomycin inhibited 
preparation of W256 cells. Oxygen consumption was stimulated by 25% 
reaching 40% of the basal rate. However, this response was transient, 
lasting for between 5 to 10 minutes. Cellular oxygen uptake rates 
decreased to the same value as the oligomycin inhibited rate, 35% of 
the basal uptake rate. Rotenone (3uM) abolished the response.
The effect of addition of DNP, oligomycin, rotenone and R6G to fresh 
preparations of rat hepatocytes is shown in Figure 5.6. DNP (lOuM) 
stimulated oxygen consumption rates of fresh cell preparations by 15% 
(Figure 5.6A). Oligomycin (5uM) reduced this response by only 30%. 
Antimycin (5uM) inhibited cellular oxygen uptake completely. 
Antimycin in place of rotenone with freshly prepared hepatocytes was 
more effective at reducing cell oxygen consumption. Oligomycin 
(4.2uM) when added to fresh preparations of rat hepatocytes reduced
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Figure 5*5: The effect of sequential addition of antimitochondrial
agents upon the basal rate of oxygen uptake expressed 
as percent of control in intact preparations of W256.
Following characterisation of fresh cell preparations 
with classical antimitochondrial agents DNP, oligomycin 
and rotenone (A and B), the effect of R6G upon the 
basal rate of oxygen uptake (C) and the oligomycin 
inhibited rate of oxygen uptake (D) in W256 was 
assessed. The dual response of cells to R6G is denoted 
by Rl and R2. An RGR value of 3.6 was obtained with 
this preparation.
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Hie effect of sequential addition of antimitochondrial 
agents upon the basal rate of oxygen uptake expressed 
as percent of control in freshly isolated preparations 
of rat hepatocytes.
Following characterisation of fresh cell preparations 
with classical antimitochondrial agents DNP, oligomycin 
and rotenone (A and B), the effect of R6G upon the 
basal rate of oxygen uptake (C) and the oligomycin 
inhibited rate of oxygen uptake (D) in rat hepatocytes 
was assessed. An RCR value of 1.4 was obtained with 
this preparation.
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cell oxygen consumption by 50% (Figure 5.6B). DNP (lOuM) stimulated 
cell oxygen consumption to within 30% of basal rates. Antimycin (5uM) 
almost completely inhibited cellular oxygen uptake, reducing oxygen 
consumption to 10% of basal rates. Addition of R6G (10uM) to fresh 
preparations of rat hepatocytes stimulated respiration by 30% above 
basal rates (Figure 5.6C). Oligomycin (5uM) had no effect upon this 
response, although antimycin (5uM) inhibited all respiratory activity.
Adding R6G (lOuM) to an oligomycin inhibited preparation elicited a 
stimulation of respiratory activity to within 10% of the basal rate 
(Figure 5.6D). Antimycin sensitivity was indicated by antimycin 
mediated inhibition of respiratory activity.
Effect of Lamprene on the oxygen uptake of cells following 
manipulation with classic antimitochondrial agents
The effect of sequential addition of DNP, oligomycin and rotenone to 
fresh preparations of WIL in the oxygen electrode are shown in Figure 
5.7A. Addition of DNP (lOuM) results in stimulation of the oxygen 
uptake rate by 10%. Oligomycin (4.2uM) reduces the oxygen consumption 
rate to only 65% of the basal rate. Rotenone (3uM) fully inhibited 
oxygen consumption in this preparation. Oligomycin (4.2uM) when added 
to fresh preparations of WIL reduced oxygen consumption by 80% (Figure 
5.7B). DNP (lOuM) stimulated oxygen consumption to within 30% of the 
basal rate. Rotenone (3uM) fully inhibits the oxygen uptake rate. 
Lamprene (lOuM) when added to a fresh preparation of WIL elicits a 
stimulation of the oxygen uptake rate to above 25% of the basal rate 
(Figure 5.7C). Oligomycin (4.2uM) reduces this by only 15% above the 
basal rate and the oxygen uptake rate is completely inhibited with 
rotenone (3uM). Addition of lamprene (lOuM) to an oligomycin 
inhibited preparation (Figure 5.7D) caused an increase in the rate of 
oxygen consumption uptake to within 10% of the basal rate. Rotenone 
(3uM) fully inhibited oxygen consumption in this preparation.
The sequential addition of DNP, oligomycin and rotenone to fresh 
preparations of W256 cells is shown in Figure 5.8A. DNP (lOuM) 
stimulated oxygen consumption to 50% above basal rates. Addition of
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Figures'.8.J The effect of sequential addition of antimitochondrial 
agents upon the basal rate of oxygen uptake expressed 
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Following characterisation of fresh cell preparations 
with classical antimitochondrial agents DNP, oligomycin 
and rotenone (A and B), the effect of lamprene upon the 
basal rate of oxygen consumption (C) and the oligomycin 
inhibited rate of oxygen uptake (D) in W256 was 
assessed. An RCR value of 276' was recorded for this 
preparation.
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Figure 15.7i The effect of sequential addition of antimitochondrial 
agents upon the basal rate of oxygen uptake expressed 
as percent of control in intact preparations of IWIL S. 
Following characterisation of fresh cell preparations 
with classical antimitochondrial agents DNP, oligomycin 
and rotenone (A and B), the effect of lamprene upon the 
basal rate of oxygen consumption (C) and the oligomycin 
inhibited rate of oxygen uptake (D) in WIL I, was 
assessed. An RCR value of 3^ 6. was recorded for this 
preparation.
oligomycin (4.2uM) reduced this response to only within 5% of the
basal rate. Cellular oxygen consumption was inhibited by rotenone
(3uM). Oligomycin (4.2uM) reduced the oxygen uptake rate bv 70% of 
. DNP stinulates oxygen uptake by 40-s
the basal rate (Figure 5.8B). x Rotenone CJum; tuiiy inhibited the 
(figure.5.8B). . 1
oxygen upcaxe of W256 cells. Lamprene (lOuM) when added to fresh
preparations of W256 cells elicits an increase in the oxygen uptake
rate by 25% above the basal rate (Figure 5.8C). Oligomycin (4.2uM)
reduces this response to only 3% above the basal oxygen uptake rate,
though rotenone (3uM) inhibits the consumption of oxygen by this cell
preparation. Lamprene (lOuM) when added to an oligomycin inhibited
preparation of cells stimulated cellular oxygen consumption by 25% of
the basal rate (Figure 5.8D). Rotenone 3uM abolished the oxygen
uptake of this preparation. DMSO which was required to solubilise
lamprene for these experiments had no effect upon respiratory activity
in coupled or uncoupled preparations of WIL or W256.
Effect of Anafranil and Ludiomil on the oxygen uptake of cells 
following manipulation with classic antimitochondrial agents 
Anafranil and Ludiomil at concentrations of lOuM had no effect upon 
coupled or uncoupled respiratory activity (Tables 5.1 and 5.2).
CONDITIONS OXYGEN UPTAKE 
ng at/mg 
protein/min
OXYGEN UPTAKE 
ng at/ug 
DNA/min
PERCENT OF 
CONTROL
RCR
control 11.62 0.23 100 5.06
10 uM Anafranil 11.62 0.23 100
4.2uM Oligomycin 1.80 0.04 16
3 uM Rotenone 0 0 0
control 10.30 0.20 100 5.06
4.2uM Oligomycin 2.18 0.04 21
10 uM Anafranil 2.18 0.04 21
3 uM Rotenone 0 0 0
control 12.30 0.30 100 4.89
10 uM Ludiomil 12.30 0.30 100
4.2uM Oligomycin 1.80 0.04 14
3 uM Rotenone 0 0 0
control 12.75 0.32 100 4.89
4.2uM Oligomycin 2.68 0.07 21
10 uM Ludiomil 2.68 0.07 21
3 uM Rotenone 0 0 0
Table 5.1: The effect of sequential addition of. antimitochondrial
agents upon the basal rate of oxygen uptake as 
expressed as percent of control in intact preparations 
of WIL.
Cell preparations were characterised with classical 
antimitochondrial agents DNP, oligomycin and rotenone 
as described.
The effect of anafranil and ludiomil upon the oxygen 
consumption rate in WIL was then determined. RCR
values following characterisation of each preparation 
were recorded as shown.
CONDITIONS OXYGEN UPTAKE OXYGEN UPTAKE PERCENT OF RCR 
ng at/mg ng at/ug CONTROL
protein/min DNA/min
control 11.34 0.21 100 3.06
10 uM Anafranil 11.34 0.21 100
4.2uM Oligomycin 3.26 0.06 29
3 uM Rotenone 0 0 0
control 10.06 0.18 100 3.06
4.2uM Oligomycin 4.02 0.07 40
10 uM Anafranil 4.02 0.07 40
3 uM Rotenone 0 0 0
control 8.80 0.15 100 2.40
10 uM Ludiomil 8.80 0.15 100
4.2uM Oligomycin 3.52 0.06 40
3 uM Rotenone 0 0 0
control 8.09 0.13 100 2.40
4.2uM Oligomycin 3.41 0.06 43
10 uM Ludiomil 3.41 0.06 43
3 uM Rotenone 0 0 0
Table 5.2: The effect of sequential addition of antimitochondrial
agents upon the basal rate of oxygen uptake as 
expressed as percent of control in intact preparations 
of W256.
Cell preparations were characterised with classical 
antimitochondrial agents DNP, oligomycin and rotenone 
as described.
The effect of anafranil and ludiomil upon the oxygen 
consumption rate in W256 was then determined. RCR 
values following characterisation of each preparation 
were recorded as shown.
DISCUSSION
The results described in this chapter suggest that lamprene behaves as 
a classic uncoupler of oxidative phosphorylation, stimulating oxygen 
uptake in the presence of an inhibitor of phosphorylation. In 
contrast the action of R6G is more complex. There appeared to be a 
biphasic response in oxygen consumption following incubation of cells 
with R6G. A transient stimulation of oxygen consumption, independent 
of phosphorylation and characteristic of uncoupling was observed 
initially. However, this was followed by a steady state inhibition of 
oxygen consumption also independent of phosphorylation indicating 
subsequent inhibition of electron transport.
2.4 Dinitrophenol stimulated oxygen uptake when incubated with fresh 
cell preparations as respiratory oxygen consumption was uncoupled from 
phosphorylation of ADP. Accelerated oxygen uptake was a result of 
decreased availability of ATP and NADH which regulate substrate 
cycling through glycolysis and the TGA cycle. Both R6G and lamprene 
behaved similarly. With an inhibitor of ADP phosphorylation, 
oligomycin, blocking phosphorylation had relatively little effect upon 
the rate of (uncoupled) oxygen uptake. However in all cell types, the 
rate of uncoupled oxygen consumption was reduced somewhat. Oligomycin 
did reduce oxygen consumption in coupled preparations. The electron 
transport chain inhibitors rotenone and antimycin did inhibit oxygen 
uptake in both coupled or uncoupled preparations. Although tumour 
cell respiration was completely inhibited with rotenone, full 
inhibition of respiration in intact hepatocytes was not achieved. 
Antimycin was more effective as an inhibitor of respiratory chain 
activity and associated oxygen consumption.
R6G showed a potent uncoupling activity. The increase in respiratory 
oxygen uptake by fresh preparations of hepatocytes, WIL and W256 
tumour cells following exposure to R6G reflects an initial uncoupling 
of phosphorylation from electron transport and associated oxygen 
consumption rather than a stimulation of both phosphorylation hence 
oxygen uptake. Stimulation of respiratory activity was independent of 
any effect by oligomycin hence phosphorylation. This uncoupling
activity was transient and an associated steady state inhibition of 
cellular oxygen consumption following. This was observed in tumour 
cell preparations. Furthermore the effect was also independent of 
phosphorylation, occurring even in the presence of oligomycin. An 
important observation with the high concentration of R6G (lOuM) was 
stimulation of hepatocyte respiratory function indicative of 
uncoupling of respiratory activity from phosphorylation. It is 
proposed however, that the magnitude of changes associated with the 
concentration of R6G used is less than the effect of this 
concentration of R6G upon tumour cell respiratory activity (Chapter 
4). In view of this observation it may be more realistic to examine 
whether a concentration of R6G may be used which has an effect upon 
tumour cell oxidative function and little or no effect upon non­
neoplastic host cells. The 3uM concentration cited by Gear (1974) at 
which inhibition of bioenergetic function in rat liver mitochondria is 
thought to occur may only pertain to the isolated organelle and may be 
of less importance to whole cells or intact tissue.
The effects of lamprene upon WIL and W256 tumour cells appear to be 
less complex than that of R6G. Lamprene showed clear uncoupling of 
respiratory control. The oxygen consumption rate in both cell lines 
was stimulated, even in the presence of oligomycin. Therefore, 
stimulation of oxygen uptake did not reflect an increase in associated 
phosphorylation of ADP. The electron transport inhibitor rotenone 
inhibited all respiratory activity in both cell types pretreated with 
lamprene.
Respiratory control indices for cell preparations examined in the 
studies described in this chapter varied between 2.4 and 6.2 for the 
tumour cell preparations and were adequately indicative of respiratory 
coupling. However, indices for hepatocytes were much lower and 
therefore imply that the degree of respiratory control in such 
preparations was limited.
The electron transport chain inhibitor rotenone is thought to act at a 
site close to the NADH-Dehydrogenase enzyme complex I. Treatment of 
cells with rotenone would not prevent channelling of electrons onto
ubiquinone via the succinate dehydrogenase enzyme complex II 
[succinate = (acceptor) oxidoreductase E.C. 1.3.99.1]. Therefore, 
some respiratory activity would be predicted even after cells were 
pretreated with rotenone. Since this was not observed with either 
tumour cell line examined the contribution of FAEH- linked electron 
transfer to net electron transport in tumour cells might be 
negligible. Oxygen uptake by hepatocytes continued after treatment of 
cells with rotenone. Antimycin, which acts at a site further along 
the respiratory chain, past ubiquinone, the crossover point for both 
complex I and complex II did fully inhibit oxygen consumption in 
hepatocytes.
The observed inhibitory action of R6G upon oxygen uptake by tumour 
cells that occurs even in the presence of an inhibitor of 
phosphorylation, is in agreement with observations by other workers. 
Results obtained with isolated rat liver mitochondria exposed to the 
analogous cationic dye rhodamine 123, suggest that rhodamine dyes may 
also have inhibitory activity at a site on the electron transport 
chain (Modica-Napolitano et al, 1984; Emaus et al, 1986).
R6G stimulated oxygen uptake was fully inhibited by rotenone in the 
tumour cell lines examined. As stated previously, following exposure 
to R6G, hepatocyte respiratory activity was not fully inhibited with 
rotenone, but was fully inhibited with antimycin. The studies with 
hepatocytes imply that any inhibitory effect that R6G has upon 
electron transport is exerted at a site further along the respiratory 
chain from ubiquinone, either near mitochondrial enzyme complex III or 
complex IV (cytochrome oxidase; ferricytochrome-C : Oxygen
oxidoreductase E.C. 1.9.3.1). Studies with tumour cells indicate that 
such inhibition is certainly further along from mitochondrial enzyme 
complex I as shown by the ability of rotenone to abolish the response 
and assuming the respiratory chain is fully intact. Other workers 
have shown that in isolated rat liver mitochondria, R6G and cyanide 
based dyes have sites of action associated with NAD linked rather than 
FAD linked enzyme activity (Conover and Schneider, 1981). The studies 
described in this Chapter have not fully investigated the possible 
sites of action of R6G induced inhibition of electron transport,
therefore it may be possible that following uncoupling of 
phosphorylation from oxygen consumption and associated electron 
transport, the decrease in oxygen uptake and electron transport 
induced with R6G may be merely reflections of a cytotoxic action upon 
cell metabolism.
There is evidence to suggest other possible mechanisms of action of 
R6G on mitochondrial respiratory function. From studies with isolated 
rat liver mitochondrial preparations and submitochondrial particles 
obtained from rat liver Gear (1974) concluded that R6G could be 
exerting its action by inhibition of the adenine nucleotide 
translocase on the inner mitochondrial membrane, resulting in an 
inhibition of phosphorylation. However Higuti et al (1980) believed 
that inhibition of energy transduction by R6G was caused by a 
reduction of proton ejection during electron transport and a 
subsequent inhibition of the ATP synthase enzyme preventing 
phosphorylation. It is apparent that the inhibitory effects of R6G 
upon bioenergetic function may be contributed to by inhibition of more 
than one bioenergetic process.
Lamprene exhibited a clear uncoupling of respiratory activity. Oxygen 
consumption in tumour cell preparations was stimulated even in the 
presence of oligomycin. Rhodes and Wilkie (1973) suggested that 
Lamprene mediated inhibition of respiration in yeast was due to 
lamprene acting as an artificial electron acceptor rather than an 
uncoupler by passing the terminal cytochrome oxidase complex IV on the 
respiratory chain. This was because lamprene mediated stimulation of 
respiratory activity was not fully inhibited with the cytochrome 
oxidase inhibitor cyanide. The experiments with tumour cell 
preparations described in this chapter did not appear to support this 
theory. Lamprene was inhibited with rotenone in both tumour cell 
types examined. Rotenone induced inhibition reflects NAD+ linked 
transport as described. FAD+ linked electron transport does not 
appear to contribute to oxygen consumption in tumour cells. Rotenone 
sensitivity implies that lamprene mediated stimulation of respiratory 
activity, reflecting an enhancement of electron transport can still be 
inhibited with electron transport chain inhibitors. Therefore the
idea that lamprene accepts electrons in order to reduce molecular 
oxygen cannot be correct as,such a process should not be sensitive to 
rotenone.
Addition of oligomycin to DNP treated preparations of cells resulted 
in small but significant reductions in oxygen consumption. This might 
have reflected the fact that the concentration of DNP causing 
uncoupling was submaximal and thus a reduction in the rate of oxygen 
consumption was characteristic of a subpopulation of coupled 
mitochondria within the preparation. It is necessary to emphasize 
that the degree of respiratory control achieved with intact cells is 
less than with preparations of isolated mitochondria. This is 
reflected in the respiratory control indices of the cell preparations, 
ranging between 1.2 and 6.2 in certain cases. Any addition of drug is 
dependent therefore, upon uptake which is assumed, but not necessarily 
to be exhibiting saturation kinetics. Concentrations of DNP, 
oligomycin, rotenone and antimycin were selected from studies with 
isolated mitochondria. In such studies not only was plasma membrane 
permeability not a feature, but organelle density within a preparation 
was far greater. Therefore any time delay to a particular response to 
drug was much less. If this were so, RCR valves calculated would have 
been meaningless as subpopulations of mitochondria within each 
preparation would not have been exposed to drug. From work with 
hepatocytes it is clear that stimulation of uncoupled activity is 
maximal with DNP and could not be further stimulated by addition of 
lamprene or R6G. This occurred with tumour cell preparations 
incubated in the oxygen electrode in approximately similar 
concentrations to hepatocytes. Thus the drug concentrations selected 
did suffice for maximal responses not only with hepatocytes, but also 
tumour cells. Coarser responses to antimitochondrial agents incubated 
with tumour cells are more likely to be due to a reduction in 
respiratory control in whole cell preparations as compared to isolated 
tumour mitochondria.
Further evidence exists in the literature to show that maximal 
responses to antimitochondrial agents may be achieved at lower drug 
concentrations with preparations of intact cells as compared to
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isolated mitochondria (Gregg et al, 1968; Gregg, 1972). In 
conclusion, with the drug concentrations used maximal cellular 
responses were observed in experiments with the oxygen electrode. 
Thus the studies described in this chapter may be summarised as 
follows.
From experiments with the oxygen electrode, intact rat hepatocytes and 
tumour cells respond to classic antimitochondrial agents as predicted 
from the organisation of components of their inner mitochondrial 
membrane. R6G incubated with tumour cells exerts a dual action upon 
respiratory activity. An initial uncoupling of oxygen consumption 
from phosphorylation occurs, followed by a phosphorylation independent 
inhibition of electron transport. It would appear that the effect of 
R6G upon tumour cell bioenergetic function is complex and there may be 
several sites at which this compound acts. R6G does appear to exert 
an inhibition upon hepatocyte oxidative metabolism which follows a 
similar mechanism of action. However at low drug concentrations R6G 
exerts an inhibition upon tumour cell mitochondrial respiratory 
function with little or no effect upon the metabolism of normal cells. 
Lamprene uncouples respiratory activity from phosphorylation in the 
tumour cell preparations examined in these studies. There is no 
evidence to suggest: that ludiomil or anafranil at the lOuM 
concentrations selected had any effect upon coupled or uncoupled 
respiratory activity.
In conclusion, evidence presented in this chapter support the idea 
that R6G and lamprene exert a clear inhibition of tumour cell 
bioenergetic function in vitro.
CHAPTER 6
INHIBITION OF TUMOUR CELL MITOCHONDRIAL BIOGENESIS
INTRODUCTION
So far the approach to selective inhibition of tumour cell energy 
metabolism has concentrated on the inhibition of tumour mitochondrial 
function. An alternative approach to limiting energy production in 
tumour cells is to deplete cells of their mitochondrial content by 
interfering in the ability of tumour cell mitochondria to replicate.
In order to examine these concepts further, some of the aspects of 
mitochondrial genetics must be understood. These demonstrate how 
inhibitor titration has helped to elucidate differences between 
nuclear and mitochondrial contributions to mitochondrial replication. 
Mitochondria, not only play an important role in cellular metabolism, 
but they also possess their own unique genetic system. This system is 
responsible for the assembly of mitochondrial ribonucleic acids and a 
number of subunits of hydrophobic proteins of the inner mitochondrial 
membrane. Most of the mitochondrial DNA translation products are 
part of the enzyme complexes involved in ATP generation. Therefore 
inhibition of the function of the mitochondrial genetic system may 
have severe energetic and metabolic consequences for the cell (Van den 
Bogert, 1983).
All eukaryote mitochondria, examined to date contain double stranded 
circular molecules of DNA measuring about 5 microns and are equivalent 
to about 16,000 base pairs (Kroon and Saccone, 1980). The DNA 
contained constitutes the minimal amount of genetic information 
necessary for mitochondrial function. Much of this DNA is conserved. 
The DNA codes for 2 ribosomal RNA's and 22 transfer RNA*s. All 
enzymes needed to transcribe mitochondrial DNA (mtDNA) and to 
translate messenger RNA (rriRNA) are present (Van den Bogert, 1983; 
Clayton, 1984). Most of the reading frames of human mtDNA correspond 
to functional genes. Genes encoded for include the cytochrome C
oxidase subunits 1, 2 and 3, cytochromes b and c, a subunit of the ATP 
synthase complex and components of the NADH-ubiquinone reductase 
enzyme complex (Anderson et al, 1980; Attardi, 1981; Bibb, 1981; 
Chomyn et al, 1985).
Mitochondria are able; to incorporate amino acids into protein and this 
process is sensitive to specific inhibitors (Galper and Darnell, 1971; 
Schatz and Mason, 1974). Thus animal mitochondria contain a 
functional genetic system, whose polypeptide products are part of 
enzyme complexes involved in oxidative phosphorylation (Kolarev et al, 
1981). The majority of proteins found within mitochondria are encoded 
by nuclear DNA and are synthesized in the cytoplasm. These 
polypeptides once assembled must be transported, often as precursors 
to the sites of activity across the inner mitochondrial membrane. 
Examples of these proteins include the polypeptide subunits of 
succinate dehydrogenase which is involved in oxidative phosphorylation 
(Reid, 1985; Clarkson et al, 1987). The interaction between 
cytoplasmic and mitochondrial protein synthesis and mechanisms which 
regulate the processes are not clearly understood. However it is 
likely that mitochondrial protein synthesis will influence cytoplasmic 
transcription and translation. A severe lack of functional 
mitochondria would have fatal consequences for the strictly aerobic 
mammalian cell. Two models exist which attempt to explain how 
mitochondrial biogenesis may be regulated by the cell.
One model suggests that a protein synthesized in mitochondria 
represses the synthesis of enzymes coded for in the nucleus. If the 
number of functional mitochondria is lowered, the concentration of 
this repressor becomes reduced and inhibition is then abolished. 
Evidence for this model however is lacking. The second model proposes 
that impairment of oxidative phosphorylation serves indirectly as a 
signal for the synthesis of mitochondrial proteins. Data available, 
based upon evidence from non mammalian cells such as saccharomyces 
favours this model (Barath and Kuntzel, 1972; Van den Bogert, 1983).
Much of the evidence cited, referring to mtdna and subsequent 
transcription and translation in mammalian cells was obtained from
human Hela and rat hepatoma cells. It is likely that some tumour 
cells will contain aberrant forms of mtDNA and protein synthesis in 
tumour mitochondria is likely to differ in certain tumours relative to 
normal cells (Pedersen, 1978).
Agents which interfere in the ability of mitochondria to undergo 
biogenesis were first studied in lower eukaryotes such as 
saccharomyces. Chloramphenicol was demonstrated to show a highly 
selective inhibition of mitochondrial protein synthesis (Clark-Walker 
and Linnane, 1967). Subsequent evidence indicated that mammalian cell 
mitochondrial protein synthesis was sensitive to chloramphenicol. 
There appeared to be two forms of protein synthesis occurring in 
mammalian cells, one form was susceptible to the effects of inhibition 
with cycloheximide, while another was unaffected by cycloheximide. 
The cycloheximide resistant process however showed a selective 
inhibition to chloramphenicol. From these studies it was concluded 
that the cycloheximide sensitive cytoplasmic protein synthesis was 
quite separate from mitochondrial protein synthesis resistant to 
cycloheximide. Chloramphenicol, however exerted a selective 
inhibition on cycloheximide resistant mitochondrial protein synthesis 
(Ennis and Lubin, 1964; Galper and Darnell, 1971).
Attempts were made to isolate chloramphenicol resistant mutant 
mammalian cells. Such cells were found to be deficient in respiratory 
chain components, requiring glycolytic substrates in order to maintain 
growth and proliferate. Cloning such respiratory deficient mutants 
gave rise to daughter cells, which were also respiratory deficient 
(Spolsky and Eisenstadt, 1972; Wiseman and Attardi, 1979; Howell and 
Sager 1979).
It was apparent that cytoplasmic genetic transfer between parent and 
daughter cells must be occurring, conserving the parent phenotype in 
daughter cells. Evidence with both these antibiotic agents indicated 
that protein synthesis in mitochondria could be selectively inhibited, 
furthermore biogenesis of mitochondria as a result of treatment with 
these agents was also reduced and thus a method was available for 
depleting cells of their mitochondria if treatment was prolonged.
Other antibiotics implicated in having inhibitory effects upon 
biogenesis were carbomycin and doxycycline (tetracycline) (De Vries et 
al, 1971; Van den Bogert et al, 1986(a); Van den Bogert et al, 
1986(b)). Other agents described as having a selective inhibitory 
effect upon tumour mtDNA metabolism include ethidium bromide and 
methyl glyoxalbis (guanyl hydrazone) (MGBG) (Zylber et al, 1969; 
Feuerstein et al, 1979; Nass, 1984; Patel et al, 1984; Bugeja et al, 
1987). Agents such as ethidium bromide or MGBG are thought to 
interfere with mitochondrial nucleic acid metabolism where as the 
antibiotics doxycycline or chloramphenicol are thought to interfere at 
the translational level following transcription of mRNA.
Any agent, which interferes in nucleic acid metabolism at the nuclear 
level can theoretically interfere in mitochondrial biogenesis. Many 
anticancer chemotherapeutic agents belong to this category. Examples 
include adriamycin, bleomycin and 5-fluorouracil (5FU). How selective 
this action is, is unclear. Early studies with inhibitors of the 
mitochondrial genetic system as stated previously were carried out on 
lower eukaryotic systems.
5FU was demonstrated to promote aberrant mitochondrial biogenesis in 
■j yeast " (Oliver and Williamson, 1976(a); 1976(b)). This 
was demonstrated to occur as a result of incorporation of 5FU into 
certain species of RNA (Oliver and Williamson, 1977). The effect of 
5FU upon mammalian cells is inhibitory. Growth inhibition of cells is 
thought to be as a result of inhibition of the enzyme thymidylate 
synthetase [Thymidylate Synthase E.C. 2.1.1.45]. DNA synthesis is 
inhibited indirectly as the source of deoxyuridine monophosphate, is 
removed. Since ultimately this is converted and phosphorylated to 
deoxy-thymidine triphosphate, an essential nucleotide required for 
DNA, DNA synthesis is inhibited. This inhibition of DNA synthesis by 
5FU was considered to be the primary mechanism of achieving tumour 
cell cytostasis (Ardalan and Glazer, 1981; Schornagel et al, 1982; 
Heidelberger, 1975). However 5FU is also thought to have important 
effects upon RNA metabolism. Metabolism of 5FU by tumour cells gives 
rise to several nucleotide derivatives including Fluorodeoxyuridine 
monophosphate (FdUMP) and Fluorouridine Monophosphate (FUMP). FdUMP
is responsible for the inhibition of thymidylate synthetase and 
ultimately DNA synthesis. FUMP however, may be incorporated into RNA 
following phosphorylation to fluorouridine triphosphate. This import­
ant effect upon RNA synthesis in tumour cells has been stressed 
(Spiegelman et al, 1980; Cory et al, 1979; Mandel, 1981). Thus 
circumstantial evidence did exist with which to inhibit mitochondrial 
RNA metabolism with non cytotoxic concentrations of 5FU, hence reduce 
the expression of mitochondrial encoded proteins such as cytochrome 
oxidase. Recent evidence, provides more support for this theory that 
5FU interferes with mitochondrial biogenesis in both saccharomyces and 
cultured mammalian guinea pig keratocytes (Bugeja et al, 1987).
The methods for assaying mitochondrial biogenesis were designed to 
examine whether a reduction in the synthesis of mitochondrial 
components following continuous exposure of tumour cells with 5FU in 
vitro occurred. A reduction in mitochondrial enzyme activity in 
response to long term incubation of cells with biogenetic inhibitors 
could be monitored. A reduction in mitochondrial activity would 
correspond to a decrease in mitochondrial enzyme content.
Enzyme activities measured, following long term exposure of cells to 
5FU included cytochrome oxidase (CQX) (ferrocytochrome C: oxygen
oxidoreductase E.C. 1.9.3.1) which is encoded for on the mitochondrial 
genome. Also measured was succinate-cytochrome C reductase (SCR) 
activity. This enzyme system corresponds to a combination of the 
activities of succinate-dehydrogenase enzyme complex II (succinate- 
ubiquinone reductase E.C. 1.3.9.9.1) encoded in the nucleus, and 
ubiquinone-cytochrome C reductase enzyme complex III [E.C. 1.10.2.2]. 
Thus activity from a crude cell preparation was a reflection of 
electron transport in crude segments of the respiratory chain. 
Assaying individual respiratory chain enzymes would have necessitated 
specific purification steps including penetration of the inner 
mitochondrial membrane, not justifiable at this stage. As rotenone 
was omitted from the assay, entry of electrons via NADH dehydrogenase 
complex I could not be excluded. The main purpose of the assay was to 
see what effect growth of cells in 5FU achieved upon mitochondrial
enzyme content rather than on an individual enzyme (Takemori and King, 
1964; King and Takemori, 1964; Singer, 1966).
These methods measure the products of mtDNA transcription and 
translation as well as the cytoplasmic contribution to mitochondrial 
biogenesis. A more direct method was thus made available as compared 
to the spec tropho tome trie methods which measured a reduction in the 
absorbance spectra of mitochondrial cytochromes resulting from 
treatment with biogenetic inhibitors (Morais, 1980; Bugeja et al, 
1987). Furthermore it provided a more rapid answer as compared to 
more accurate gel electrophoretic methods for determining 
disappearance of protein bands following 5FU treatment. At any rate 
such methods would have involved mitochondrial isolation from cells 
grown up in tissue culture, a time consuming and expensive process.
The main aim of the studies presented in this chapter is to examine 
whether suitable chemotherapeutic agents may be selected which might 
inhibit tumour mitochondrial biogenesis. If mitochondrial biogenesis 
can be inhibited at least in vitro, preventing the ability of 
mitochondria to replicate, combining such agents with R6G may enable 
tumour cell energy metabolism to be inhibited at the expense of host 
cell metabolism.
The growth behaviour of WIL exposed to 5FU was examined in order to 
select non cytotoxic concentrations of drug for further experiments. 
An assay of cytotoxicity was designed to assess what concentration of 
drug inhibited growth. Growth rate experiments were also carried out 
to confirm what effect non toxic concentrations of 5FU had upon 
population growth rates of WIL. In comparison, similar experiments 
were carried out to determine the effects of functional inhibitors of 
tumour mitochondria R6G and lamprene on chemosensitivity and 
population growth rates. Mitochondrial enzyme activities were then 
investigated following continuous exposure of cells to 5FU.
METHODS
Assay of Cytotoxicity
Chemosensitivity was determined by an assay recently established 
within the Department of Medical Oncology. The assay is based on that 
described by Carmichael et al (1987). A full description of this 
assay is given in chapter 2.
Estimation of growth rates
Estimation of cell growth rates were carried out as described in 
chapter 2.
Mitochondrial Enzyme Activities
1. Cytochrome oxidase (ferrocytochrome C : oxygen oxidoreductase E.C.
1.9.3.1). This was determined by the method of Rafael (1983).
The basis of the assay was as follows:
2 Cytochrome C (Fe^ +) + % O2 qqx ^  Cytochrome (Fe +^) + 0^"
The uptake per unit time of oxygen dissolved in the assay is used 
as a measure of the catalytic activity of COX. Cytochrome C is 
kept in the reduced form by ascorbate. TMPD (N,N,N;N; 
Tetramethyl-p-phenylene diamine) mediates electron transport. 
Oxygen uptake in the assay is measured polarographically with a 
Clark-type oxygen electrode calibrated as described previously 
(chapter 2). The assay blank which exhibits an oxygen uptake rate 
due to auto-oxidation of ascorbate and TMPD respectively is 
subtracted from the measured oxygen uptake.
Reagents were prepared as follows:
1. Fhosphate-EDTA solution (phosphate buffer 50mM, EDTA ImM adjusted 
to pH 7.2). Buffer was prepared by dissolving KH2 PO4, 4.288g and 
EDTA - Na2 ^.2^0, 0.234g in distilled water, 450ml. pH was 
adjusted to 7.2 with KOH, 10M (KOH, 5.61g dissolved in distilled 
water, 10ml) added dropwise to the buffer. The buffer was made up 
to a final volume of 500ml.
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2. Ascorbic Acid, lOOmM. Ascorbate, 26.4mg was dissolved in 
phosphate-EDTA buffer, 1.5ml. pH was adjusted to 6 with 2 to 3 
drops of KOH, 2M.
3. Lubrol, lOmg per ml. Lubrol, lOOmg was dissolved in phosphate-EDTA 
buffer, 10ml at room temperature.
4. TMPD, 50mM. Repurified TMPD, 11.8mg was dissolved in distilled 
water 1ml.
Repurification of the general purpose grade reagent was achieved 
as follows:-
5 to 10 grams of TMPD was dissolved in 85% ethanol, 20 to 30ml 
containing 2 to 3 drops of concentrated jHCli, in a pyrex beaker. 
The solution was heated on a hotplate in the fume cupboard to form 
a supersaturated solution. Recrystallisation was allowed to occur 
by cooling to room temperature. Crystals obtained were separated 
from solvent by filtration through a buchner funnel. Crystals 
were briefly rinsed in ethanol, 85%. If necessary the process was 
repeated. Purity was assessed from the colour of the solute. 
From impure gray coloured crystals, pure white crystals were 
obtained following two recrystallisation steps.
5. Cytochrome C ll.lmg per ml. Tris-acetate buffer.
The following purification steps were carried out to ensure that 
cytochrome C monomer was present in the assay.
Sephadex G100 was prepared as follows: Beads, 2g were mixed with 
Tris-acetate buffer, 40ml. Buffer was made up by dissolving Tris- 
base, 1.514g in acetic acid, 250ml (lOOmM). pH was adjusted to 7.5 
before making up to volume. 50ml of this buffer was sterile 
filtered and a few milligrams of sodium azide were added to keep 
the solution sterile. Beads were allowed to take up buffer over a 
72 hour period at room temperatures in a sealed buchner funnel. 
Prior to use, the mixture was degassed with a vacuum pump. 
Several short tipped paster pipettes were set up vertically on 
clamp stands. Pipettes were fitted with silicon tube ends and 
clamped. Glass wool, wetted in fresh buffer was inserted into 
each tube. Gel was carefully pipetted into each tube leaving a 1
to 2cm gap at the top. Azide-free buffer was washed through the 
columns to remove traces of sodium azide. Cytochrome C, 1ml made 
up in buffer, containing protein lOOmg, and a few crystals of 
dithionate to keep the protein reduced was layed onto each column. 
Protein eluted from the column in a distinct band. Dilution was 
negligible. Polymer free preparations could be stored at -20°C 
and aliquots were used as required at a final concentration of
ll.lmg per ml. Aliquots of cytochrome C were thawed out just 
before use.
Solutions 2 and 4 were freshly prepared each time.
All solutions were kept at 4°C prior to the assay.
Preparation of Cells
WIL was seeded into flasks (75cm^ ) at an approximate concentration of 
5 x 105 cells per flask (1.25 x 10^ cells per ml). Attachment and 
growth was allowed to take place over 48 hours. W256 cells were 
seeded into flasks (75cm^ ) at an approximate concentration of 1 x 10^ 
cells per flask (2.5 x 10^ cells per ml). Growth was allowed to take 
place over a 48 hour period.
Cells were fed with fresh medium containing 5FU, 200uM. Control 
flasks were fed with fresh medium. Thereafter cells were fed with 
fresh medium or medium containing 5FU daily. 72 hours after
initiating drug treatment, assays of cytochrome oxidase were carried 
out.
Cells were harvested as described in chapter 2. Harvested cells were 
counted and resuspended in Hanks Balanced Salts Solution (HBSS) 
containing phenol red, glucose 6mM and bicarbonate 5mM. Cells were 
washed with this medium and resuspended in fresh HBSS. Samples, 0.2ml 
were taken and placed in distilled water. 0.1ml of sodium
deoxycholate, 50% was added to this and samples were stored at -20°C 
for subsequent analysis of protein (see chapter 2). Cells were broken 
up with a cell disruptor at pressures of between 600 to 800 psi for 
WIL and 500 to 700 psi for W256. Samples, 0.2ml were collected and 
stored at -20°C for subsequent analysis of protein as described
previously. Dilution of the cell preparation was estimated from 
differences in protein content of the preparation following cell 
disruption. Cells were diluted further by addition of lubrol 
(solution 3), 5ml.
Enzyme Reaction
Phosphate-EDTA, 1.06ml was equilibrated for 2 to 3 minutes in the 
oxygen electrode. Once a stable baseline was obtained on the chart 
recorder output ascorbate, 0.1ml, cytochrome C, 0.120ml and TMPD,
0.02ml were added sequentially to the electrode with a hamilton 
syringe. A net auto-oxidation rate was observed which was less than 
8% per minute (full recorder range was 100%) and normally 4 to 5% per 
minute. Cell suspension, 0.1ml was added after 2 to 3 minutes. From 
each chart recorder trace, a blank rate was obtained which was 
subtracted from the sample rate and the net activity recorded as a 
change in oxygen consumption. Catalytic activity was calculated in 
nanomoles electrons per second per milligram of protein at' 25°C from 
the equation:
Net Slope x 960 x Total volume in electrode (1.4ml) x Fraction of Full
Sample Volume (0.1ml) scale deflection ,
-r Number of milligrams protein per litre x 1000
where 960 = micromoles of electrons per litre transferable 
as oxygen dissolves at 25°C.
1000 '« conversion factor to nanomoles.
Results were also expressed in terms of activity per 10^ cells. To 
take into account the different buffers, cells were incubated in prior 
to assay, appropriate controls were run in the oxygen electrode.
Mitochondrial Enzyme Activities II
2. Succinate - Cytochrome C reductase (SCR)
Methods were essentially as described by King (1967).
The basis of the assay was as follows:
Succinate + DCIP; "^ Fumarate + DCIPH2
Reduction of the artificial electron acceptor 2, 6, - dichlorophenol 
indo-phenol (DCIP) is followed on a spectrophotometer at a wavelength 
of 600nm. The assay medium contained phosphate buffer, EDTA, 
succinate, DCIP and potassium cyanide (necessary to block competition
with cytochrome oxidase). The reaction was initiated by addition of
crude homogenate, 0.2ml
Reagents were prepared as follows:
1. Potassium cyanide ImM. Solution prepared from dilution (1:7.69 
v/v) of a stock solution of KCN, 0.5% in saline, 0.85%.
Dilution was carried out with saline, 0.85%.
2. Sodium Hydroxide 1M. NaOH, 4g was dissolved in distilled water, 
100ml.
3. Sorensons phosphate buffer.
Solution A : KH2PO4, 0.2M. KH2PO4, 2.721g was dissolved in
distilled water, 100ml. pH of the resulting solution was 
approximately 4.4.
Solution B : Na2HP0 ,^ 0.2M. Na2HP0 ,^ 2.84g was dissolved in
distilled water, 100ml. pH of the resulting solution was 
approximately 9.2.
Buffer was made up by mixing A, 19.6ml with B, 80.4ml. pH was 
adjusted to 7.4 by dropwise addition of A or B depending on the 
initial pH of the mixture.
4. EDTA 3mM. EDTA-Na2H2 2^0, 11.8mg was dissolved in distilled 
water, 10ml.
5. Succinate 600mM. Na COO CH2CH2 COO H 6H2O, 0.97g was dissolved in 
distilled water, 10ml.
6. DCIP 0.53mM. DCIP, 1.54mg was dissolved in distilled water 10ml.
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Solutions 4, 5 and 6 were freshly prepared. All solutions were kept 
on ice at 4°C.
Preparation of Cells
WIL and W256 were prepared as described previously (Chapter 2). 
Treatment of cells with 5FU was similar to methods described for 
assaying COX activity. However the incubation period with drug was 96 
hours. Cell disruptor pressures were 750 psi for WIL and 600 psi for 
W256. In initial experiments cell aliquots were diluted with lubrol 
(solution 3 in COX assay) in order to penetrate mitochondrial 
permeability barriers to assay reagents. However mechanical 
disruption appeared to be sufficient and further treatment with lubrol 
did not significantly alter results. Dilution of cells was estimated 
from differences in protein content of the preparation following cell 
disruption. Protein was assayed as described in chapter 2.
Enzyme Reaction
Enzyme activity was measured in an assay volume of 3ml. To a 5ml 
cuvette was added phosphate-EDTA buffer 1.5ml, EDTA 0.3ml, DCIP 0.3ml, 
succinate 0.1ml, cyanide 0.3ml and distilled water 0.3ml. The 
absorbance of the assay mixture was determined in a spectrophotometer 
linked to a chart recorder at a wavelength of 600nm. The absorbance 
zero was set with distilled water. Basal absorbance values of the 
assay mixture ranged between 0.6 and 0.8 at a wavelength of 600nm. 
The reaction was initiated by addition of crude homogenate 0.2ml. 
This reaction was linear for up to 2 minutes. Recorder traces of the 
initial slope were obtained as a change in absorbance per minute. 
Enzyme activities were calculated as nanomoles succinate used per 
minute per milligram of protein at 25°C. From the equation:
Activity - Slope x 2x10 x ^000 
V x C x 7
where 2 x 10”  ^is the absorbance change in units per chart recorded 
division
V = Volume of homogenate in 3ml
C = Amount of protein in milligrams per ml homogenate 
7 = Conversion factor obtained from absorbency index
Absorbency index for DCIP is 21mM~^ cnf^ at 600nm at 25°C.
1000 - Conversion factor from micromoles to nanomoles 
succinate.
Enzyme activities were also calculated as activity per 10^ cells. To 
check on the specificity of the reaction, aliquots of homogenate were 
preincubated with sodium malonate, 5 to 15mM, to determine effects 
upon enzyme activity.
Statistical analysis
Statistical differences between drug treatment cells and controls were 
determined by Students t-test for unpaired samples (Bailey, 1972).
RESULTS
Determination of Cytotoxicity
The ID^q values for each drug screened against WIL is shown in table 
6.1. R6G is observed to be the most toxic compound, with an ID5Q 
value ranging between 0.3uM to 0.5uM. Lamprene appears to be less 
toxic to WIL than R6G, exhibiting ID^q values of 34uM and 36uM. 
However 5FU shows the least effect upon WIL. Absorbance at 570nm is 
reduced to 50% with a concentration of around 500uM
Effect of R6G, lamprene and 5FU upon the growth rate of WIL 
The effect of a 24 hour exposure to R6G (10, 50 or lOOuM) on the 
growth rate of WIL is shown in figure 6.1. R6G caused an inhibition 
of cell proliferation. However, after a lag phase cell proliferation 
was observed with a R6G concentration of lOuM. In contrast, no 
recovery was observed with R6G at a concentration of 50 or lOOuM.
The effect of a 24 hour exposure of WIL to lamprene (10 and 50uM) is 
shown in figure 6.2. Lamprene solubilised in DMSO (4%) caused a 
significant inhibition of cell proliferation. However after a lag 
phase cell proliferation resumed when cells were treated with DMSO 
(4%) alone. Initially, cells treated with lamprene, lOuM resumed 
growth up to 4 days after treatment. However subsequent to this, cell 
growth did not continue and proliferation was inhibited. In contrast 
no recovery was observed at a lamprene concentration of 50uM«
The effect of 5FU (lOuM, 50uM and lOOuM) upon the growth rate of WIL, 
following a 24 hour exposure of cells to drug is shown in figure 6.3. 
Cell proliferation is not inhibited with 5FU. However a significant 
growth delay is observed in cells exposed to 5FU, 50uM and lOOuM. 
Cell number reaches a plateau of 90 to 100 x 10^ cells per well at 
these drug concentrations. In contrast, cells exposed to 5FU, lOuM 
continue to grow although at a reduced rate when compared with 
controls.
DRUG ID50 VALUE (Molar)
Rhodamine 6G 5.0 x icr7 3.0 x 10-7
Lamprene 3.6 x lO""* 3.4 x 10-5
5-Fluorouracil 7.0 x 10'4 3.0 x 10-4
Table 6.1: ID5Q values for WIL exposed to R6G, lamprene and 5FU.
Duplicate values were recorded. Determinations of ID^q 
were made from dose response curves following the MIT 
assay. MIT reduction was assayed 3 days after cells 
were exposed.
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Figure 6.1: The growth rate of WIL following 24 hour exposure to
R6G. Growth rate expressed as cell number per well 
versus time in days. N - 3 + SEM. Cells were seeded at 
day -3. Drug exposure as indicated was from day 0 to 
day 1. Recovery over a 7 to 8 day period was recorded.
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Figure 6.2: Growth rate of WIL following 24 hour exposure to
lamprene. Growth rate expressed as cell number per well 
versus time in days . N * 3 + SUM. Cells were seeded 
at day -3. Drug exposure as indicated was from day 0 to 
day 1. As lamprene was solubilized in DMSO, an 
appropriate control was run. Recovery was recorded over 
a 7 to 8 day period.
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Figure 6.3: Growth rate of WIL following 24 hour exposure to 5FU.
Growth rate expressed as cell number per well versus 
time in days. N = 3 + SEM. Cells were seeded at day 
-3. Drug exposure as indicated was from day 0 to day 1. 
Recovery was recorded over a 7 to 8 day period.
Effect of 5FU upon mitochondrial enzyme activity following 
prolonged exposure of cells to drug
Cytochrome oxidase activity determined after exposure of W256 to 5FU, 
200uM, for 72 hours is shown in table 6.2. The activity of succinate- 
cytochrome C reductase determined after exposure of WIL and W256 to
5FU, 200uM for 96 hours is also shown in table 6.2.
Exposure to 5FU was continued for 96 hours prior to assay of SCR 
activity and not 72 hours as for COX activity in order to determine 
whether prolonging exposure had any further effect upon mitochondrial 
enzyme expression. Cytochrome oxidase activity could not be detected 
in WIL even though several variations in the methods described for 
enzyme were used. Treatment of W256 with 5FU does not show a 
reduction in enzyme activity. There was no significant difference 
between the activity of this enzyme in treated and untreated cells (p< 
0.1). Succinate-cytochrome C reductase activity is shown for both 
cell lines WIL and W256. For WIL, exposure of cells to 5FU resulted 
in a 150% increase in enzyme activity relative to controls. This
result was statistically significant (p< 0.001). The activity of SCR
was reduced by 50% (p< 0.001) when W256 was exposed to 5FU (200uM) for 
96 hours (table 6.2).
A 20 to 30% reduction of SCR activity (table 6.2) may be observed when 
concentrations of sodium malonate (5mM) were preincubated with 
preparations of cell homogenate prior to determinations of SCR 
activity.
ENZYME ACTIVITIES
COX Activity _
nmoles electrons per 10' cells per sec.
+/- SEM
W256 control 
W256 + 5FU
435
1230
63
301
P< 0.1 Not Significant
SCR Activity _
nmoles succinate per 10' cells per min.
+/- SEM
WIL control 361 18
WIL + 5FU 550 14
W256 control 442 17
W256 + 5FU 211 18
W256 control + 
5mM Malonate
347
* P< 0.001 Significant
Table 6.2: Mitochondrial enzyme activities of WIL and W256
following exposure to 50FU, 200uM. N = 3 + SEM. 
Cytochrome oxidase (COX) activity expressed as nmoles 
electrons per 10^ cells per second. Values recorded for 
W256 cells exposed to 5FU and drug free controls. P 
values obtained from unpaired t-tests.
Succinate cytochrome C reductase (SCR) activity 
expressed as nmoles succinate per 10  ^cells per minute. 
Values recorded for WIL and W256 cells exposed to 5FU 
and drug free controls. P values obtained from unpaired 
t-tests.
DISCUSSION
Results of experiments described in this chapter indicate that of the 
three agents R6G, lamprene and 5FU investigated, R6G was the most 
toxic to the cell line WIL. ID5Q values for this agent ranged between 
0.3 and 0.5uM. Lamprene, solubilized in DMSO was less toxic with ID^q 
values of between 34 and 36uM. 5FU had the least effect upon WIL. 
The drug concentrations required to decrease the absorbance at 570nm 
by 50% were between 300 and 700uM. The growth behaviour of WIL was 
examined over a 7 to 8 day period following a 24 hour exposure to each 
of the agents described R6G, lamprene and 5FU. R6G inhibited cell 
proliferation at all concentrations used. However, over the 8 day 
period during which recovery was measured cells recovered from the 
lOuM concentration of drug. No recovery was observed from higher 
concentrations of R6G. Lamprene also inhibited cell proliferation at 
concentrations of lOuM and 50uM. Although cells did appear to 
partially recover, 3 days after exposure to the lOuM concentration, 
further proliferation was subsequently inhibited and cell number 
decreased. Initially 5FU did not inhibit proliferation of WIL. Rates 
of cell growth did decrease after a lag phase. At concentrations of 
5FU, 50 and lOOuM cell number achieved a constant value 3 days after 
exposure of cells to drug. The 10-uM concentration, caused a delay in 
cell growth up to 2 days after exposure of cells to drug. 
Subsequently cell growth resumed following a similar growth pattern to 
that of controls.
Clear inhibition of mitochondrial enzyme activity of WIL and W256 
following continuous exposure of cells to a concentration of 5FU, 
200uM is not observed. Cytochrome oxidase activity in W256 was not 
significantly altered following treatment with 5FU. Succinate- 
cytochrome C reductase activity in preparations of WIL showed a 
stimulation of enzyme activity following treatment with 5FU. However 
W256 cells when exposed to 5FU, 200uM exhibited a significant 
reduction in enzyme activity compared to controls.
At first, a comparison of results obtained with the MTT assay do not 
appear to be consistent with results obtained from growth rate
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experiments. However, although a response to a 24 hour exposure to 
drug was measured, the MIT assay monitored recovery after a 3 day 
period, whereas growth rate recovery from drug exposure is measured 
over an 8 day period. Thus for results with R6G, although cells 
appear to recover from a concentration of lOuM in the growth rate 
experiments, this concentration is equivalent to approximately 20-fold 
greater than ID q^ . Ihe growth rate of WIL exposed to R6G, 3 days 
after exposure is very low and could be interpreted within the context 
of a cytotoxic dose. From both experiments, it is clear that R6G does 
exert a prolonged inhibition of growth, although at low drug 
concentrations recovery may occur after a definite time delay.
From experiments with lamprene measured with the MIT assay, as the 
compound was insoluble in aqueous solution, a residue of drug remained 
in wells up until the point of addition of MIT. It is possible that 
the drug residue may have had a direct effect upon cell metabolism and 
ultimately reduction of MIT. The residue of the drug that did remain 
did not interfere with the absorbance of Formazan measured at 570nm, 
following addition of DMSO to the plate. DMSO was required to 
disperse lamprene prior to addition to cells for the MIT assays. It 
appeared that the concentration of DMSO used had little effect on cell 
growth rate, yet results indicated from growth rate experiments that 
the 4% concentration required to dissolve lamprene did have an 
inhibitory effect. lOuM lamprene solubilized in DMSO is inhibitory to 
growth, yet lamprene at this concentration in the MIT assay is not 
toxic. These consistent results might possibly indicate that the net 
effect of lamprene and DMSO on cell growth might make WIL more 
sensitive to the toxic effects of lamprene. This requires 
confirmation by treating cells with lamprene in the absence of DMSO 
and at this stage remains unproven.
Antimetabolites such as 5FU, are structural analogues of cell 
metabolites and interfere in metabolic pathways very often by 
incorporation into an enzyme active site. Further metabolism is 
prevented due to inactivation of the enzyme. 5FU and other 
conventional chemotherapeutic agents interfere with nucleic acid 
metabolism and are most effective at a single point or several points
1 0 1 .
along the cell cycle (Hill, 1978), The proportion of cells undergoing 
division is gradually reduced. Cells are reduced to a non 
proliferating state yet cell number is not reduced, a cytostatic 
effect is thus induced. With 50uM and lOOuM concentrations of 5FU 
cell growth is inhibited, but cell number is not reduced. However, 
with higher concentrations of 5FU, as shown with the MIT assay, 600uM 
to 800uM, not only incurs non recovery, but also a reduction in cell 
number, hence cytotoxicity.
The effects of 5FU upon mitochondrial enzyme activity remains 
ambiguous. The activity of SCR in WIL and W256 was assessed in crude 
preparations of cells. Even if contamination with cytoplasmic 
dehydrogenases occurred and the activity of SCR was only part of the 
net dehydrogenase activity measured, interference in nucleic acid 
metabolism following treatment with 5FU should have resulted in 
reduced translation of both nuclear and mitochondrial polypeptides. 
All genomic translation should have been reduced with 5FU.
It is possible that during the 48 hour growth period prior to 5FU 
administration to cell cultures, enzyme synthesis per cell was 
optimal. The portion of cells undergoing subsequent mitosis may have 
been less than the proportion of cells already present in each flask. 
Biogenetic inhibition of mitochondria may only have been achieved 
thereafter. Net enzyme activity in either untreated controls or 
treated cells would have remained the same.
A remote possibility raised by the apparent stimulation of SCR 
activity in WIL with SCR, is that non-cy to toxic 5FU might stimulate 
mitochondrial enzymes by mechanisms as yet unclear.
Experiments conducted upon L1210 mitochondria indicate that bleomycin 
induced damage of mitochondrial DNA is less effective in intact 
mitochondria (Lim and Neims 1987).
The susceptibility of mitochondrial enzymes to inhibition with 
adriamycin is also reported to depend on lysis of the outer membrane 
of the mitochondrion with either digitonin or osmotic shock (Manella
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et al, 1986). Therefore it may be possible that the experimental 
protocol here did not facilitate entry of 5FU into the mitochondrion. 
As a consequence enzyme activity detected, follow cell disruption and 
treatment with the detergent lubrol released intact enzyme activity.
Attempts to adequately inhibit mitochondrial biogenesis in cultured 
cells, such as chick embryo fibroblasts have not been wholly 
successful. It has been shown that the concentrations of carbomycin 
and mikamycin required to inhibit mitochondrial protein synthesis have 
failed, the drugs being cytotoxic at concentrations where protein 
synthesis on mitoribosomes is not suppressed (Morais, 1980). It has 
also been shown that in order to suppress COX activity with ethidium 
bromide in primary chick fibroblasts, long term drug treatment, 
exceeding 20 days was necessary (Desjardins et al, 1985). Therefore 
it is likely that either the concentration of 5FU required to inhibit 
mitochondrial protein synthesis was suboptimal, or treatment was not 
of long enough duration to adequately achieve inhibition of 
mitochondrial biogenesis.
All the possible reasons presented to explain the inability to inhibit 
mitochondrial biogenesis with 5FU assume relative sensitivity of the 
cells to 5FU. The high ID^q values ( 300 to 700uM) obtained with 5FU 
from the MIT assay indicate that cells from the tumour may have 
developed resistance to the effects of 5FU. Resistance of cells to 
5FU has been extensively studied. Early experiments reported that RNA 
synthesis in resistant cells was blocked by a reduction in pyrimidine 
incorporation into ribonucleotides. Reduced RNA synthesis was thought 
to be a feature of resistant cells and that 5FU metabolism to FdUMP 
could still proceed (Reichard et al, 1959; Heidelberger et al, 1960; 
Goldberg et al, 1966). It became apparent from later studies that 5FU 
had different effects upon both RNA and DNA metabolism. Cells 
resistant to 5FU were thought to lose the ability to synthesize FdUMP 
from ribonucleotides, but continued to do so through 
fluorodeoxyuridine (Wilkinson and Crumley, 1977; Cory et al, 1979; 
Wright et al, 1980). Subsequent evidence showed that resistant cells 
expressed elevated levels of thymidylate synthetase, the enzyme which 
FdUMP was supposed to inhibit. This implied that resistant cells lost
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the ability to synthesize FdUMP (Cory et al, 1979; 0*Byme-Ring and 
Duke, 1980).
Recent theories concerning resistance to anticancer drugs are based 
upon the concept that a drug resistant phenotype in cells arises 
spontaneously prior to exposure to drug. Exposure of drug to this 
phenotype results in an increased frequency of mutation (De Vita, 
1983; Carter, 1984; Riordan and Ling, 1985). Thus resistance to 
adriamycin for example would spontaneously lead to resistance 
developing to other drugs (Merry et al, 1986; Merry et al, 1987).
From early theories of resistance to 5FU which indicate the resistance 
to 5FU implies defective RNA metabolism taking place in cells, to the 
more recent concepts of a spontaneously generated mutation resulting 
in resistance to 5FU, it would appear that if cells were in any way 
resistant to the effects of 5FU and RNA metabolism was therefore 
altered in such cells, inhibition of mitochondrial biogenesis may not 
take place as a result of 5FU treatment. If, however, RNA metabolism 
was altered in such cells, mitochondrial biogenesis might be less 
under the control of RNA metabolism than first envisaged.
Studying expression of mitochondrial enzymes as a means of indicating 
the effectiveness of biogenetic inhibitors is a powerful and useful 
technique. The approach used here expressing mitochondrial enzyme 
activities as a function of inhibition is not the most sensitive 
method. With hindsight, gel electrophoretic techniques are more 
sensitive, although this would have required mitochondrial isolation 
from cells obtained from a tissue culture source. Well documented 
inhibitors of biogenesis could have been selected for these studies, 
but would not have had much clinical relevance with particular 
reference to anticancer chemotherapy.
The studies described in this chapter may be summarised as follows:
R6G exerts a clear inhibitory effect upon cell growth and at specified 
concentrations exerts a cytotoxic effect upon WIL. Lamprene is less 
toxic than R6G, but is also inhibitory upon the growth of WIL. 5FU 
appeared to be the least effective compound against the growth of WIL.
However, it did appear to exert a cytostatic effect upon the growth of 
WIL. Toxicity data indicate that cells might be resistant to the 
effects of the drug. Continuous exposure of WIL and W256 had little 
effect upon the induction of mitochondrial enzymes measured, although 
this might be a reflection of suboptimal duration of exposure to drug 
or a subinhibitory concentration of 5FU. No inhibition of tumour 
mitochondrial biogenesis was observed in vitro.
CHAPTER 7
ENHANCEMENT OF THE CYTOTOXIC EFFECT OF ANTIMITOCHONDRIAL AGENTS ON 
CELLS GROWN IN GLUTAMINE AS AN ENERGY SOURCE
INTRODUCTION
Cells in culture are thought to utilise glucose as a major energy
source. Under anaerobic conditions cells obtained limited quantities
of ATP from glucose., Glucose is oxidized to pyruvate and undergoes 
reduction to lactate by anaerobic glycolysis with the production of 
ATP (Eagle, 1955; Paul, 1965;, Gregg, 1972; Weinhouse, 1982). For 
some time glutamine was described as an essential requirement of cells 
in culture, although early studies emphasised its importance in the 
biosynthesis of non-essential amino acids and incorporation into 
protein (Eagle, 1959; Patterson, 1972). More recent studies have
indicated that if cells are provided with glutamine, ATP might be 
derived from mitochondrial activity. Studies with ^C-labelled
glucose and glutamine have shown that oxidation of glutamine provides 
a major source of carbon for energy production in a variety of cells. 
(Zielke et al, 1976; Donnelly and Scheffler, 1976; Pardridge et al, 
1978; Reitzer et al, 1979; Wice et al, 1980; Moreadith and Lehninger, 
1984; Patel et al, 1984; Zielke et al, 1984).
In normal intact tissues as well as cultured cells, glutamine entry 
into the TCA cycle is achieved through formation of ct -ketoglutarate 
(Meister 1965). Recently it has been postulated that in tumour cells 
glutamine serves as a source of pyruvate. Glutamine is converted to 
-ketoglutarate and via the TCA cycle forms Malate. Malate serves as 
a source of pyruvate which is then oxidized to acetyl CoA by the 
multienzyme pyruvate dehydrogenase complex. The acetyl CoA formed 
serves as the main carbon skeleton for subsequent oxidation. The 
participation of the mitochondrial Malic enzymes, in this process have 
been emphasised. In particular the NAD(P)+ dependent Malic enzyme 
[Malate Dehydrogenase (oxaloacetate-decarboxylating) (NADP+) EC
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1.1.1.40], which is absent or low in activity in normal mitochondria 
has been identified in both hepatomas and mouse ascites [Sauer and 
Dauchy, 1978; Sauer et al, 1980]. Pyruvate formed by this enzyme is 
thought to stay within the mitochondria, thus the whole process is 
thought to occur within this organelle. However, Moreadith and 
Lehninger [1984] claim that the oxidation of glutamine by tumour 
mitochondria is accompanied by metabolic interactions with cytosolic 
Malate and/or pyruvate.
Oxidative breakdown of glutamine by cells in culture cannot proceed 
without molecular oxygen as the final electron acceptor. Under 
culture conditions, it was thought that cell metabolism was purely 
anaerobic. However, it has been demonstrated that oxygen is a 
necessary requisite for cell survival in culture (Brosemar and Rutter, 
1961; Paul, 1965; Thomas, 1986). From estimates of the oxygen 
utilisation of Hela cells and the rate of depletion of glutamine by 
cultured Hela cells, a minimum of 9ATP molecules per molecule of 
glutamine utilised are thought to be generated (Reitzer et al, 1979).
In chapter 5, experimental evidence was presented which showed that 
R6G inhibited tumour cell mitochondrial function in vitro. The aim of 
the studies described in this chapter was to examine possible 
mechanisms by which the effects of R6G could be improved. Cells made 
dependent on mitochondrial energy metabolism show increased 
sensitivity to antimitochondrial agents (Patel et al, 1984). Thus the 
cytotoxic action of R6G might be enhanced in cells grown in glutamine 
as an energy source, since cellular ATP could be maintained only in 
the presence of functional mitochondria.
The cytotoxic action of R6G was investigated in tumour cells grown in 
medium containing either glucose and glutamine or glutamine alone as 
the energy source. Oligomycin, a specific inhibitor of the 
mitochondrial ATP synthase, was also examined in this system. 
Considerable evidence exists to suggest how oligomycin is thought to 
interact with a component of the ATP synthase. The oligomycin 
sensitive protein is a region of the enzyme complex thought to bridge 
the proton translocating element to the main ATP synthetase component,
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the F*l complex. Inhibition with oligomycin is therefore thought to 
stop energy transduction as proton translocation is uncoupled from ATP 
synthesis (Shaw, 1967; Senior, 1979; Prebble, 1981). The cytotoxic 
action of oligomycin upon tumour cells grown in medium containing 
glutamine as the energy source should confirm whether or not the 
approach is suitable for application to screening antimitochondrial 
agents as described.
Initially suitable media were selected for use in these studies. Once 
these were established, the toxicity of antimitochondrial agents was 
assessed in cells grown either in glucose and glutamine or glutamine 
alone. The tissue culture media selected for these experiments were 
developed from Patel et al (1984).
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METHODS
Growth Media
Growth media for cells were as follows:-
1. Hams F10 : DMEM (50 : 50) supplemented with FCS (10%) and 
glutamine (2mM); This medium contained approximately 15mM 
glucose.
2. Minimal Essential Medium (MEM) with Hanks balanced salts solution 
(HBSS) (Flow Laboratories, Irvine) supplemented with FCS (10%) and 
glutamine (2mM). The medium contained approximately 5.5mM 
glucose.'
3. MEM with glucose-free HBSS (Flow Laboratories, Irvine) 
supplemented with FCS (10%) and glutamine (2mM).
4. MEM with glucose-free HBSS supplemented with glutamine (2mM), and 
dialysed FCS (10%). 200ml serum was dialysed against 1 litre of 
physiological saline (NaCl, 0.9%) for 6 to 8 hours at 4°C. The 
saline was replaced with fresh NaCl four times during dialysis. 
Serum was sterilised by filtration (Sterivex G, 0.22um, Millipore, 
Harrow, Middlesex).
Estimation of growth rates
The effect of serum dialysis upon the growth of WIL was determined as 
follows. Cells were seeded into 25cm^ flasks (Falcon, Becton
Dickinson, Cowley, Oxford) at an initial concentration of 7 x lcA 
cells per flask (1.4 x 10^ cells per ml). Cells were seeded and fed 
with either medium 2, 3 or 4. After allowing cells to attach and 
initiate growth for 2 days, cells were fed every 48 hours. Flasks 
were observed under phase contrast for growth characteristics. 
Estimation of growth rates was carried out as described in chapter 6.
Determination of the glucose content of the growth media
WIL was seeded into flasks (25cm )^ at a concentration of 1.4 x 10^
cells per ml. Cells were fed at 48 hour intervals with either medium
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1, 2 or 3. Once the cells demonstrated exponential growth, they were 
fed and samples (0.2ml) of the medium were removed at intervals over 
the following 48 hour period. The samples were stored at -20°C prior 
to determination of the glucose content.
Estimation of the glucose content of growth media
Glucose was estimated by the Sigma-toluidine method (Hultman, 1959) 
with modifications by Hyvarinen and Nikkila (1962). A kit for 
assaying glucose by this method was purchased from Sigma, Poole, 
Dorset.
Sigma-toluidine reacts with glucose as follows:
O-toluidine + Glucose Acid  Coloured Complex
^eat (blue-green)
The intensity of the coloured complex was measured with a 
spectrophotometer at a wavelength of 635nm. The reaction of glucose 
with toluidine is stoichiometric and the amount of coloured complex 
formed is directly related to the glucose concentration in the sample.
Assay Method
Reagents for the assay are as follows:
A. Sigma-toluidine solution 6% (v:v) Sigma-toluidine in glacial 
acetic acid with thiourea added as a stabiliser.
Reagent was stored at room temperature.
B. Glucose stock solution. Glucose, lOg per litre (55.5mM) in 
distilled water with benzoic acid added as preservative.
A standard curve was constructed with appropriate serial dilutions of 
solution B (glucose, 0 to 13.75 mM). The assay procedure was as 
follows. Sample or standard, 0.1ml was placed in pyrex test tubes, in 
duplicate. To each was added solution A (5ml). Tubes were agitated 
by vortex mixing. All tubes were placed in a boiling water bath for 
10 minutes. Tubes were removed and cooled to room temperature by 
placing in tapwater for approximately 3 minutes. Tube contents were 
transferred to glass cuvettes and absorbance read at 635nm in a
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spectrophotometer. Readings were stable for 30 minutes. Appropriate 
controls were set up to ensure non-interference of phenol red and 
other components in samples with the assay. A linear relationship 
between absorbance at 635nm and glucose concentration was obtained 
(figure 7.1). The line of best fit was determined by regression 
analysis. The glucose concentration of unknowns were obtained for 
each sample time point in different media. Results, expressed as mM 
glucose concentration, were plotted against time.
Assay of Cytotoxicity
Cytotoxicity was determined by an assay based on the reduction of a 
tetrazolium dye, MIT, as described in chapter 2 (page 31 )•
Uptake of Rhodamine 6G into Cells
Cells were plated onto petri dishes at a concentration of 1 x lcA 
cells per ml of either medium 1, 2 or 3. Cells were allowed to attach 
and grow for 96 hours. Cells were then fed with fresh medium 
containing R6G (20uM). At intervals of 1, 10, 30 and 60 minutes 
medium was removed from cells and dishes were rinsed with PBS. A 
coverslip was placed over cells and they were observed by fluorescence 
microscopy (Polyvar microscope, Reichert Jung, Vienna, Austria). An 
excitation wavelength of 546nm was selected to observe R6G 
autofluorescence.
ABSORBANCE AT 635 NM
0.35
0
Figure 7.1:
16 mM
Absorbance at 635nm expressed against mM glucose 
concentration for a colorimetric method for assaying 
glucose concentration. A linear relationship between 
absorbance at 635nm and glucose concentration is obtained 
for the Sigma-toluidine method. The regression line fits 
the equation y = 0.039 x + 0.0322 where the correlation 
coefficient r = 0.994.
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Plate 7.1: WIL, cells after 8 days in culture in MEM containing
glucose and glutamine supplemented with undialysed FCS 
(10%). (X66 magnification).
Plate 7.2
Plate 7.3
: WIL, cells after 8 days in culture in MEM containing
glutamine supplemented with undialysed FCS (10%).
(X66 magnification).
: WIL, also after 8 days in culture in MEM containing
glutamine supplemented with dialysed FCS (10%).
(X66 magnification).
RESULTS
Effect of dialysed serum upon the growth of WIL in MEM containing 
glutamine
Plates 7.1, 7.2 and 7.3 show the appearance of cultures of WIL 8 days 
after seeding in various media. Growth and attachment of cells is 
observed in cells incubated with MEM containing glucose and glutamine 
or glutamine alone provided undialysed FCS (10%) is present (Plates 
7.1 and 7.2). Cells incubated in medium containing dialysed serum 
showed very limited growth (Plate 7.3).
Growth of WIL medium containing either glucose and glutamine 
or glutamine
The growth of WIL in MEM containing either glucose and glutamine or 
glutamine alone is shown in figure 7.2. There is a slight increase in 
the growth rate of cells in glutamine compared to cells grown in 
medium containing both glucose and glutamine. Cells grown in
glutamine reach saturation density in 6 to 7 days compared to 10 days 
in the presence of glucose.
Glucose content of the culture medium
Figure 7.3 shows the glucose content of the growth medium sampled at 
various times after addition to the cells. Initially the glucose 
concentration in F10:DMEM was about 15mM, the concentration decreased 
to lOmM, 48 hours after incubation with cells. The glucose 
concentration in MEM containing glucose and glutamine decreased from 
6mM to 3.5mM over the same period. The glucose concentration in
medium containing glutamine alone was negligible over the 48 hour 
period. Plates 7.4, 7.5 and 7.6 show cells in the respective media at 
the end of the incubation period. There was no significant difference 
in the appearance of the cells grown in MEM containing glucose and 
glutamine or glutamine. The cells grown in F10:DMEM did however 
appear to exhibit a higher cell density after 48 hours growth.
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Figure 7.2: The growth of WIL in medium containing glucose and 
glutamine or glutamine alone. Results expressed as cell 
number per well against time in days. Cells were seeded 
at day - 3 and cell counts taken at 2 days intervals from 
day 0 onward.
Values are mean + SEM (n = 3).
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Figure 7.3: Glucose concentration of medium incubated with WIL over a
48 hour period.
Results expressed as mM glucose against time in hours. 
Media incubated with cells included F10:DMEM, MEM 
containing glucose and glutamine and MEM containing 
glutamine. Cells were fed at 0 hours and 48 hours.

Plate 7.
Plate 7.5
Plate 7.6
: WIL, cells after 8 days in culture in FlOsDMEM.
(X33 magnification).
: WIL, cells after 8 days in culture in MEM containing both
glutamine and glucose. (X33 magnification).
: WIL, also after 8 days in culture in MEM containing
glutamine. (X33 magnification).
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Effect of Rhodamine 6G on the growth of WIL in medium 
Containing either glutamine or glucose and glutamine 
The effect of a 24 hour exposure to R6G (1, 10 or 50uM) upon the 
growth rate of WIL in medium containing glucose and glutamine is shown 
in Fig. 7.4. R6G caused a significant inhibition of cell 
proliferation. However, after a lag phase cell proliferation was 
observed with a R6G concentration of luM. In contrast, no recovery 
was observed with R6G at a concentration of 10 or 50uM. The effect of 
a 24 hour exposure of WIL to R6G (1, 10 or 50uM) in medium containing 
glutamine is shown in Fig. 7.5. Again R6G caused a significant 
inhibition of cell proliferation. After a lag phase, cell growth was 
observed with R6G concentrations of both 1 and lOuM. No recovery was 
observed at a R6G concentration of 50uM.
Cytotoxic action of R6G and Oligomycin
Table 7.1 shows the ID^q of R6G and oligomycin for cells grown either 
in medium containing glutamine or glucose and glutamine. For R6G the 
ID50 is similar regardless of the medium used. However, for 
oligomycin there is a 9-fold reduction in the ID^q in medium 
containing glutamine when compared to that in medium containing 
glucose and glutamine.
Effect of Medium Composition on Rhodamine 6G uptake
Plate 7.7, shows the distribution of R6G 1 minute after addition to
cells. Cells were grown in either F10:DMEM, MEM containing glutamine
only or MEM containing glucose and glutamine. There appeared to be no
difference in the distribution of dye in cells in any of the three
media.
Plate 7.8 shows the distribution of R6G 30 minutes after addition to 
cells. Cells were grown in F10:DMEM, MEM containing glutamine or MEM 
containing glucose and glutamine respectively. There was no 
difference in the distribution of dye in cells in any of the three 
growth media. However, compared to the drug distribution in plate 
7.7, fluorescence was much greater in the cytoplasm and appeared to be 
less specific in intracellular distribution.
CELL N O f x io 4 )
140
a OUM
DRUG l uM
70
10 UM
50 uM
DAYS
Figure 7.4: Growth of WIL in glucose and glutamine following exposure 
of cells to R6G for 24 hours.
Results are expressed as cell number per well against 
time in days. Cells were seeded at day -3 and cell 
counts taken at 2 day intervals from day 0 onward. 
Values are mean + SEM (n - 3).
Drug incubation (luM, lOuM, 50uM) was carried out on day 
0, Recovery was measured over a 14 to 16 day period.
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Figure 7.5; Growth of WIL in glutamine alone following exposure of 
cells to R6G for 24 hours.
Results expressed as cell number per well against time in 
days. Cells were seeded at day -3 and cell counts taken 
at 2 day intervals from day 0 onward. Values are mean + 
SEM (n - 3). Drug incubation (luM, lOuM, 50uM) was 
carried out on day 0.
Recovery was measured over a 14 to 16 day period.
id50 (M)
DRUG
MEM
GLUCOSE + GLUTAMINE N
MEM
GLUTAMINE N
Rhodamine 6G 1.05 + 0.46 x 10-6 4 1.06 + 0.5 x 10’6 4
Oligomycin 1.55 x 10"8 2 1.72 x 10"9 2
Table 7.1: The amount of drug required to kill 50% of the cells
( I D ^ q )  for each growth medium. Values are mean + SEM.
Plate 7.7
Plate 7.8
Plate 7*7: WIL grown in F10:DMEM following exposure to R6G, 20uM
after 1 minute. (X225 magnification).
Fluorescence Excitation wavelength = 546nm.
Plate 7.8: WIL grown in MEM containing glucose and glutamine
following exposure to R6G, 20uM after 30 minutes (X225 
magnification).
Photographic conditions as for plate 7.7.
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DISCUSSION
The results of experiments described in this chapter show that the 
human non-small cell lung cancer line WIL can maintain growth and 
proliferate when glutamine is supplied as a primary energy source in 
place of glucose. R6G inhibited cell proliferation in media 
containing either glucose and glutamine or glutamine. Growth in 
glucose-free medium allowed recovery from a higher concentration of 
R6G than was observed in medium containing glucose. From assays of 
cytotoxicity, ID^q values obtained with R6G were identical for cells 
grown either in glucose and glutamine or glutamine alone. Thus there 
appeared to be no enhancement of the cytotoxic action of R6G in cells 
dependent on glutamine. Clearly, alteration of cellular energy 
metabolism has no effect upon the sensitivity of cells to R6G. The 
increased recovery from R6G (lOuM) of cells grown in glutamine alone 
as an energy source may reflect the more rapid growth of cells in this 
medium. Alternatively cells grown in glutamine may exhibit 
alterations in their handling of R6G. However, studies which examined 
the uptake of R6G in media containing either glutamine or glucose and 
glutamine did not show any difference in the uptake or handling of R6G 
as determined by fluorescence microscopy.
Results with the classic mitochondrial inhibitor oligomycin showed a 
decrease in the ID^q from 15.5nM to 1.7nM. Thus a 9-fold enhancement 
of cytotoxicity to oligomycin in cells grown in glutamine was 
observed. These results suggest that when cells are dependent upon 
their mitochondria for an energy supply, agents such as oligomycin are 
indeed more cytotoxic. However, this was not the case for R6G. This 
supports the observations (discussed in chapter 5) that R6G is not 
simply an antimitochondrial agent, but may have other sites of action 
which are responsible for cytotoxicity.
Rhodamine 1, 2, 3 an analogue of R6G has been described as exerting 
its cytotoxic action by some mechanism other than by inhibition of 
mitochondrial function, possibly inhibiting mitochondrial protein 
synthesis (Abou-Khalil et al, 1986). More recently R6G has been shown 
to exhibit inhibitory activity upon protein phosphorylation in rat
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brain extracts (OfBrian and Weinstein, 1987). Therefore, although R6G 
does have antimitochondrial activity in vitro, this may be only one of 
its cytotoxic actions.
An essential requirement for studies of this nature is the adequate 
removal of glucose from cells. The use of dialysis to remove glucose 
from serum in the culture media resulted in an inability of the medium 
•to support cell growth. This may have been due to loss of essential 
small molecules such as growth factors, as well as glucose during 
dialysis. The glucose content of the glutamine medium containing 
undialysed FCS did appear to be negligible. However, glucose 
requirements for cells in culture can be as little as 0.8 to 0.3mM 
(Graff, et al, 1965; Racker, 1965). The technique selected for 
determination of glucose content of the culture medium was a fairly 
insensitive method. However, this method was chosen rather than the 
more specific and sensitive glucose oxidase based assays capable of 
detecting nanomole quantities of glucose in serum. The method 
selected is not specific and detects other (^ -D-glucopyranose molecules 
such as fructose, galactose or mannose which are favoured glycolytic 
substrates for cells in culture, and would also have been detected if 
present in large enough concentrations (Cristofalo and Kritchevsky, 
1965; Reitzer, et al, 1979). It is known that tumour cells in culture 
have access to glycogen stores, although the amount of stored glycogen 
in cells is rapidly depleted if the glucose concentration of the 
medium is reduced (Wu, 1959; Paul, 1965; Racker, 1965). It is not 
clear whether glucose is primarily a glycolytic substrate as there is 
evidence to suggest that glucose derived pyruvate may fuel significant 
mitochondrial metabolism (Pardridge, et al, 1978). If glutamine is 
more important as an energy substrate, the residual glucose present in 
tissue culture medium as a result of supplementing media with 
undialysed serum may be of less importance as an energy source.
In order to confirm that cells are more sensitive to antimitochondrial 
agents when glutamine is supplied as the major carbon source, 
glutamine must be shown to be metabolised by mitochondrial pathways. 
Other workers have indicated that up to 60% of glutamine is utilised 
by mitochondrial oxidation. However, 10 to 20% of the glutamine
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supplied, may undergo transamination to generate pyruvate for lactate 
fermentation. Primary metabolism is therefore mitochondrial, but 
significant amounts of ATP may be derived from non-mitochondrial 
utilisation (Windmueller and Spaeth, 1974; 1975; Reitzer, et al, 1979; 
McKeehan, 1982). Lactate production through oxidation of glutamine is 
not necessarily indicative of glycolysis however. Some workers have 
stated that lactate production may be a way of generating acetyl CoA 
for auto-oxidation via the TCA Cycle (Zielke, et al, 1980). Others 
have suggested that glutamine oxidation may merely serve as a stimulus 
for glycolytic cleavage of glucose when supplied exogenously (Lanks,
1986). More recently it has been suggested that glutamine utilisation 
is primarily required for end product biosynthesis of amino acids or 
TCA cycle intermediates, with energy production as a secondary 
feature. Thus the TCA cycle is essentially used as a linear pathway 
to generate aspartate or citrate for example, from glutamine carbon, 
though some ATP is generated through oxidative phosphorylation (Lanks,
1987). An assessment of lactate production and ammonia production 
would have been useful in confirming to what extent mitochondrial 
utilisation of glutamine had occurred. There are other substrates 
present in tissue culture medium which may have been utilised as a 
carbon source, such as branched chain amino acids or free fatty acids. 
The extent to which these substrates are utilised might be a feature 
of the cell type under study. For example, mouse macrophages may 
utilise some of these substrates as a carbon source (Newsholme, et al, 
1987; Thomas, 1986).
In order to maintain cells in glutamine, cells had to be fed at not 
more than 48 hour intervals, although the protocol for some 
experiments necessitated a 24 hour period between feeding. This might 
have reflected the lability of glutamine which is known to be unstable 
in culture medium at 37°C, although some workers claim that the 
compound is stable for 5 to 6 days. (Tritsch and Moore, 1962; 
Griffiths and Pirt, 1967). Alternatively it is possible that rapid 
utilisation of glutamine or a build up of toxic ammonia might have 
inhibited growth in flasks where feeding periods exceeded 48 hours. 
It has been recognised that cells in culture have a carbohydrate 
requirement for utilisation in the pentose phosphate pathway,
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essential for the manufacture of deoxyribose and thus nucleic acid 
synthesis (Reitzer, et al, 1979; Zielke, et al, 1984; Thomas, 1986). 
This requirement would only have been met by residual glucose present 
in serum or endogenous glucose derived from stored glycogen. 
Depletion would have effectively halted cell growth, though the time 
course within which this would have occurred is uncertain. Some 
hexoses formed as a result, such as Fructose-6-phosphate would have 
been generated as glycolytic substrates, though in very small amounts 
(Lehninger, 1975; Pardridge, et al, 1978).
Some workers have shown that cell growth can take place in the 
presence of mitochondrial inhibitors and have reasoned that energy 
production by glycolytic means has greater significance for the cell 
than mitochondrial pathways (Donnelly and Scheffler, 1976; Wiseman and 
Attardi, 1979; Morais, 1980). Results obtained in these studies show 
that the increased sensitivity to oligomycin by cells grown in 
glutamine confirm that the energy contribution by glycolysis was 
limited.
Cells may have a preference for other substrates and therefore, any 
enhancement of cytotoxicity might reflect metabolic instability if 
access to a preferred substrate is denied (Donnelly and Scheffler, 
1976; Morais, 1980; Newsholme, et al, 1986). Furthermore it might not 
necessarily be possible to show that an antimitochondrial agent shows 
a selective cytotoxic effect over general cytotoxic agents with cells 
grown on non-glycolytic substrates. Any general cytotoxic agent would 
inhibit cellular energy metabolism by a secondary or tertiary action. 
However, the results obtained with oligomycin and R6G show that a 
general cytotoxic agent whose toxicity is not determined by a specific 
antimitochondrial action does not show any enhanced toxic effect 
against cells grown in glutamine.
The experiments described in this chapter may be summarised as 
follows:-
A system was established to determine whether a mitochondrial energy 
source made cells more sensitive to antimitochondrial agents. Cells 
were able to grow in culture medium containing glutamine as the major
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energy source. This medium was shown to be essentially free of
glucose. An enhanced sensitivity to the specific antimitochondrial 
agent oligomycin was observed with cells grown in glutamine as an 
energy source. R6G did not appear to show an enhanced cytotoxic
action upon cells grown in glutamine. Although this compound has 
antimitochondrial activity, this may not be its major cytotoxic 
property.
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CHAPTER 8
SELECTIVE MANIPULATION OF TUMOUR CELL ENERGY METABOLISM:
STUDIES IN VIVO
INTRODUCTION
The studies described in this chapter were aimed at evaluating how 
effective novel combination chemotherapies directed at tumour cell 
energy metabolism would be in retarding growth of tumours which were 
resistant to conventional therapy in vivo.
Studies carried out with fluorescent cationic dyes such as R123 
indicate that rhodamine has a highly specific affinity for tumour 
cells in vitro. Uptake of R123 appeared to be specific for neoplastic 
and transformed cell lines and resulted in selective toxicity toward 
tumour cells at concentrations which were non toxic to non-neoplastic 
cells (Bernal et al, 1982(b); Lampidis et al, 1983; Nadakavukaren et 
al, 1985). R123 and an analogue R6G were observed to have a highly
specific affinity for mitochondria and thus selective toxicity was 
attributed to inhibition of tumour cell bioenergetic function in vitro 
(Gear, 1974; Higuti et al, 1980; Davis et al, 1985; Modica-Napolitano 
and Aprille, 1987). Experiments described in chapter 4 confirmed that 
R6G does exert an inhibitory action upon tumour cell respiration, 
hence energy metabolism vitro at concentrations which appear not to 
alter respiratory activity in normal cells.
R123 when given in combination with 2-deoxyglucose, an inhibitor of 
glycolysis, was effective in increasing the survival times of mice 
bearing Ehrlich ascites tumours. This treatment however was of 
limited value when applied to a variety of other tumours or leukaemias 
(Bernal et al, 1983). 2-deoxyglucose is a non metabolisable analogue 
of glucose. It is thought to prevent metabolism along the glycolytic 
pathway at the reaction catalysed by hexokinase (E.C. 2.7.1.1) to form 
2-deoxyglucose-6-phosphate from 2-deoxyglucose. Glycolytic inhibition 
is thought to result from competition between 2-deoxyglucose and
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glucose for hexokinase. A consequence of this is that phospho- 
glucoisomerase (E.C. 5,3.1.9) which normally catalyses conversion of 
glucose-6-phosphate to fructose-6-phosphate is inhibited by 2- 
deoxyglucose-6-phosphate (Wick et al, 1957; Barban and Schulze, 1961). 
Studies with 2-deoxyglucose have had some success in reducing growth 
of animal tumours. It is thought that the effects upon respiration of 
2-deoxyglucose are responsible for the antitumour effect (Woodward and 
Hudson, 1954; Ball et al, 1957).
Initial studies carried out in this Department were designed to 
evaluate to what extent tumour growth could be reduced with inhibitors 
of mitochondrial function, R123 and R6G, in combination with the 
antiglycolytic agent 2-deoxyglucose. Preliminary work with R123 was 
carried out on the Walker 256 (W256) rat carcinosarcoma. R123 
injected alone intraperitoneally (I.P.) did reduce the rate of growth 
of the tumour. When administered in combination with the glycolytic 
inhibitor 2-deoxyglucose, the growth rate was reduced by more than 75% 
provided that the drugs were administered 24 hours after implantation. 
When given 48 hours after implantation no such inhibition was 
observed. If however, a related compound R6G was administered 48 
hours after implantation, tumour growth inhibition was apparent 
(Fearon et al, 1985(a)). Since drug therapy was initiated immediately 
after inoculation of animals with tumour, it is possible that 
inhibition of angiogenesis rather than tumour growth might have been 
observed. Thus a more rigorous approach was required for these 
studies.
The antileprosy agent lamprene (clofazamine hydrochloride) is known to 
inhibit respiratory function hence energy metabolism in both yeast and 
isolated rat liver mitochondria (Rhodes and Wilkie, 1973). A possible 
role in cancer chemotherapy has been implicated for this compound 
following similar results obtained with transformed fibroblasts 
(Wilkie, 1979). Experiments described in chapter 4 confirmed that 
lamprene inhibited tumour cell bioenergetic function in vitro. As yet 
no studies have been carried out to ascertain the potential of 
lamprene in experimental cancer chemotherapy in vivo.
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The earlier work with the W256 tumour allowed rapid accumulation of 
preliminary results since this tumour has a rapid growth rate. 
However, in order to examine whether manipulation of tumour cell 
energy metabolism is a valid approach to chemotherapy, a model more 
closely related to human tumours was required. Studies were therefore 
initiated to investigate a human non-small cell bronchial carcinoma, 
WIL which grows subcutaneously in immuno-incompetent athymic mice. 
This tumour has been shown to be resistant to conventional 
chemotherapeutic agents such as adriamycin and etoposide (Merry et al,
1986).
From previous studies with rhodamine, the compound appears to remain 
in tumour cells for some time (3 to 5 days) after administration both 
in vivo and in vitro (Summerhayes et al, 1982; Beckman Jr et al,
1987). This suggested that repeated injections were likely to exceed 
toxicity threshold. As described in chapters 4 and 5, lamprene 
required solubilisation in dimethylsulphoxide (DMSO). This suggested 
that insolubility might pose a major barrier to metabolic breakdown 
and excretion by tumour cells and thus drug accumulation was likely to 
occur in aqueous cell compartments over several days. 5-Fluorouracil 
(5FU), an antimetabolite of uracil used as a conventional anticancer 
agent has been shown to inhibit mitochondrial biogenesis in both lower 
eukaryotes and cultured mammalian cells (Oliver and Williamson, 1977; 
Bugeja et al, 1987). Preliminary work in this Department indicated 
that at a concentration well below that used in conventional 
chemotherapy, 5FU inhibited the growth rate of the W256 tumour by 
about 50%. When combined with a dose of R6G, which on its own caused 
a 10% reduction in tumour growth, a synergistic effect was observed, 
such that tumour growth was almost completely inhibited provided that 
rhodamine 6G was given within 8 hours of 5FU administration. 5FU is 
retained for up to 72 hours, throughout a variety of tissues in mice 
(Chadwick and Rodgers, 1972; Liss and Chadwick, 1974). Thus it would 
appear that all the agents selected for the study had prolonged 
retention times and single administration was likely to suffice for 
experimental purposes, at least initially.
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The effectiveness of any therapy directed against solid malignancies 
implanted subcutaneously in athymic mice must be accurately assessed. 
Methods used previously are based upon estimating tumour growth from 
caliper measurements of the tumour and estimating tumour volume from 
the equation:
Tumour Volume = T T x (diameter)^ (Steel, 1977;
6 Poulsen et al, 1982).
This method assumes a uniform shape of the tumour and lacks precision. 
A method was required which was both accurate and precise. In these 
studies a novel method has been developed with which to estimate 
tumour volume. It is based upon casting moulds of each tumour in 
dental alginate and determining the volume of water required to fill 
each impression cast. Thus precise estimates of tumour volume could 
be made. This method was sufficiently sensitive to be able to detect 
small changes in growth rates.
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METHODS
Animals
Batches of newly weaned female a thymic mice of the MF-1 strain were 
obtained from commercial sources (OLAC, Bicester, Oxon) or from 
animals bred in sterile isolators in the CRC Department of Medical 
Oncology. Animals were kept in sterile cages in vertical laminar flow 
hoods during the course of experiments. Pre-sterilised food (Special 
Diet Services, Essex) and water were given to mice ad libitum. Cages, 
food and water were sterilised by autoclaving with steam at 120°C for 
30 minutes. Groups of 32 to 40 mice, of the same age were used in 
each experiment. Experimental animals were implanted with WIL tumour 
from animals passaged routinely in the animal house.
Tumours
The tumour was the same as that used for the studies jui vitro. This 
was the lung adenocarcinoma WIL. It was maintained by routine passage 
every 4 to 6 weeks in a thymic nude mice. Tumour passage was carried 
out under sterile conditions within the laminar flow hood which housed 
the mice. All instruments were sterilised by autoclaving. A tumour 
bearing animal was killed by cervical dislocation and the tumour 
removed to a sterile petri-dish. Viable tumour was dissected into
o
pieces, 2 - 3mm. Animals for implantation were anaesthetised with 
ether in a sterile ether jar. Anaesthesia was maintained with a 
sterile cotton wool pad, soaked in ether, placed over the nose. An 
incision was made in the skin, 3 - 4mm long above one of the hind 
limbs with fine tipped scissors. The scissor tips were inserted 
subcutaneously and widened slightly to open the incision. With a pair 
of fine forceps the incision was held open and with a second pair of 
forceps, a piece of tumour was inserted into the wound. Once in place 
the skin was secured by sterile clips (Vicary Davidson, Glasgow). 
Animals were placed in fresh sterile cages in the laminar flow hood.
Determination of Tumour Volume
Tumour volumes were estimated from moulds of each tumour cast in 
dental impression material. All procedures were carried out in a 
laminar flow hood as aseptically as possible. Tumour bearing mice
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were anaesthetised with ether. Whilst the animal was being 
anaesthetised, 2 to 5g of elastigel (Wrights Dental Suppliers, Dundee, 
Scotland) was mixed with an equal quantity of tap water and poured 
into a plastic bottle top (30mm diameter x 20mm height). The 
anaesthetised animal was held over the cast for 2 - 3  minutes, such 
that, the tumour formed an impression in the elastigel. Anaesthesia 
was maintained by a nose cone containing cotton wool steeped in ether. 
The animal was replaced in its cage. The set mould was removed from 
the cast by means of a microspatula. The number assigned to each 
animal by means of ear tags was recorded on a strip of card. This 
number was then clipped on to each mould with rocket clips (Vicary 
Davidson, Glasgow). Moulds were stored at 4°C for between 24 and 48 
hours in plastic sandwich boxes. Storage beyond this resulted in 
deterioration of the cast. Tumour volume was estimated by determining 
the weight of water required to fill each impression.
Experimental Protocols
Mice were implanted with the tumour. After 4 to 6 weeks, when the
o
tumour volume was about 500mm , the mice were randomised into four 
groups of 8 to 10. Animals were identified by means of numbered ear 
tags. Tumour volumes were measured for each mouse and the total body 
weight recorded. Drugs were then administered as a single I.P. 
injection at a dose related to the body weight of each mouse. Control 
animals received an equal volume of phosphate buffered saline (PBS). 
Drugs were administered either alone or in combination. R6G was 
administered at a concentration well below the toxic dose as assessed 
from previous experiments (4 2mg/kg). A single non cytotoxic dose of 
5FU (50 mg/kg“ )^ was administered as determined by the LD50 in normal 
mice (LD50 = 50mg kg“  ^ day"^ for 10 days, Roche, Personal
Communication). Lamprene was administered at a concentration that was 
also well below the LD^q in normal mice (LD50 > 4000mg kg“  ^ Merck 
Index, 1983). Because of problems with solubility, lamprene was given 
orally. The mouse diet was ground to a fine powder, sterilised, mixed 
with lamprene (0.05% of the diet by weight) and moistened to a mash 
with sterile water. Mice were given this diet for 15 days. Tumour 
volumes were measured at intervals of 7 days following drug 
adminis tration•
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Estimation of Tumour doubling times
Growth of subcutaneously implanted tumours proceeds according to a 
pattern that deviates from exponential growth and is described as 
gompertzian (Laird, 1964; Laird, 1965; Steel, 1977; Poulsen et al, 
1982). Tumour growth over the period of study however was almost 
linear. Tumour doubling times were therefore estimated over a 7 day 
period or over the duration of the experiment. Tumour doubling times 
were estimated as follows
Vt = Volume at any given time t
x = Time in days of duration of experiment
Vo = Volume in ml on day of drug administration (week 1)
Vx = Volume in ml at end of experiment (week 4).
where growth per day = Vx - Vo
x
Tumour doubling time in days = 2 x Vt
Growth per day
Statistical Analysis
The significance of any difference was determined by Students *tf 
test.
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Treatment Time After Treatment Doubling Time SEM N
Dose_________ Days________________ Days___________________
Control 17 39.1 2.9 6
2 Deoxyglucose 15 55.3 3.0 6 *1
0.5g/Kg
Lamprene 16 61.8 3.1 6 *2
0.05% Diet
2 Deoxyglucose + 16 52.4 4.2 6 *3
Lamprene
0.5g/Kg
0.05% Diet
P<0.005 *1
P<0.0005 *2
P<0.025 *3
Table 8.1: Effect of 2-deoxyglucose and lamprene, administered
individually and in combination upon the estimated
tumour doubling time of WIL xenografts implanted
subcutaneously in a thymic mice. Results are expressed
as mean doubling times in days + SEM, where n = 6.
Statistical analyses performed with unpaired t-tests.
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RESULTS
Estimation of Tumour Volume
Figure 8.1 shows the relationship between tumour volume estimated from 
caliper measurements and the actual weight of the tumour after 
excision from the animal. Figure 8.2 shows the relationship obtained 
when tumour volume is estimated by a mould cast from the same tumours. 
Both estimates correlate well with the actual tumour weight. However, 
when tumour volume is estimated from moulds there is far less scatter 
about the regression line than when calipers are used.
Effect of Lamprene and 2-deoxyglucose on the growth rate of WIL 
Table 8.1 shows the effect of 2-deoxyglucose and lamprene on the 
growth of WIL implanted subcutaneously in athymic mice. Both lamprene 
and 2-deoxyglucose administered alone, produced a significant increase 
in the tumour doubling time (P<0.005; P<0.0005 respectively). No 
synergistic effect on tumour doubling times was observed when the 
compounds were administered together. However, significant tumour 
growth delay was induced with this combination (P<0.025).
Effect of R6G and 2-deoxyglucose on the growth rate of WIL 
Table 8.2 shows the effects of R6G and 2-deoxyglucose on the growth of 
WIL implanted in nude mice. There was no increase in tumour doubling 
times regardless of whether the agents are given alone or in 
combination. Moreover it is clear that tumour doubling times for 
animals treated with R6G or 2-deoxyglucose in combination with R6G are 
significantly decreased when compared with controls (P<0.025).
Effect of R6G and 5FU on the growth rate of WIL
The effect of 5FU and R6G on the growth of WIL implanted 
subcutaneous ly in athymic mice is shown in Table 8.3. Each agent when 
administered alone did not significantly alter tumour doubling time 
relative to controls. However in combination, an almost 2-fold 
increase in doubling time was obtained (P<0.05).
Treatment
Dose
Time After Treatment Doubling Time SEM N
Days________________ Days___________________
Control 14 41.3 1.6 6
2 Deoxyglucose 14 41.5 2.2 6
0.5g/Kg
Rhodamine 6G 14 34.4 2.0 5
1.6mg/Kg
2 Deoxyglucose + 14 33.7 2.3 5
Rhodamine 6G
0.5g/Kg
1.6mg/Kg
P<0.025 *
Table 8.2: Effect of 2-deoxyglucose and R6G, administered
individually and in combination upon the estimated 
tumour doubling time of WIL xenografts implanted 
subcutaneous ly in athymic mice. Results are expressed 
as mean doubling times in days + SEM, where n = 5 to 6. 
Statistical analyses performed with unpaired t-tests.
Treatment Time After Treatment Doubling Time SEM N
Dose__________Days_______________ Days__________________ *
Control 7 19.5 1.7 6
Rhodamine 6G 7 23.0 2.7 7
2mg/Kg
5 Fluorouracil 7 18.7 1.7 7
50mg/Kg
Rhodamine 6G + 7 34.3 5.3 7
5 Fluorouracil
2mg/Kg
50mg/Kg
P<0.05 *
Table 8.3: Effect of R6G and 5FU, administered individually and in
combination upon the estimated tumour doubling time of 
WIL xenografts implanted subcutaneously in athymic mice. 
Results are expressed as mean doubling times in days + 
SEM, where n a 6 to 7. Statistical analyses performed 
with unpaired t-tests.
BODY W E IG H T  G R A M S
{  PB S N = 8 ±  SEM
INJECTION T=0
R6G N = B T 0 8 iS E M  
5FU
112*51 1501
1631
TIME DAYS
Figure 8.3: Effect of R6G (3.6mg/Kg~^) and 5FU (50mg/Kg” )^ in
combination upon mean body weight of athymic mice 
implanted with WIL tumour xenografts. Figures in 
parenthesis indicate percentage mortality in 
experimental group following single drug administration 
at T - 0. Controls received equivalent injection 
volumes of phosphate buffered saline.
3 0 - B O D Y  W E IG H T G R A M S
INJECTIO NS T = 0
LAMPRENE 12DG  
N = 7  IS  EM
T IM E  DAYS
Figure 8,4: Effect of lamprene (0.05% of diet) and 2-deoxyglucose
(0.5g/Kg“ )^ in combination upon mean body weight of 
athymic mice implanted with WIL tumour xenografts. 
Controls received equivalent injection volumes of 
phosphate buffered saline.
1 2 6 .
Effect of R6G and 5FU upon whole body weight
The effect of combined administration of 5FU and R6G upon whole body 
weight of athymic mice implanted with WIL tumour subcutaneously is 
shown in Figure 8.3. When compared to animals given saline injections 
(PBS) there is a clear reduction in body weight in animals given 
combination of R6G (3.6mg/Kg) and 5FU (50mg/KG). It is also apparent 
that the combination is toxic over a period of several weeks after 
drug administration, with mortality at 12.5% at 7 days after drug 
administration increasing to 63% at 21 days after administration.
Effect of Lamprene and 2-deoxyglucose upon whole body weight 
The effect of combined administration of lamprene and 2-deoxyglucose 
upon the whole body weight of nude mice implanted subcutaneously with 
WIL tumour is shown in Figure 8.4. When compared to animals given 
saline injections (PBS), a clear reduction in body weights is observed 
in animals given combinations of lamprene (0.05% by weight mixed with 
diet) and 2-deoxyglucose (0.5g/Kg~^). There was however, no enhanced 
toxicity in this experimental group when compared to controls 
administered with saline.
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DISCUSSION
From the results obtained in this study it is clear that both R6G and 
5FU in combination and lamprene and 2-deoxyglucose in combination 
delay the growth of WIL tumour implanted subcutaneously in athymic 
mice. With an accurate and precise method established for estimating 
changes in tumour volume it is also clear that R6G or 5FU administered 
individually have little effect upon tumour growth. However a clear 
synergism is observed when each drug is given in combination with a 
second agent. Lamprene and 2-deoxyglucose individually delay tumour 
growth and although synergism is not observed when each compound is 
administered in combination, a significant delay in tumour growth is 
still achieved. It is possible that this drug combination resulted in 
a reduced food intake, as indicated by a reduction in body weight in 
animals treated with lamprene and 2-deoxyglucose.
Mice administered with R6G and 2-deoxyglucose showed a significant 
reduction in tumour doubling time. This drug combination was in fact 
toxic and therefore weight loss associated with drug treatment 
probably accounted for a reduced tumour doubling time.
Weight loss induced in host animals bearing subcutaneous tumours does 
occur without drug treatment. Such a condition described as cachexia 
is defined as "the sum of those effects produced by neoplasms in the 
host, which are not the immediate result of mechanical interference 
with recognisable structures" (Costa, 1977). A major
symptom of this condition, weight loss, is not simply related to 
caloric intake, tumour burden or tumour cell type. Among controls, 
the WIL tumour does not induce cachetic weight loss although 
individual animals, sometimes exhibit cachexia like symptoms. This is 
not widespread. However, drug induced toxicity such as that caused by 
R6G and 2-deoxyglucose also causes animals to become sickly and lose 
weight, but this is more likely due to a reduced food intake.
The main aim of the work described in this chapter was to determine 
whether indeed selective manipulation of tumour cell energy metabolism 
could be achieved to inhibit or delay tumour growth without associated
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effects upon host metabolism. Lamprene and 2-deoxyglucose as 
antimitochondrial agent and antiglycolytic agent respectively, did 
appear to achieve delays in tumour growth, but clearly an effect upon 
host metabolism was observed following severe weight loss. R6G and 2- 
deoxyglucose as antimitochondrial and antiglycolytic agent 
respectively had no significant benefit in delaying tumour growth. 
Results indicate that although antimitochondrial therapy may prove to 
be of benefit in tackling growth of tumours resistant to conventional 
forms of chemotherapy, the choice of agents available may prove to be 
limiting.
2-deoxyglucose as an inhibitor of glycolysis might not be ideal. It 
was selected because earlier studies showed some success as a tumour 
specific antiglycolytic agent in studies with animal tumours (Ball et 
al, 1957; Bernal et al, 1983). Its mode of action is thought to occur 
via competitive inhibition of glycolytic enzymes (Wick et al, 1957; 
Barban and Schulze, 1961). It is conceivable therefore that prolonged 
contact of tumour areas supplied with blood glucose could eventually 
remove the effects of inhibition. Other workers have described other 
possible selective inhibitors of tumour cell glycolysis which have yet 
to be assessed (Floridi et al, 1981(a); Floridi et al, 1981(b); 
Guminska et al, 1986). Thus a thorough study of how best to maintain 
inhibition of glycolysis in vivo, so that effects upon tumour growth 
could be shown is required. Similarly single bolus injections of 
antimitochondrial agents are also likely to be of limited value unless 
it could be shown that the active component of each drug is exposed to 
the tumour for long enough, as observed with R6G.
A major drawback in utilising R6G, apart from the severe general toxic 
effects this agent has, even at very low doses, is the non specific 
nature of its tumour selective toxicity as described in Chapter 7. 
Recent studies having indicated possible modes of action of this 
compound other than inhibition of mitochondrial activity, which might 
explain toxicity. Both Abou-Khalil et al (1986) and Kuzela et al 
(1986) imply that rhodamine may exert biogenetic inhibition of 
mitochondria in normal mammalian cells. Furthermore, OfBrien and
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Weinstein (1987) indicate that R6G may exert a cytotoxic action upon 
cells following inhibition of protein kinase C.
The synergistic effects of 5FU and R6G upon tumour growth delay cannot 
be critically discussed in terms of biogenetic inhibition of tumour 
mitochondria being induced with 5FU and functional inhibition of 
tumour mitochondria being induced with R6G. From results obtained in 
Chapter 6, it was established that a clear inhibition of mitochondrial 
enzyme activity indicative of reduced expression of mitochondrial 
enzymes was not obtained with non-cytotoxic concentrations of 5FU in 
vitro. It can be assumed therefore that some mechanism other than 
inhibition of tumour cell mitochondrial activity must be responsible 
for the delay in tumour growth that is observed. It is well known 
that 5FU is both an inhibitor of RNA metabolism and inhibitor of DNA 
synthesis in tumour cells (Heidelberger, 1975; Mandel, 1981). It is 
possible therefore that R6G merely facilitated permeation of 5FU at 
non-cytotoxic concentrations into the tumour. Thus accumulation of 
5FU may have enabled inhibition of tumour growth by this agent alone. 
This disappointing possibility does detract from the main aim of this 
thesis, to effect selective manipulation of tumour cell energy 
metabolism and thus reduce tumour growth by this means.
Work referred to, which showed reduced tumour growth following 
delivery of combinations of antimitochondrial agents and 
antiglycolytic agents were successful with both the W256 rat tumour 
and the Ehrlich ascites murine tumour (Fearon et al, 1985a; Bernal et 
al, 1983). Both studies had one feature in common. That is, 
chemotherapy was initiated immediately after inoculation of animals 
with tumour. The studies described in this chapter, as a consequence 
were aimed at a tumour of human origin which had been implanted and 
allowed to grow for several weeks before therapy was initiated. If it 
is possible to make use of drugs whose main function is to alter 
tumour energy metabolism, then methods for prolonging contact of these 
drugs with tumour in vivo must be developed. Inhibition of energy 
metabolism may thus be maintained over several weeks in an animal 
model. Furthermore, such studies would require improvements in site 
specific delivery of a compound or combination of compounds, but also
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maintenance of the therapeutic effect via slow release of drug(s) for
example.
Recent work in this Department has shown that inhibitors of 
gluconeogenesis such as 3-mercaptopicolinic acid or hydrazine sulphate 
can potentiate the reduction in growth of W256 tumours implanted in 
rats when given in conjunction with the antimitochondrial agent 
Ehodamine-6-G. Furthermore this effect was dependent on the metabolic 
state of the animals in the study. Rats which had been starved, i.e. 
made hypoglycaemic prior to advent of drug therapy were found to show 
greater responses in tumour growth inhibition with combinations of 
antimitochondrial and antigluconeogenic agents. The effects of these 
drugs correlated well with a reduction in blood glucose concentration 
over the same time period (Fearon et al, 1985(a); Fearon et al, 1987).
Therefore, a more stringent approach is required to evaluate the 
potential of inhibitors of tumour cell energy metabolism in vivo, 
particularly if such agents can selectively inhibit growth of those 
tumours of human origin which are resistant to conventional forms of 
cancer chemotherapy. When such agents are incorporated into novel 
regimens, directed at solid human malignancies, unless attempts are 
made to prolong contact of such agents with the neoplasm, significant 
growth inhibition of tumour will not be achieved. Thus the potential 
of using inhibitors of tumour energy metabolism is likely to be 
missed.
Studies described in this chapter may be summarised as follows:
A precise method for assessing the growth of tumours in athymic mice 
implanted subcutaneously with solid malignancies has been developed. 
Thus a more accurate appraisal of the effects of how novel 
chemotherapeutic regimens exert their effects in such models can be 
made. Preliminary work with combinations of antiglycolytic and 
antimitochondrial agents do not produce significant delays in tumour 
growth that are characteristic of an inhibition of tumour cell energy 
metabolism. However, this may reflect the choice of agents selected 
for the study as clear evidence exists in the literature which 
supports the hypothesis that manipulation of tumour energy metabolism
may provide a way of inhibiting tumour growth in vivo. R6G and 5FU 
did produce a significant delay in tumour growth in athymic mice 
implanted with the WIL tumour. Although this effect was reproducible, 
the mechanism by which growth inhibition was achieved remains to be 
established.
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CHAPTER 9
GENERAL DISCUSSION
The main purpose of these studies was to identify antimitochondrial 
agents which could be used to inhibit tumour cell energy metabolism 
without adversely altering the energy metabolism of host cells. Of 
the compounds examined, Rhodamine 6G (R6G) and lamprene showed most 
promise in altering cellular energy metabolism of tumour cells in 
vitro, as well as appearing to retard growth of tumour in vivo.
In order to select appropriate antimitochondrial agents a screening 
system was required so that such compounds might be compared in their 
relative ability to specifically block tumour cell energy metabolism 
without adversely affecting energy metabolism in non tumour cells.
Chapter 1, the introduction to this work described the limitations of 
conventional cancer chemotherapy, in particular its non-selectivity 
affecting both neoplastic and also rapidly growing normal tissues such 
as bone marrow and GI tract. A major assumption behind the 
development of agents in use is that all tumour cells are more rapidly 
growing than normal cells. Not only are there normal tissues which 
exhibit comparable growth rates and are thus susceptible to the toxic 
effects of anti-cancer chemotherapy, but slowly growing well 
differentiated tumours exist which are hardly affected by conventional 
drugs. Thus the aim of this project was to assess whether differences 
\diich might exist between the energy metabolism of tumour cells and 
normal tissues could be exploited so that novel, tumour selective 
compounds might be developed for cancer chemotherapy in the future.
A review of the literature indicated that tumour energy metabolism 
could be broadly classified according to tumour cell growth 
characteristics. Rapidly growing tumours were more often highly 
glycolytic and poorly differentiated, containing structurally abnormal 
mitochondria. Slowly growing tumours existed however with comparably 
normal growth rates being well differentiated and containing
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mitochondria similar in morphology to normal tissues from which the
tumour was derived. The aim of this work was to develop a suitable
therapy against both tumour types.
Experiments described in Chapter 3 were thus designed not only to test 
whether the oxidative capacity of a poorly differentiated, glycolytic 
tumour was indeed impaired relative to normal tissue, but also whether 
such an experimental system might be used as the basis of a screen in 
vitro for monitoring the effectiveness of antimitochondrial agents 
against tumour cell energy metabolism. Studies were initiated to look 
at the respiratory properties of isolated mitochondrial preparations 
obtained from the highly glycolytic, rapidly growing rat W256 tumour 
carcinoma and from normal rat liver. Respiratory activity was 
monitored with a Clark-type oxygen electrode. Results indicated that 
not only were preparations of tumour mitochondria structurally intact, 
oxygen consumption was coupled to phosphorylation of ADP, but tumour 
mitochondria were also able to metabolise oxidizable substrates
2TcL*tOS
succinate, malate and pyruvate. Oxygen consumption were somewhat less
A
than liver mitochondria, but this was attributed to a lower 
mitochondrial content in tumour tissue relative to liver. A major 
deficiency in W256 mitochondria was the inability to metabolize B-OH 
butyrate. The non-utilisation of B-OH butyrate was attributed to 
reduced activity of succinyl-CoA : 3-oxo acid CoA transferase (E.C. 
2.8.3.5) and Acetyl-CoA transferase (E.C. 2.3.1.9), enzymes which have 
been found to be either reduced or absent in other tumour tissues 
(Tisdale and Brennan, 1983). In the longterm, isolated mitochondrial 
preparations proved to be unsuitable for screening compounds which 
might inhibit tumour cell energy metabolism. Such a study could not 
reveal much information about the integration of mitochondrial 
pathways of energy metabolism into the metabolism of the intact cell. 
Furthermore, practical difficulties in obtaining isolated 
mitochondrial preparations from either animal tumours or xenografts 
implanted in athymic mice were envisaged. As tumours are made up of 
several cell types it could not be established whether the 
mitochondrial preparation obtained was solely tumour in origin. For 
screening purposes therefore, a second model was required to establish
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which antimitochondrial agents had potential as anti-cancer agents in 
vitro.
Whole cells obtained from a tissue culture source were not only of a 
single cell type, but correspond most probably to a pure, cloned 
subpopulation of cells from the tumour. Furthermore a better 
indication of cell viability could be made with a variety of tests 
designed for continuous cell lines in culture, thus doubts as to the 
viability of the preparation observed with mitochondrial preparations, 
following contamination with tumour necrosis, were not present.
Experiments in Chapter 4 were designed to examine whether cultured 
tumour cells could be used to screen potential antimitochondrial 
agents. Two tumour cell lines, the rat carcinosarcoma W256 and human 
bronchial tumour WIL, were compared with freshly isolated rat 
hepatocytes, a source of non-malignant cells. The W256 tumour is 
characteristic of a poorly differentiated, rapidly growing glycolytic 
tumour, whereas the WIL tumour is representative of a more 
differentiated tumour cell type. Thus agents investigated in this 
study were directed at both types of tumour cell which would leave the 
energy metabolism of the non-malignant cell type unaltered.
Of the compounds studied, R6G, lamprene, anafranil and ludiomil all 
had inhibitory effects upon tumour cell energy metabolism. Cellular 
oxygen consumption was altered and the glycolytic response measured by 
lactate production rates increased as a result of treatment with these 
agents. However, both lamprene and R6G exerted their action at 
concentrations which were lower than anafranil and ludiomil. At 
concentrations of lOuM and 15uM, R6G had a biphasic action upon tumour 
cellular oxygen consumption. A transient stimulation was followed by 
a steady state inhibition of oxygen uptake in all three cell types 
examined. The dose dependent inhibition of oxygen consumption was 
more pronounced in the tumour cell lines and R6G, lOuM had little 
effect upon steady state oxygen consumption by hepatocytes. Lamprene 
stimulated oxygen consumption in both tumour cell lines. Examining the 
glycolytic response, both drugs stimulated lactate production in the 
tumour cell lines examined, although hepatocyte lactate production was
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unaltered. Data obtained in these studies was not adequate to draw
any firm conclusions at this stage, but results obtained with R6G and
lamprene did warrant further investigation.
Clear evidence of the potential antimitochondrial activity of R6G and 
lamprene could only be obtained by comparing the inhibitory action 
such agents might have on mitochondrial function relative to classic 
inhibitors of mammalian mitochondrial function. Experiments described 
in Chapter 5 examined the effects of the classical mitochondrial 
inhibitors DNP, an uncoupler; oligomycin, a phosphorylation inhibitor; 
and electron transport chain inhibitors rotenone and antimycin, when 
incubated with WIL, W256 or rat hepatocytes in the oxygen electrode. 
Fresh cell preparations, incubated in the polarographic oxygen sensor 
responded to DNP, oligomycin, rotenone and antimycin as predicted from 
the organisation of the electron transport chain in each cell type. 
R6G, lOuM stimulated oxygen uptake in tumour cell preparations, 
independently of phosphorylation, characteristic of uncouplers. This 
transient effect was followed by a steady state inhibition of oxygen 
uptake, also independently of phosphorylation indicating possible 
inhibition of electron transport. Lamprene, which stimulated oxygen 
uptake independently of phosphorylation, exhibited behaviour 
characteristic of an uncoupler. Thus a clear demonstration of the 
inhibitory effects of both R6G and lamprene on mitochondrial function 
could be obtained.
Results obtained did lead to speculation that the site of inhibition 
of electron transport induced by R6G in tumour cells occurred either 
at mitochondrial enzyme complex III or IV. Recent evidence with an 
analogue of R6G, R123 indicated that primary antimitochondrial 
activity is directed at the FIFO complex of the ATP synthase and that 
any associated inhibition of electron transport was thought to occur 
at mitochondrial enzyme complex I (Modica-Napolitano and Aprille, 
1987).
Results obtained in Chapter 5, while not specifically investigating 
the ATP synthase as a site of action indicated that R6G did exhibit 
uncoupler like behaviour and implicated the enzyme complex III or IV
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as a site of inhibition of electron transport. The stimulatory 
activity of R6G on oxygen uptake in isolated mitochondria under 
specific conditions has been confirmed by some groups (Higuti et al, 
1980), but not others (Mai and Allison, 1983). Experiments which 
utilise a whole cell model for examining tumour energy metabolism, 
while not suitable for examining the mechanism of action of inhibitors 
is admirably suited to confirming whether respiratory inhibition is 
induced by antimitochondrial agents. As rat hepatocytes did respond 
to the concentration of R6G used in this study, it was postulated that 
concentrations of R6G might exist which altered tumour cell 
mitochondrial activity without affecting non tumour tissue (Lampidis 
et al, 1983; Nadakavukaren et al, 1985).
Experimental methods for inhibiting tumour cell energy metabolism were 
not confined to functional inhibitors of tumour mitochondria in vitro. 
In Chapter 6 agents which interfered in the ability of mitochondria to 
replicate were examined for use with functional inhibitors to block 
tumour energy metabolism. Inhibition of mitochondrial biogenesis in a 
variety of eukaryotic cells has been achieved with compounds such as 
chloramphenicol and tetracycline both in vitro and in vivo (Galper and 
Darnell, 1971; Van den Bogert et al,1986(b)). Circumstantial evidence 
existed which indicated that tumour mitochondrial biogenesis might be 
inhibited with non cytotoxic concentrations of the conventional anti­
cancer agent 5FU (Oliver and Williamson, 1976(a); 1976(b); Bugeja et 
al, 1987). Subtoxic concentrations of 5FU were employed to try and 
deplete mitochondrial protein content. Activity of specific 
mitochondrial enzymes were assayed as a function of a reduction in 
biogenesis.
The cytochrome oxidase enzyme complex IV, which is coded for by 
mitochondrial DNA (Pfanner and Neupert, 1987; Nelson, 1987), was 
assayed by a polarographic method following exposure of tumour cells 
to 5FU for 72 hours. Succinate-cytochrome C reductase activity, a 
combination of the activities of succinate dehydrogenase, enzyme 
complex II and ubiquinone-cytochrome C reductase, enzyme complex III 
was monitored by a spectropho tome trie method following exposure of 
tumour cells to 5FU for 96 hours. Of these enzymes, complex II is
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thought to be coded for by the nucleus and imported into mitochondria
in precursor form, while complex III is coded for by mitochondrial DNA
(Pfanner and Neupert, 1987; Nelson, 1987).
Results from these experiments were not conclusive. Possible reasons 
for why inhibition of biogenesis was not observed following treatment 
of cells with 5FU included too short a duration of drug exposure to 
cells or that higher concentrations of 5FU were required to inhibit 
biogenesis and these concentrations might have been cytotoxic.
The results presented in Chapter 5 suggest that NAD-linked respiration 
is of more importance in tumour cells than FAD-linked respiration. 
However, results obtained in Chapter 3 showing that succinate could 
stimulate respiration in tumour cell preparations and results in 
Chapter 6 which showed that succinate dehydrogenase was intact and 
fully functional contradicted results obtained in Chapter 5. Clearly, 
use of rotenone, a potent inhibitor of electron transport at complex I 
gave misleading results implying that succinate-linked respiration was 
not operating optimally in tumour cells. Titration of rotenone with 
rat hepatocytes in the oxygen electrode failed to block oxygen uptake 
completely, although antimycin fully inhibited oxygen consumption. 
Perhaps therefore, the specificity of rotenone in tumour cells is open 
to question.
Experiments described in Chapter 7 were designed to examine whether 
the cytotoxic action of the antimitochondrial agents under study were 
due to the inhibitory effects these compounds had upon tumour cell 
energy metabolism. The effects of R6G and oligomycin, a specific 
inhibitor of mitochondrial phosphorylation, were examined on the 
growth of tumour cells grown in either glucose and glutamine or 
glutamine alone as the major carbon source. Glutamine utilisation by 
tumour cells in culture requires mitochondrial participation, in the 
absence of a glycolytic substrate. The inhibitory effects of R6G on 
the growth of cells on either glucose and glutamine or glutamine alone 
was contrary to expected results. Sensitivity to R6G was equal with 
cells grown under either conditions. ' In fact, growth delay of cells 
in glutamine was less than cells supplied with glucose. However,
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there did not appear to be any difference in the uptake of the drug as 
indicated by photomicrographic evidence of cells incubated with R6G in 
each medium.
Cytotoxicity assays based on the reduction of MIT as an indicator of 
cellular viability, indicated that cells supplied with glutamine were 
more sensitive to oligomycin. Cells grown in glutamine exhibited a 9- 
fold reduction in the ID q^ to oligomycin as compared to cells grown in 
the presence of glucose. ID q^ values for R6G were equal for cells 
grown in either glucose or glucose depleted medium. Although R6G has 
antimitochondrial activity, this might not be its major cytotoxic 
property. This series of experiments has shown that cytotoxic 
compounds whose toxic effect is determined by antimitochondrial action 
such as oligomycin, might thus be identified by the experimental 
techniques described in this chapter.
Any evaluation of compounds which selectively inhibit tumour cell 
energy metabolism in vitro must be studied further and it is therefore 
necessary to study the effectiveness of such agents in an experimental 
model of cancer which reflects the situation in vivo. Thus the 
experiments in Chapter 8 monitored the ability of the agents R6G, 
lamprene and 5FU to inhibit the growth of a human tumour xenograft 
implanted subcutaneously in colonies of immune-incompetent athymic 
mice. I
The non-small cell lung tumour WIL used for these studies has 
previously shown to be resistant to conventional forms of chemotherapy 
(Merry et al, 1986; 1987). The growth of tumours implanted
subcutaneously above the hind limbs of female athymic mice was 
monitored as a function of the time course of tumour growth and tumour 
doubling times could be calculated as a consequence.
A novel method for accurately and precisely estimating tumour volume 
was developed. Moulds of growing tumours were cast in dental 
impression material. Tumour volumes estimated from the volume of 
water required to fill the cast were found to more accurately predict
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growth of tumours as compared to conventional caliper measurements and 
subsequent estimation of tumour volume.
Experiments were designed to show the possible effects of 
antimitochondrial agents upon an established tumour growing in vivo 
and moreover, therapy was directed at a tumour which was human in 
origin. This approach represented an advance on previous experiments 
which utilised animal tumour models and furthermore, only showed an 
enhancement of anti-tumour action if treatment commenced soon after 
inoculation of animals with tumour (Bernal et al, 1983; Fearon et al, 
1985(a)).
The effects of different experimental chemotherapies was examined 
using the delay in tumour doubling time as a parameter of therapeutic 
efficacy. Combining the antiglycolytic agent 2-deoxyglucose with the 
antimitochondrial agents R6G or lamprene gave results which were in 
part encouraging. 2-deoxyglucose and R6G did not potentiate tumour 
growth delay. In combination, severe toxicity was observed and this 
resulted in a reduction in tumour doubling time. However when 2- 
deoxyglucose was combined with lamprene, growth delay of tumours was 
observed by each drug alone and in combination. No synergism between 
the two was noted. The delay in growth with these drugs was not 
however, necessarily valid as animals did not remain weight stable 
throughout the course of treatment as a probable result of reduced 
food intake. Clearly from studies reported in the literature, 
combining antiglycolytic and antimitochondrial agents to alter tumour 
energy metabolism in vivo is a valid approach, although the choice of 
drugs has proved to be limiting (Bernal et al, 1983; Fearon et al,
1987). R6G and 5FU in combination did produce a significant delay in 
tumour growth although the mechanism by which this was achieved 
remains to be established. The original hypothesis of utilising a 
functional inhibitor of mitochondria with a proposed inhibitor of 
mitochondrial biogenesis was found to be invalid following the 
inconclusive results obtained in Chapter 6. It is clear that in order 
to explain any of the effects upon tumour growth observed with the 
drugs used, assays in vitro were essential in attempting to assign
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possible mechanisms of action to explain how these agents delayed 
tumour growth.
From the work presented in this thesis, two compounds of those studied 
have shown to behave as antimitochondrial agents. The 
antimitochondrial activity of R6G however does not appear to define 
its cytotoxicity. More work is required to determine whether or not 
the action of lamprene upon tumour cells is selective. Unless a 
definite mechanism of action can be attributed to a particular 
experimental anti-cancer agent cited in the literature then basic 
studies are required at the subcellular level to determine the 
mechanism of action. Such studies might involve experiments at the 
mitochondrial level, submitochondrial level or enzyme level. Only 
when this has been established will studies at the level of the whole 
cell or intact animal remain unambiguous. Such an approach is not 
only valid for antimitochondrial agents, but also for potential 
antiglycolytic agents (Floridi et al, 1981(b); Guminska et al, 1986) 
and biogenetic inhibitors of tumour mitochondria (Van den Bogert, 
1983).
The animal model chosen represents the least controlled system with 
which an experimental chemotherapy can be investigated. The 
procedures adopted for work described here represent a more rigorous 
approach as compared to previous studies (Bernal et al, 1983). 
However, more work is required to ensure that a cytotoxic drug 
concentration is maintained at the tumour site. Methods of drug 
administration and site delivery must be developed further. The delay 
in tumour growth obtained with R6G and 5FU requires explanation. It 
is just conceivable that evidence obtained for a drug*s mechanism of 
action in vitro might not be applicable in vivo. However, until 
proven otherwise, only further work carried out with models in vitro 
will indicate how R6G and 5FU potentiate delay of tumour growth. The 
toxic effects of R6G upon tumour cell metabolism might be related to 
an inhibition of mitochondrial biogenesis (Abou-Khalil et al, 1986; 
Kuzela et al, 1986) or metabolism that is not primarily related 
(0*Brien and Weinstein, 1987). Other mitochondrial probes exist with
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similar properties and might be evaluated further (Conover and 
Schneider, 1981; Mai and Allison, 1983).
It is hoped that differences in cellular energy metabolism between 
tumour and non tumour cells represent a promising path for selectively 
inhibiting the growth of tumour relative to host cells in cancer 
patients. This approach has found favour with other groups (Bernal et 
al, 1983; Fearon et al, 1987).
Khodamine-6G has served as a laboratory based reference for the 
selective manipulation of tumour cell energy metabolism. However, 
real benefit may be derived from an investigation of agents such as 
lamprene which in the future might be used clinically.
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